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General introduction and  




Colorectal cancer is reported as the second most−common cancer in the Netherlands 
and the third most−common cancer worldwide.1,2 Up to 40% of patients with 
colorectal cancer develop peritoneal metastases (PM) during the course of the 
disease.3-6 Colorectal PM has long been considered a terminal disease, with most 
patients dying within a few months after diagnosis.3,7 The effect of modern systemic 
chemotherapy regimens and molecular targeting agents remains limited and only 
extends the median overall survival (OS) rate up to 24 months.8-12 Long−term 
survivorship with these regimens alone has never been achieved.
Three decades ago, a paradigm shift occurred when colorectal PM was recognised 
as a locoregional spread of disease rather than an expression of diffuse metastatic 
disease. This hypothesis resulted in the development of a comprehensive 
locoregional treatment strategy combining aggressive cytoreductive surgery with 
hyperthermic intraperitoneal chemotherapy (CRS+HIPEC).13-16 This extensive surgical 
treatment radically changed the survival outcomes in selected patients with limited 
and resectable colorectal PM, with reported median OS up to 63 months and 5­year 
survival rates of up to 54%.17-20 During the 9th International Congress on Peritoneal 
Surface Malignancies in Amsterdam in 2014, CRS+HIPEC was established as standard 
care for selected patients with colorectal PM.
PRINCIPLES OF CRS+HIPEC
CRS+HIPEC procedures are performed worldwide with a variety of different 
techniques; as such, only the main concept and our standardised Dutch HIPEC 
protocol are summarised below.20
Cytoreductive surgery
The goal of cytoreductive surgery is to remove all macroscopic visible tumour 
deposits from the peritoneal surface in the abdominal cavity by performing both 
peritoneal and organ resections. CRS is only performed if the colorectal PM is 
deemed completely resectable during an exploratory laparotomy.
Hyperthermic intraperitoneal chemotherapy
After a complete cytoreduction has been achieved, the HIPEC procedure is 
performed to eliminate all remaining microscopic tumour cells in the abdominal 
cavity. At the UMCG, the open Coliseum technique is used for the administration of 
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a heated chemotherapeutic agent to the abdominal cavity.21 In this open technique, 
the abdominal wall is pulled upward and a closed circuit is created using inflow and 
outflow drains attached to a perfusion device. Mitomycin C (35 mg/m2) is used as the 
preferred chemotherapeutic agent in patients with colorectal PM, at a temperature 
of 41–42°C for 90 min. The addition of hyperthermia to the chemotherapeutic 
agent increases the local concentration and the penetration depth in the sites of 
tumour deposits.22-24 Thereafter, the fluid is evacuated from the abdominal cavity 
and reconstruction surgery including bowel anastomoses with or without a stoma 
is performed.
IMPACT OF CRS+HIPEC
Treatment−related morbidity and mortality
CRS+HIPEC is a complex oncologic abdominal procedure associated with high 
postoperative morbidity rates and long hospital stays. A systematic review from 10 
international high−volume referral centres reported major postoperative morbidity 
rates between 12 and 52% and mortality rates between 0.9 and 5.8%.25 The 1−year 
mortality rate is 13%, and approximately 50% of patients will experience recurrence 
of the disease within the first year after CRS+HIPEC.18,26-30 Severe complications after 
CRS+HIPEC have major consequences for our patients and our healthcare system, 
as they are associated with a diminished quality of life (QoL), a significant decrease 
in survival outcomes, and a serious increase in hospital costs of approximately 
320%.28,31-33
Quality of life
Most studies report a significant decrease in various domains of QoL during the 
first six months after surgery.34,35 Overall, at least 6–12 months recovery time is 
necessary to restore the QoL to preoperative levels.
PATIENT SELECTION FOR CRS+HIPEC
Patients who benefit the most in terms of survival and QoL with acceptable 
treatment−related morbidity and mortality should be selected for CRS+HIPEC. A 
complex interplay of patient, tumour, and treatment−related factors determines 
these postoperative outcomes. According to the available literature, survival 
outcomes after CRS+HIPEC are strongly determined by the extent of peritoneal 





Extent of peritoneal disease
The extent and distribution of colorectal PM is directly correlated to the complexity of 
the surgical procedure, the risk of developing major postoperative complications, and 
survival outcomes after CRS+HIPEC. The extent of peritoneal disease is scored by the 
peritoneal cancer index (PCI), which combines peritoneal lesions sizes with the exact 
distribution over 13 abdominopelvic regions (Figure 1). The PCI score ranges from 0 
to 39 points; a higher score indicates a more extensive tumour burden. The optimal 
cut−off value of the PCI score remains a topic of debate, although most guidelines 
recommend performing CRS+HIPEC only in patients with colorectal PM with a PCI 
<20.45 No extensive disease of the small bowel and its mesentery may be present, as 
complete resection will certainly lead to short bowel syndrome, which is a contra−
indication to perform CRS+HIPEC. In addition, distant metastases are a contra−
indication for CRS+HIPEC, with the exception of up to three resectable liver metastases.
Completeness of macroscopic cytoreduction
The completeness of cytoreduction score (CC−score) measures the amount of 
macroscopically visible disease after CRS. Completeness of cytoreduction is 
so essential that current guidelines recommend only performing HIPEC after 
a complete cytoreduction (CC−0, no visible residual disease) or nearly complete 
cytoreduction (CC−1, residual tumour lesions less than 2.5 mm) has been achieved.45 
The likelihood of achieving a complete cytoreduction depends on the extent and 
distribution of colorectal PM.
Signet ring cell histology
Colorectal tumours with histopathological confirmation of signet ring cells seem to 
metastasise more easily to the peritoneum, causing a greater peritoneal burden of 
disease.46 There is a higher risk of the occurrence of a non−therapeutic laparotomy 
or the need to perform extensive resections with associated high postoperative 
morbidity rates in these patients. In addition, survival outcomes after CRS+HIPEC 
are poor, with no patients reported to be alive at 5−year follow−up.42-44
Other important patient−related factors
Moderate or severe comorbidity (i.e., American Society of Anaesthesiologists [ASA] 
score >3) and poor performance status (i.e., World Health Organization [WHO] score >2) 
are absolute contra−indications to perform CRS+HIPEC, because patients have to be 
able to withstand 8−12 h of surgery.13,45 Obesity is reported as a risk factor for pulmonary 
complications but is not considered an absolute contra−indication.47 Older age might 







































CHALLENGES IN PATIENT SELECTION FOR CRS+HIPEC
There is no doubt that adequate patient selection is the main challenge in the field of 
CRS+HIPEC. Current preoperative imaging modalities fail to estimate the PCI to predict 
the possibility of achieving a complete cytoreduction.49-52 Direct visualisation of the 
abdominal cavity is the most accurate method to assess the extent and distribution 
of colorectal PM, which causes patient selection to take place in the operating 
room rather than in an outpatient setting. Up to 50% of patients are excluded for 
CRS+HIPEC directly upon an exploratory laparotomy.53-57 Identification of patients 
for whom CRS+HIPEC is not suitable at an earlier stage could spare these patients 
the morbidity of an unnecessary laparotomy. Additionally, a cancelled CRS+HIPEC 
procedure is time consuming and expensive from a healthcare perspective.
Preoperative patient selection is thus preferential, because it allows for a more 
patient−tailored approach, increased patient information, less morbidity, quick 
referral for systemic therapy in the case of extensive disease, and ultimately, 
better patient survival. Furthermore, prognostic factors that can be preoperatively 
assessed prevent unnecessary imaging, admission, and operations with associated 
costs. The search for prognostic factors that could further improve patient selection 
for CRS+HIPEC is constantly ongoing.
OUTLINE OF THIS THESIS
Patients with colorectal PM who benefit the most in terms of survival and QoL 
with acceptable treatment−related morbidity and mortality should be selected 
for CRS+HIPEC. Currently, the most powerful prognostic factors for survival after 
CRS+HIPEC are determined at the time of operative exploration rather than in 
a preoperative setting. The aim of this thesis is to identify new and promising 
preoperative factors in patients with colorectal PM to predict postoperative morbidity 
and survival outcomes after CRS+HIPEC. This thesis is subdivided into two parts.
PART I – Biological and clinical prognostic factors to further optimise 
patient selection for CRS+HIPEC
Tumour biology is very likely to play a key role in the survival outcomes after 
CRS+HIPEC for patients with colorectal PM, as the presence of signet ring cell 
histology is one of the most important independent predictors of poor survival 
after CRS+HIPEC. The onset of development of colorectal PM (i.e., synchronously or 
metachronously) might also be of relevance; the difference in either tumour biology 
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and behaviour or adequate initial treatment might influence survival outcomes 
after CRS+HIPEC. In Chapter 2, the impact of onset of colorectal PM on survival 
outcomes after CRS+HIPEC was retrospectively assessed from merged prospectively 
maintained institutional databases from two Dutch tertiary referral hospitals.
The PCI scoring system is used worldwide as a static single−time−point scoring 
system to assess the extent of peritoneal disease during an exploratory laparotomy 
for potential CRS+HIPEC and as such does not include disease progression over time. 
Since 2012, HIPEC surgeons from our academic centre have introduced diagnostic 
laparoscopy (DLS) as a part of the preoperative workup for CRS+HIPEC in patients 
with suspicion of colorectal PM to pathologically confirm the presence of peritoneal 
disease and to systematically assess the extent and resectability according to the 
PCI scoring system in an earlier stage. The aim of Chapter 3 is to assess the impact 
of an increase in PCI between DLS and exploratory laparotomy (i.e., ∆PCI) on survival 
outcomes after CRS+HIPEC to create a more−dynamic prognostic factor.
Previous retrospective studies concluded that DLS is a safe, feasible, and accurate 
staging tool to assess tumour burden in patients with PM and could prevent 
non−therapeutic laparotomies. However, the limitations of these studies are the 
small number of patients, the variety of primary tumour types, and the highly 
selected way DLS is used. Chapter 4 aims to determine the feasibility and safety of 
performing DLS routinely in a large cohort of patients with suspicion of colorectal 
PM to evaluate suitability for CRS+HIPEC. In addition, the perioperative reasons to 
exclude patients for CRS+HIPEC during DLS were investigated. The introduction of 
DLS in our preoperative workup for CRS+HIPEC provides the opportunity to compare 
a historical cohort of patients with colorectal PM who were scheduled for CRS+HIPEC 
before the introduction of DLS to those with colorectal PM who were scheduled 
for CRS+HIPEC after DLS was part of the preoperative workup. In Chapter 5, both 
cohorts are investigated to evaluate the implementation of DLS in the preoperative 
workup for CRS+HIPEC and to investigate the impact of DLS on preventing non−
therapeutic laparotomies in this vulnerable patient population.
The extent of surgery (i.e., number of resected anatomical structures) during 
CRS+HIPEC is a well−known risk factor for treatment−related morbidity and mortality. 
Surgeons’ abilities to correctly predict the extent of surgery in advance seems to 
be one of the key elements to estimate the individual risk for treatment−related 
morbidity. The large number of publications about the limitations of current imaging 




up to 50% of the patients suggest that surgeons experience difficulties in predicting 
the extent of surgery in advance. In Chapter 6, surgeons’ abilities to correctly predict 
the extent of surgery in advance to CRS+HIPEC is described for the first time in a 
prospective, observational cohort study including 131 cases.
PART II – New Avenues for Research
Surgery−related muscle loss (SRML) occurs in at least one out of three cancer 
patients within one week after major surgery. However, this important phenomenon 
has hardly been investigated. The few reported studies demonstrate that clinically 
relevant SRML might be a major problem for our current healthcare system based 
on its impact on several short−term postoperative problems and its postoperative 
impact on QoL and fatigue up to six months after surgery. Prevention of clinically 
relevant SRML can be a promising strategy to improve morbidity and mortality and 
increase QoL after major surgery. Chapter 7 extensively describes the design of 
the MUSCLE POWER study, an observational sing−centre prospective cohort study 
that investigates the presence, impact, and possible predictors for clinically relevant 
SRML in 178 cancer patients after major abdominal surgery using ultrasound 
measurements, squeeze and force measurements, and QoL questionnaires. Daily 
physical activity during the hospital stay will be monitored by a motility tracker, and 
protein intake will be monitored by a dietician. Crucial information regarding possible 
predictors for clinically relevant SRML can be used in future intervention studies 
to prevent postoperative muscle loss and subsequently improve postoperative 
outcome and QoL. The MUSCLE POWER study is open for inclusion and more than 
50 patients have been enrolled over the past four months. Final results can be 
expected at the end of 2020.
Another promising line of research at the UMCG are the use of intraoperative 
imaging techniques to improve tumour detection during surgery. In patients with 
colorectal PM, complete cytoreduction during CRS+HIPEC is necessary to achieve 
long−term survival, and surgeons currently depend on visual and tactile inspection 
only to differentiate between benign and malignant lesions during surgery. In 
recent years, molecular fluorescence guided surgery (MFGS) has emerged as a 
promising real−time intraoperative imaging technique to improve tumour detection 
by using tumour−targeted fluorescence tracers. This technique can be applied 
intraoperatively to serve as a ‘red−flag’ imaging technique to assist in optimal 
tumour identification. Improved detection of tumour tissue could not only help 
attain a more complete cytoreduction but might also facilitate tailored surgery 
avoiding unnecessary resections of benign lesions and organs. Chapter 8 provides 
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a chronological overview of MFGS development in patients with colorectal PM, 
including two completed phase I clinical trials using two different tumour−targeted 
fluorescence tracers during exploratory laparotomy. Bevacizumab­IRDye800CW, 
one of the promising tumour−targeted fluorescence tracers, will be used for a new 
phase I trial to detect tumour tissue from colorectal PM during DLS (i.e., the SELECT 
trial). If Bevacizumab­IRDye800CW is also feasible during DLS, it might provide a 
more accurate investigation of the extent of peritoneal disease at an earlier stage. 
Ultimately, these new strategies may reduce overtreatment, morbidity, and costs 
while maintaining the same or better effectiveness with a lower recurrence rate 
and improved QoL.
In Chapter 9 the previous chapters are summarised and discussed in a broader 
perspective. A summary of the work undertaken is given in English and Dutch. 
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Careful selection of patients with colorectal peritoneal metastases (PM) for 
cytoreductive surgery (CRS) with HIPEC is crucial. It remains unknown whether the 
time−of−onset of colorectal PM (synchronous versus metachronous) influences 
surgical morbidity and survival outcomes after CRS+HIPEC.
Methods
Patients with histologically proven colorectal PM who underwent CRS+HIPEC 
between February 2006 and December 2017 in two Dutch tertiary referral hospitals 
were retrospectively included from a prospectively maintained database. The 
onset of colorectal PM was classified as synchronous (PM diagnosed at the initial 
presentation with colorectal cancer) or metachronous (PM diagnosed after initial 
curative colorectal resection). Major postoperative complications (Clavien−Dindo 
grade ≥3), overall survival (OS), and disease−free survival (DFS) were compared 
between patients with synchronous and those with metachronous colorectal PM 
using Kaplan−Meier analyses, proportional hazard analyses, and a multivariate Cox 
regression analysis.
Results
The study enrolled 433 patients, of whom 231 (53%) had synchronous colorectal 
PM and 202 (47%) had metachronous colorectal PM. The major postoperative 
complication rate and median OS were similar between the patients with 
synchronous and those with metachronous colorectal PM (26.8 vs 29.7%; p = 0.693 
and 34 vs 33 months, respectively; p = 0.819). The median DFS was significantly 
decreased for the patients with metachronous colorectal PM versus patients with 
synchronous colorectal PM (11 versus 15 months; adjusted hazard ratio, 1.63; 95% 
confidence interval, 1.18−2.26).
Conclusions
Metachronous onset of colorectal PM is associated with early recurrence after 
CRS+HIPEC compared with synchronous colorectal PM, without a difference in OS 
or major postoperative complications. Time−of−onset of colorectal PM should be 
taken into consideration to optimise patient selection for this major procedure.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 1.4 
million new cases and more than 700,000 deaths per year.1 Approximately 30−40% 
of CRC patients experience peritoneal metastases (PM) at some point in time after 
initial diagnosis.2-7 With the systemic therapy regimens, the median overall survival 
(OS) for patients with colorectal PM traditionally ranges from 12 to 24 months.8-10
Almost three decades ago, a curative−intent treatment option arose: cytoreductive 
surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy 
(HIPEC).11,12 The main principle of this extensive procedure is removal macroscopic 
disease during CRS, followed by HIPEC for microscopic malignant tissue, resulting in 
an OS of up to 5 years for highly selected patients with colorectal PM.11-13 However, 
CRS+HIPEC is accompanied by substantial early recurrence rates (up to 50% 
during the first year after treatment), morbidity (16−64%) and mortality (0−8%).14-20 
Therefore, careful patient selection is pivotal to prevention of early recurrence and 
therefore overtreatment, with the aim to increase survival and reduce morbidity 
and mortality.
At this writing, the most powerful prognostic factors for survival after CRS+HIPEC 
are extent of disease measured by the peritoneal cancer index (PCI), completeness 
of the performed cytoreduction, and signet ring cell histology.21-27 These prognostic 
factors, on which surgeons rely heavily, are determined during or after the surgical 
procedure rather than in a preoperative setting. Therefore, more research on 
preoperative prognostic factors is of utmost importance to improvement of the 
decision−making process.
The development of PM metachronously or synchronously with the primary CRC 
diagnosis might be of relevance. The difference in either tumour biology and 
behaviour, or adequate initial treatment might influence OS and DFS. In an attempt 
to discover novel preoperative risk factors for worse outcomes, this study aimed to 
investigate the impact of the synchronous versus metachronous onset of colorectal 





Design, setting, and participants
In this multicentre observational study, data from all consecutive patients 
with histologically proven colorectal PM who underwent CRS+HIPEC between 
February 2006 and December 2017 were retrospectively extracted from a merged 
prospectively maintained institutional database of two Dutch tertiary referral 
hospitals.
No worldwide consensus exists concerning the definitions of synchronous and 
metachronous formation of PM. The most common definitions used in scientific 
literature were selected. Patients with synchronous colorectal PM had colorectal 
cancer diagnosed at the time of presentation, either on routine staging, on computed 
tomography (CT), or at laparotomy. Patients with metachronous colorectal PM were 
deemed to be clear of peritoneal disease at the initial “curative” colorectal resection, 
but subsequently became symptomatic during the follow−up period and had PM 
diagnosed on CT (Figure 1). The study was approved by the Institutional Ethics 
Committee of the University Medical Center Groningen (METc 201800395).
Preoperative evaluation and management
All the patients underwent a standardised preoperative workup to evaluate 
eligibility for CRS+HIPEC, with the aim of achieving complete cytoreduction with 
acceptable risk of treatment−related morbidity and mortality. This preoperative 
workup consisted of a clinical examination, preoperative laboratory testing, and 
thoracic, abdominal and pelvic CT with oral and intravenous contrast agents to 
quantify the peritoneal disease burden and rule out extra−abdominal metastases. 
If deemed necessary, a diagnostic laparoscopy (DLS) was performed to assess 
the location and extent of peritoneal disease using the PCI scoring system, as 
described by Sugarbaker et al.28 Clinically suspect lesions during DLS were biopsied 
for pathological confirmation of colorectal PM.
Next, the eligibility for CRS+HIPEC according to the preoperative workup was 
determined for each patient at a multidisciplinary oncology team meeting. In 
the Netherlands, candidates for CRS+HIPEC are generally those with colorectal 
PM amenable to complete cytoreduction, a PCI below 20, no extra−abdominal 
metastases, and a performance status that allows for major surgery. The presence 
of up to three resectable liver metastases is not an absolute contraindication for 
CRS+HIPEC.17
29










































































































































































Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
For the patients in this study, CRS was performed only if the colorectal PM was 
deemed to be completely resectable after exploratory laparotomy, whereas HIPEC 
was performed only in case of a (near) complete cytoreduction. The two institutions 
performed CRS+HIPEC under the same standardised Dutch HIPEC protocol, as 
previously described.17 Restrictions were imposed on the extent of surgery as far 
as it was compatible with sufficient postoperative function. At the end of surgery, the 
completeness of cytoreduction (CC) score was determined, with CC−0 indicating that 
no residual tumour was visible or palpable in the peritoneal cavity, CC−1 indicating 
residual tumour deposits smaller than 2.5 mm, CC−2 indicating residual tumour 
deposits between 2.5 mm and 2.5 cm, and CC−3 indicating residual tumour deposits 
above 2.5 cm or a confluence of nodules. 28
The HIPEC procedure was then performed by circulating a heated solvent infused 
with chemotherapeutic medication throughout the abdomen using the open 
Coliseum technique.29 In most cases, mitomycin (35mg/m2) was administered in the 
open abdominal cavity, with a temperature of 41−42⁰C for 90 minutes. After this, the 
fluid was evacuated from the abdomen, and the continuity of the gastrointestinal 
tract was restored. After surgery, patients were admitted to the intensive care unit 
for at least one postoperative day until both cardiac and pulmonary functions were 
stable.
Follow−up
All the patients were followed by a standardised follow−up protocol. Physical 
examination and carcinoembryonic antigen (CEA) measurements were performed 
on a 3− to 6− month basis for a minimum of 4 years. If recurrence of the disease 
(e.g., clinical symptoms or increase in CEA levels) was suspected, a CT of the thorax 
and abdomen was performed, with tissue biopsies in selected cases.
Data collection
Data on patient characteristics, tumour characteristics, operative characteristics, 
postoperative morbidity and mortality, recurrence, and overall survival were 
collected prospectively. Data on postoperative complications were collected up to 60 
days after CRS+HIPEC and registered according to the Clavien−Dindo classification 
system.30 Data regarding the use of perioperative chemotherapy were divided into 
three categories. Chemotherapy before CRS+HIPEC was recorded as “neoadjuvant 
chemotherapy”. Chemotherapy after CRS+HIPEC was recorded as “adjuvant 
chemotherapy”, and when chemotherapy was used in the past (e.g., before or after 
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a primary colorectal tumour resection), it was recorded as “prior chemotherapy”. 
Data were collected and stored in compliance with the Declaration of Helsinki.
Primary and secondary outcomes
The primary outcome was overall survival (OS), defined as the time between 
CRS+HIPEC and death, or date of the last follow−up visit in censored cases. The 
secondary outcomes were disease−free survival (DFS) and major postoperative 
complications. In this study, DFS was defined as the time between CRS+HIPEC and 
the date of the first recurrence or last follow−up visit in censored cases. Major 
postoperative complications were classified as grade 3 (severe adverse events 
requiring interventional procedures) and grade 4 (life−threatening adverse events 
requiring a return to the operating theatre or intensive care support). Procedure−
related mortality was defined as patient death within 30 days of surgery or during 
the hospital stay (grade 5).
Statistical analyses
All statistical analyses were conducted using SPSS® Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA). All p values equal to or lower than 0.05 were 
considered statistically significant. Quantitative values were reported as mean 
± standard deviation (SD) or median (interquartile range [IQR]), and categorical 
variables as numbers and percentages. Categorical variables were compared 
between patients with synchronous and those with metachronous colorectal 
PM using the Chi−square test or Fisher’s exact test. Continuous variables were 
compared between both groups by using the student t−test or Mann−Whitney U 
test. OS and DFS were compared between the two groups using Student’s t test 
or the Mann−Whitney U test. Both OS and DFS were compared between the two 
groups using the log−rank test.
Subsequently, a multivariable Cox regression analysis was performed to determine 
the impact of metachronous versus synchronous colorectal PM on survival 
outcomes after adjustment for potential confounders. The potential confounders 
included were either those with a p value lower than 0.20 in the univariate survival 
analysis or those known from the literature. Results were reported as hazard ratio 






The study analysed 433 patients with colorectal PM who underwent CRS+HIPEC. 
For 231 patients (53%) synchronous colorectal PM was diagnosed, whereas for 202 
patients (47%) metachronous colorectal PM after initial curative colorectal resection 
was diagnosed. Of the patients with synchronous colorectal PM, 202 (87.4%) 
underwent CRS+HIPEC directly, whereas 29 (12.6%) underwent primary surgery 
and were referred to one of the tertiary referral hospitals in which CRS+HIPEC was 
performed in a second stage (Figure 1).
Table 1 presents the patient characteristics, tumour characteristics, and surgical 
characteristics of the entire cohort, as well as a comparison of these characteristics 
between patients with synchronous and those with metachronous colorectal PM. 
At baseline, the patients with synchronous colorectal PM differed significantly from 
the patients with metachronous colorectal PM. The patients with metachronous 
colorectal PM less frequently presented with signet ring cell histology (1.5 vs 11.7%, 
p < 0.001), less frequently had an N2 status (25.2 vs 45.0%, p < 0.001), and were 
less frequently treated with neoadjuvant (14.9 vs 30.3%, p < 0.001) or adjuvant 
chemotherapy (21.8 vs 53.3%, p < 0.001) or neoadjuvant biological therapy (4.5 
vs 11.7%, p = 0.012). Other baseline characteristics were similar between the two 
groups.
Surgical morbidity and mortality
Table 2 presents the mortality and overall postoperative morbidity rates divided 
by type and severity of the postoperative complication. The number of major 
postoperative complications was similar between patients with synchronous and 
those with metachronous colorectal PM (26.8 vs 29.7%, p = 0.693). The perioperative 
mortality for the entire cohort was 1.6% and showed no significant difference 
between the two groups (p = 0.575). The causes of treatment−related death were 
cardiac events (n = 2), major postoperative bleeding (n = 2), anastomotic leakage 
(n = 1) and intra−abdominal abscesses (n = 2).
Survival outcomes
In the univariate analysis, the median OS was similar between the patients with 
synchronous colorectal PM and those with metachronous colorectal PM (34 vs 
33 months, p = 0.819) (Figure 2). During the follow−up period, recurrence was 
diagnosed in 270 patients (62.4%). In the univariate analysis, the median DFS was 
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significantly shorter for the patients with metachronous colorectal PM (11 months; 
95% CI 10−12 months) than for the patients with synchronous colorectal PM (15 
months; 95% CI 11−19 months)(p < 0.001 (Figure 3, Table 3).
In multivariate analysis, adjusted for tumour location, signet cell histology, PCI score, 
resection status, prior chemotherapy, and adjuvant chemotherapy after CRS+HIPEC, 
metachronous colorectal PM was associated with a worse DFS than synchronous 
colorectal PM (adjusted HR 1.63; 95% Cl 1.18−2.26; p < 0.01)(Table 3). The location 
of recurrent disease was available for 242 patients and included colorectal PM only 
(n = 113, 46.7%), colorectal PM and distant metastases (n = 70, 28.9%), and distant 
metastases only (n = 59, 24.4%).
Organ−specific localisations of the distant metastases were most likely the liver 
(n = 62, 48.0%), the lung (n = 43, 33.3%), or both organs simultaneously (n = 20, 
15.5%). The localisation of recurrent disease did not differ significantly between 
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Figure 2 | Overall survival of patients with synchronous versus metachronous colorectal 
peritoneal metastases who underwent CRS+HIPEC.
Figure 3 | Disease­free survival of patients with synchronous versus metachronous colorectal 




The OS and DFS for all 433 patients according to the PCI score are shown in Figure 
4A and B. The PCI scores were categorised into five different subgroups. A lower 
PCI score at the time of exploratory laparotomy was associated with a better OS 
and DFS (p < 0.001).
Figure 4 | Kaplan–Meier survival curves for all 433 patients according to peritoneal cancer 
index (PCI) score.
A. Overall survival (OS). B. Disease−free survival (DFS)
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Table 3 | Univariable and multivariable comparison of disease−free survival between patients 
with synchronous versus metachronous colorectal peritoneal metastases after CRS+HIPEC.
Univariate analysis Multivariate analysis
Variables HR 95% CI P value HR 95% CI P value
Onset of colorectal PM
Synchronous 1.00 - - 1.00 - -
Metachronous 1.51 1.19–1.93 0.001 1.63 1.18−2.26 <0.01
Age 0.99 0.98–1.00 0.20
Sex
Female 1.00 - -
Male 1.01 0.79–1.28 0.95
Primary tumour
Rectum 1.00 - - 1.00 - -
Right colon 0.95 0.65–1.93 0.79 1.00 0.66−1.52 0.99
Transverse colon 0.76 0.44–1.32 0.34 0.75 0.41−1.38 0.35
Left colon 1.05 0.63–1.73 0.86 1.5 0.66−2.00 0.63
Sigmoid 0.91 0.62–1.33 0.62 0.81 0.53−1.23 0.32
Signet ring cell histology
No 1.00 - - 1.00 - -
Yes 1.23 0.79–1.90 0.36 1.18 0.70−1.99 0.53
PCI score during 
CRS+HIPEC
0−5 1.00 - - 1.00 - -
6−10 1.47 1.07–2.04 0.02 1.33 0.96−1.88 0.09
11−15 2.06 1.42–2.99 <0.001 2.05 1.38−3.07 <0.001
16−20 1.99 1.27–3.11 <0.01 1.94 1.22−3.09 <0.01
>20 2.00 0.99–4.02 0.05 2.28 1.10−4.71 0.03
CC−score
CC−0 or CC−1 1.00 - -
CC ≥2 3.84 0.54−27.58 0.18
Prior chemotherapy
No 1.00 - - 1.00 - -
Yes 1.41 1.10−1.81 <0.01 1.07 0.78−1.47 0.67
Neoadjuvant chemotherapy
(CRS+HIPEC)
No 1.00 - -
Yes 0.99 0.74−1.32 0.93
Adjuvant chemotherapy
(CRS+HIPEC)
No 1.00 - - 1.00 - -




No 1.00 - -




Additional analyses of patients with metachronous colorectal PM
The patients with metachronous colorectal PM had a significantly shorter DFS than 
the patients with synchronous colorectal after CRS+HIPEC, without a difference 
in OS. Further analyses were deemed necessary to find an explanation for this 
difference, and to identify which specific metachronous colorectal PM patient is at 
risk for a decreased DFS after CRS+HIPEC.
The group of patients with metachronous colorectal PM in our cohort appeared to 
be very heterogeneous. We performed a subanalysis, comparing metachronous 
cancer patients with early (<1 year) and late (≥1 year) recurrences after CRS+HIPEC 
(Supplementary Table 1). The mean OS was significantly shorter for the early 
recurrence group (19 months; 95% Cl 16−21 months) than for the patients who had a 
late recurrence (30 months; 95% Cl 26−35 months; p < 0.001). At baseline, the patients 
who had metachronous colorectal PM with early recurrence differed significantly 
from the patients with late recurrence. The patients with an early recurrence had a 
shorter period between primary surgery and onset of metachronous colorectal PM 
(p = 0.017), a higher PCI score (p < 0.001), a longer surgery (422 vs 352 minutes; p < 
0.001), and more blood loss (800 vs 600 ml; p = 0.008) during CRS+HIPEC, which was 
accompanied by more major postoperative complications (31.2 vs 24.4%; p = 0.005) 
and a longer hospital stay (14 vs 11 days; p = 0.002) (Supplementary Table 1). We 
adjusted for these potential cofounders in the multivariate regression analyses.
The PCI score had a significant impact on OS and DFS for all 433 patients. We 
performed additional analyses to identify a possible cut−off point for the PCI 
score of the patients with metachronous colorectal PM for performing CRS+HIPEC 
regarding OS and DFS. The PCI scores of the 202 patients with metachronous 
colorectal PM were divided into the following five different subgroups: PCI of 0−5 
, PCI of 6−10, PCI of 11−15, PCI of 16−20, and PCI higher than 20. The median OS in 
the different subgroups was respectively 46 months (95% Cl 39−53 months), 34 
months (95% Cl 22−46 months), 20 months (95% Cl 15−25 months), 22 months (95% 
Cl 9−35 months), and 10 months (95% Cl 6−14 months). The DFS in the different 
subgroups was respectively 17 months (95% Cl 10−24 months), 11 months (95% Cl 
9−14 months), 9 months (95% Cl 7−12 months), 8 months (95% Cl 4−12 months), and 
9 months (95% Cl 7−11 months).
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DISCUSSION
This prospective observational study that included 433 patients with colorectal PM, 
showed that the patients with metachronous PM had a worse median DFS than the 
patients with synchronous PM after CRS+HIPEC, whereas OS and surgical morbidity 
were similar between the two groups.
Currently, most available prognostic factors for survival after CRS+HIPEC are 
determined in the operating theatre. However, these factors cannot be used 
preoperatively during multidisciplinary HIPEC meetings when clinicians are assessing 
which patient will benefit from this major procedure. The impact of the time when the 
colorectal PM developed might be of relevance in predicting outcomes. Synchronous 
onset of PM might be considered as a proof of aggressive presentation. However, our 
finding that patients with synchronous PM have an increased DFS contradicts this 
theory. On the other hand, metachronous PM could be seen as a proof of the recurrent 
character of the disease, especially when there is little time between the first tumour 
and the finding of colorectal PM. However, substantial knowledge and scientific 
evidence of the impact on survival is lacking. Currently only three studies have 
reported the impact that the onset of colorectal PM has on OS.19,31,32 The data of these 
three studies (319 patients) were combined in a meta−analysis, in which the pooled HR 
demonstrated that onset of colorectal PM has no effect on OS (HR 1.21; 95% CI 0.87−1.68]; 
p = 0.25), comparable with our results.22 None of these studies reported on DFS.
In our cohort, the patients with synchronous colorectal PM more frequently received 
neoadjuvant and adjuvant chemotherapy around the CRS+HIPEC procedure than 
the patients with metachronous colorectal PM. It could be argued that this led to the 
difference in DFS after CRS+HIPEC between the two groups. First, an explanation 
for the difference in frequencies could be that most metachronous patients 
experience PM shortly after primary resection and adjuvant chemotherapy (data 
not shown). Development of PM shortly after the use of chemotherapy can cause 
the HIPEC surgeon to decide to perform CRS+HIPEC without using neoadjuvant 
chemotherapy, because the patient is already experiencing progression of 
peritoneal disease shortly after the use of chemotherapy. We looked at the impact 
of perioperative chemotherapy on DFS in our multivariate analyses. Only the use 
of adjuvant chemotherapy was associated with an increase in DFS, but the onset 
of colorectal PM (synchronous or metachronous) remained an independent risk 
factor for a decreased DFS. Despite the widespread use of perioperative systemic 




outcomes after CRS+HIPEC, leading to controversy regarding its efficacy, timing, 
and risks. Consequently, no worldwide consensus exists on the use and timing of 
perioperative chemotherapy, which varies considerably between HIPEC centers.33 We 
hope that the CAIRO 6 trial, a multicentre, open−label, phases 2 and 3 randomised 
controlled trial (RCT), will provide some answers about the oncological efficacy of 
perioperative systemic therapy and CRS+HIPEC versus upfront CRS+HIPEC (control 
arm) for isolated resectable colorectal PM (NCT02758951).
The clinical relevance of the finding that the metachronous colorectal PM had earlier 
recurrences than the synchronous colorectal PM patients, without a difference in OS, 
raises many questions. Most metachronous colorectal PM patients undergo their 
primary colorectal tumour resection and experience their first recurrence several 
months later (e.g., colorectal PM >6 months later). Subsequently, after undergoing 
CRS+HIPEC, the patients in this cohort had their second recurrence’ after a median of 
11 months, while most were still recovering from this major surgical procedure.34-40 
Although OS between synchronous versus metachronous colorectal PM was still 
comparable, we suspect that the quality of life (QoL) in the months after the second 
recurrence for the patients with metachronous colorectal PM after CRS+HIPEC might 
be poor and can therefore not be compared with their synchronous counterparts 
who are still without a recurrence at this stage.34,41 Qualitative data about the 
true impact of CRS+HIPEC on different life domains of QoL are still lacking. At this 
writing, we are performing semi−structured interviews with patients before and 
3 months after CRS+HIPEC to identify its true impact on different life domains 
because we suspect it will contribute to the discussion about QoL after CRS+HIPEC.
The group of patients with metachronous colorectal PM in our cohort appeared to 
be very heterogeneous. Evaluating the data of our multivariate regression analysis, it 
seems that these patients had a tumour with variable pathogenesis (Supplementary 
Table 1). The Mean OS was significantly shorter for the early recurrence group (19 
months; 95% Cl 16−21 months) than for the patients who had a late recurrence (30 
months; 95% Cl 26−35 months; p < 0.001). This result is comparable with that of 
previous studies, which showed early recurrence after CRS+HIPEC to be associated 
with a decrease in OS.1,19,21,26,42-45 These findings illustrate the difficulty of predicting 
early recurrence after CRS+HIPEC.
New avenues for research
In our total cohort, the average DFS was only 13 months after CRS+HIPEC, despite 
achievement of complete macroscopic CRS in 431 patients (99.5%). This indicates 
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that the outcomes of CRS+HIPEC might be further improved only if we focus on 
microscopic (invisible) disease. Local recurrence or colorectal PM will be caused in 
particular by insufficient treatment of microscopic disease and aggressive tumour 
biology, rather than by macroscopic visible peritoneal disease. For example, several 
studies have identified four molecular subtypes among patients with colorectal 
tumours, called the consensus molecular subtypes (CMS1 to CMS4).46-49 In particular, 
CMS4 represents highly aggressive tumours, which have been associated with 
worse DFS and OS. Tumour biology could be an additional selection criterion for 
CRS+HIPEC in the future.
High recurrence rates after CRS+HIPEC also could be caused by misinterpretation 
of the completeness of cytoreduction by the HIPEC surgeons. Surgeons still rely 
on visual and tactile inspection for intraoperative differentiation between tumour 
and benign tissue to reach a complete cytoreduction. A clear need exists for an 
intraoperative imaging technique to improve tumour detection. In recent years, 
optical molecular imaging using tumour−targeted fluorescence tracers has emerged 
as a promising real−time imaging technique to improve tumour detection.50-52 The 
first phase I clinical trials have been performed.53,54 Although no conclusions can be 
drawn to date with regard to the impact on clinical decision−making, it appears that 
molecular fluorescence−guided surgery has the potential to help identify tumour 
tissue during DLS and to attain a more complete cytoreduction during CRS+HIPEC.
Strengths and limitations
The current study included a relatively large sample. Follow−up evaluation between 
the patients with synchronous and those with metachronous colorectal PM did not 
differ and could therefore not explain the difference in DFS. Although data were 
prospectively maintained, some were missing, which may have had an impact on 
the results of this study. The patients included in this study underwent surgery in 
two highly experienced and high−volume HIPEC−centres. Thus, our results might 
not be generalisable to other medical centres.
We should take into account that the patients with synchronous colorectal PM more 
frequently had signet cell histology than those with metachronous colorectal PM. 
Moreover, they more frequently had an N2 status and were more frequently treated 
with neoadjuvant and adjuvant chemotherapy. However, we adjusted for these 
potential cofounders in the multivariate regression analysis, and the development 






Patients with metachronous colorectal PM have a worse DFS after CRS+HIPEC than 
patients with synchronous colorectal PM, whereas OS and surgical morbidity are 
similar between the two groups. Therefore, we recommend extra carefulness in the 
selection of patients with metachronous colorectal PM who have a PCI above 10 
for CRS+HIPEC, because of the markedly worse OS and DFS in this specific group of 
patients. Therefore, next to other risk factors for a worse outcome, time−to−onset 
of colorectal PM development should be taken into consideration to optimise patient 
selection for this major procedure.
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SUPPLEMENTARY DATA
Supplementary Table 1 | Baseline characteristics according to early and late recurrence after 






Age, y ± SD 65 ± 10 65 ± 11 0.271







Synchronous liver metastases, n (%)
Interval primary surgery to PM, 
months ±SD










21 (18.8) 23 (26.7) 0.704
11 (9.8) 6 (7.0) 0.139
17 ± 15 18 ± 29 0.017
Neoadjuvant chemotherapy, n (%) 14 (12.5) 14 (16.3) 0.104
Adjuvant chemotherapy, n (%) 19 (17.0) 22 (25.6) 0.129
T4 primary tumour, n (%) 47 (42.0) 48 (55.8) 0.059
Perforated primary tumour, n (%) 3 (2.7) 6 (7.0) 0.156
























Blood loss, ml ± SD 800 ± 1038 600 ± 1139 0.008
Stoma post−HIPEC, n (%) 62 (55.4) 43 (50.0) 0.741
Resection status, n (%)







Length of hospital stay, days ± SD 14 ± 15 11 ± 16 0.002








Re−operation, n (%) 18 (16.1) 11 (12.8) 0.092
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The aim of the present study was to determine the feasibility and safety of 
performing diagnostic laparoscopy (DLS) routinely in patients with suspicion of 
colorectal peritoneal metastases (PM) to evaluate suitability for cytoreductive 
surgery with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC).
Methods
Data for consecutive patients who underwent DLS between 2012 and 2018 were 
extracted retrospectively from an institutional database. The primary outcome 
was the degree of visibility of the abdominal cavity during DLS. Good laparoscopic 
evaluation of the abdominal cavity was defined as visibility of at least the regions 
of the diaphragm, pelvis and small bowel. Secondary outcomes were reasons for 
perioperative exclusion for CRS+HIPEC, major postoperative complications (Clavien−
Dindo grade III or above) and difference in overall survival (OS) between patients 
deemed suitable or non­suitable for CRS+HIPEC. Kaplan−Meier analyses were 
performed.
Results
Some 184 patients were analysed. Good laparoscopic evaluation was possible in 
138 patients (75.0%), and 24 (13%) had conversion to an open procedure. Ninety­
three patients (50.5%) were excluded for CRS+HIPEC, most commonly because of 
absence of colorectal PM (34 patients, 37%) or extensive disease (peritoneal cancer 
index 20 or above)(33 patients, 35%). Major complications occurred in five patients 
(2.7%), with no postoperative deaths. Median OS was significantly decreased in 
patients who were excluded due to extensive disease (14 months; 95% CI 10−18 
months) compared with patients suitable for CRS+HIPEC (35 months; 95% Cl 30−40 
months; p < 0.001).
Conclusion
Routinely performing DLS in patients with suspicion of colorectal PM to evaluate 
suitability for CRS+HIPEC is feasible and safe, avoiding the morbidity of an 
unnecessary laparotomy in patients with extensive disease.
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INTRODUCTION
Patients with resectable peritoneal metastases (PM) from colorectal cancer can be 
treated with cytoreductive surgery combined with hyperthermic intraperitoneal 
chemotherapy (CRS+HIPEC).1-4 This abdominal procedure begins with surgical 
removal of all visible tumour tissue followed by perfusion of the peritoneal cavity 
with heated chemotherapy to eliminate remaining microscopic disease.5 The 
most powerful prognostic factors for survival after CRS+HIPEC are the extent 
of peritoneal disease (measured with the peritoneal cancer index [PCI]) and 
completeness of the performed cytoreduction (measured with the completeness 
of cytoreduction score [CC]).2,6-8 CRS+HIPEC can be performed with curative 
intent only in patients with colorectal PM with a PCI of less than 20 in whom a 
(nearly) complete cytoreduction can be achieved (for example CC−0, no visible 
residual disease, or CC−1, residual tumour deposits smaller than 2.5 mm).3,7,9-11
Current preoperative imaging modalities fail to estimate the PCI in order to predict 
the possibility of achieving a complete cytoreduction.12-14 Direct visualization of the 
abdominal cavity and its contents, such as the small bowel, seems to be the only 
reliable method to assess PCI and tumour resectability. Up to 50% of patients with 
colorectal PM are excluded for CRS+HIPEC directly on exploratory laparotomy.15-17 
Identification at an earlier stage in patients for whom CRS+HIPEC is not suitable 
could spare them the morbidity of an unnecessary laparotomy.
Direct visualisation can also be achieved with diagnostic laparoscopy (DLS), to 
evaluate the presence and resectability of colorectal PM. Some argue that adhesions 
from the cancer or previous abdominal surgery impede optimal visualisation during 
DLS, which could result in an underestimation of the PCI and an increased rate of 
intraoperative and postoperative complications. In contrast, seven retrospective 
studies concluded that DLS is a safe, feasible, and accurate staging tool for assessing 
tumour burden in patients with PM.15-21 Therefore, several institutions worldwide 
perform DLS routinely in patients with PM to investigate their presence and 
resectability. However, current publications on this subject have involved small 
series of patients with PM from a variety of primary tumour types and, most 
importantly, DLS was used in a mostly selective way and not incorporated into a 
standard preoperative workup for CRS+HIPEC.
The aim of the present study was to determine the feasibility and safety of performing 
DLS routinely in all patients with suspicion of colorectal PM to evaluate suitability for 





Design, setting, and patients
Data for all consecutive patients with suspicion of colorectal PM, based on recent 
imaging or a surgical procedure, who had DLS to examine the presence and extent 
of peritoneal disease between January 2012 and August 2018 were extracted 
retrospectively from a prospectively maintained institutional database. The study 
was approved by the Institutional Ethics Committee of the University Medical Center 
Groningen (METc 201800395).
Preoperative evaluation and staging
All patients had a standard preoperative assessment to confirm the presence of 
colorectal PM and to evaluate eligibility for CRS+HIPEC. All were staged by thoracic, 
abdominal, and pelvic computed tomography (CT). Patients with suspicion of 
colorectal PM who might be a candidate for CRS+HIPEC routinely underwent 
DLS to confirm the diagnosis of colorectal PM and to evaluate resectability of the 
metastases.
A multidisciplinary team consisting of a radiologist, gastroenterologist, medical 
oncologist, and oncological surgeons then determined eligibility for CRS+HIPEC 
according to the preoperative assessment. Contraindications to CRS+HIPEC 
included: moderate or severe co−morbidity (American Society of Anaesthesiologists 
[ASA] score above 3); extra−abdominal metastases; massive disease involvement 
of the small bowel or its mesentery; extensive peritoneal disease (PCI 20 or above); 
unresectable primary tumour; invasive growth into the retroperitoneal space; and 
Eastern Cooperative Oncology Group performance status (ECOG) greater than 2. 
Patients with no colorectal PM during DLS were also excluded from CRS+HIPEC.
Laparoscopic evaluation
Under general anaesthesia, a pneumoperitoneum was established by using an 
optical trocar. The site of first port placement during DLS was based on imaging 
and clinical findings of the patient. The 30⁰ laparoscope was introduced through 
an umbilical port. One or two additional operative trocars were positioned on 
the left and right side of the optical trocar under direct vision. Adhesiolysis was 
performed minimally. All visible areas of the peritoneal cavity were reviewed 
systematically. In all patients the laparoscopic PCI and possibility of performing a 
complete cytoreduction were determined and recorded in the operation report. 
Cytology samples and biopsies were taken as indicated. When the tumour size was 
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unacceptably large or there was unresectable disease at DLS, palliative surgery was 
performed at the surgeon’s discretion. The main reasons for perioperative exclusion 
in patients deemed unsuitable for CRS+HIPEC were noted in the medical record.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Each CRS+HIPEC procedure was started with an exploratory laparotomy. CRS was 
performed only when the colorectal PM were deemed to be completely resectable, 
whereas HIPEC was performed only when there was complete or nearly complete 
cytoreduction. CRS+HIPEC was performed according to the standardised Dutch 
HIPEC protocol.22 The CC score was classified at the end of the cytoreduction: CC−0, 
no residual tumour visible or palpable in the peritoneal cavity; CC−1, residual tumour 
deposits small than 2.5 mm; CC−2, residual tumour between 2.5 mm and 2.5 cm; 
and CC−3, residual tumour larger than 2.5 cm or a confluence of nodules.23 After 
cytoreduction, HIPEC was performed in patients with CC−0 (complete) or CC−1 
(nearly complete) cytoreduction according to the open Coliseum technique with 
mitomycin C (35 kg/m2) for 90 minutes at 40−41 ⁰C.
Follow−up
Physical examination and carcinoembryonic antigen (CEA) measurements were 
performed on a 3−monthly basis for at least 4 years. When disease recurrence was 
suspected (for example, clinical symptoms or increase in CEA level), CT of thorax 
and abdomen was performed, with tissue biopsies in selected patients.
Data collection
Data on patient characteristics, tumour characteristics, operative details, 
postoperative morbidity and mortality, and overall survival (OS) were collected 
prospectively. Data on perioperative reasons for exclusion for CRS+HIPEC were 
obtained retrospectively by reviewing the digital medical records.
Primary and secondary outcomes
The primary outcome was the degree of visibility of the abdominal cavity during 
DLS: grade I, visibility of two or fewer abdominopelvic regions; grade II, visibility of 
three to eight abdominopelvic regions; grade III, visibility of at least the diaphragm, 
pelvis and small bowel regions; or grade IV, visibility of all 13 abdominopelvic 
regions. Grade III or IV was deemed necessary for adequate judgement of the 
extent of disease, and therefore defined as a good laparoscopic evaluation of the 
abdominal cavity. Secondary outcomes were the proportion of patients excluded for 




complications, and OS in suitable and unsuitable patients. Major postoperative 
complications were defined as grade III or above according to the Clavien−Dindo 
classification system.24 OS was defined as the time between DLS and death, or date 
of last follow−up in censored cases.
Statistical analyses
All statistical analyses were conducted using SPSS Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA). Continuous values with a normal distribution are 
given as mean ± standard deviation (SD) and those without a normal distribution as 
median (interquartile range [IQR]). Categorical variables are reported as numbers with 
percentages. Patient and tumour characteristics were compared and analysed using 
the χ2 test. The Kruskal−Wallis H test was used for continuous variables. Kaplan−Meier 
survival analyses were performed to describe OS for the different groups of patients. All 
test were performed two−sided and p < 0.050 was considered statistically significant.
RESULTS
Baseline characteristics
Data for all 184 patients with suspicion of colorectal PM who had undergone DLS 
between January 2012 and August 2018 were analysed. During DLS, 91 patients 
(49.5%) were deemed suitable for CRS+HIPEC, and 93 patients (50.5%) were rejected 
for the procedure. The group of 93 patients deemed unsuitable for CRS+HIPEC was 
very heterogeneous, and for further analyses was subdivided into the following 
categories: no indication for CRS+HIPEC because of absence of colorectal PM 
(29 patients); signs of extensive disease (54 patients); and other reasons for 
perioperative exclusion (10 patients).
Table 1 provides an overview of patient and tumour characteristics for the entire 
cohort, and a comparison of these characteristics between patients suitable for 
CRS+HIPEC and patients who were unsuitable. Patients who were unsuitable for 
CRS+HIPEC owing to signs of extensive disease presented more frequently with 
signet ring cell histology compared with those who were suitable for CRS+HIPEC 
(20.4 vs 8.8%, respectively; p < 0.001). Patients with no indication for CRS+HIPEC 
were less likely to have an N2 status than those who were suitable for CRS+HIPEC 
(11 vs 40%, respectively; p = 0.034). The median age of patients who were unsuitable 
for CRS+HIPEC for other reasons was greater than that of patients who were suitable 
for CRS+HIPEC (74 vs 65 years, respectively; p = 0.021). Other baseline characteristics 
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Perioperative reasons for exclusion for CRS+HIPEC
Table 2 presents an overview of the reasons for perioperative exclusion of the 93 
patients (50.5%) deemed unsuitable for CRS+HIPEC. The reasons can be divided 
into five categories: absence of colorectal PM; signs of extensive disease; patient 
characteristics; severe complications after DLS; and tumour biology. In the majority 
of the patients (65%) only one reason resulted in exclusion for CRS+HIPEC, whereas 
for fewer patients two (28%) or three reasons (8%) reasons led to the exclusion. The 
most common perioperative reasons for exclusion for CRS+HIPEC were: absence 
of colorectal PM in 34 patients (37%) and extensive peritoneal disease (PCI 20 or 
above) in 33 patients (35%). Other signs of extensive disease (widespread colorectal 
PM in the small bowel, unresectable primary tumour, liver or lung metastases, or 
an indication for neoadjuvant chemotherapy) were present in 35 patients (38%). 
Patient characteristics were less frequently the perioperative reason for exclusion 
for CRS+HIPEC: age in three patients (3%), poor patient condition in three patients 
(3%), and presence of severe co−morbidity in five patients (5%).
Table 2 | Reasons for perioperative exclusion for CRS+HIPEC during diagnostic laparoscopy.
Criteria No. of patients (n = 93)




No signs of colorectal PM, n (%) 34 (37)
Signs of extensive disease, n (%)
PCI >20 33 (35)
Probably PCI too high during open procedure* 6 (6)
Widespread colorectal PM in bowel/mesentery 7 (8)
Rapid progression of disease 7 (8)
Indication for neoadjuvant therapy 5 (5)
Liver metastases 4 (4)
Lung metastases 5 (5)
Unresectable primary tumour 1 (1)
Patient characteristics, n (%)
Patient preference 7 (8)
Co−morbidity 5 (5)
Patient condition 3 (3)
Patient age 3 (3)
Severe complications after DLS, n (%) 3 (3)
Tumour biology (signet cell histology), n (%) 2 (2)
* Peritoneal cancer index (PCI) during diagnostic laparoscopy (DLS) below 20, but 




Visibility of abdominal cavity during diagnostic laparoscopy
Grade III or IV visibility of the abdominal cavity was possible in 138 of the 184 
patients (75.0%) (Table 3). In 24 patients (13.0%) DLS was converted to an open 
procedure because of an inadequate laparoscopic overview. Grade of visibility of 
the abdominal cavity during DLS was not significantly different between patients 
who were suitable and those who were unsuitable for CRS+HIPEC due to absence 
of colorectal PM or extensive disease (p = 0.807). In the small group of patients 
who were unsuitable for CRS+HIPEC for other reasons, the grade of visibility of the 
abdominal cavity was poor overall (7 of 10 patients, 70%; p = 0.008).
Surgical morbidity and mortality
Table 3 presents postoperative morbidity rates after DLS, by type and severity 
according to the Clavien−Dindo classification system.24 Major postoperative 
complications occurred in five patients (2.7%), who were all deemed not suitable 
for CRS+HIPEC. Three patients (1.6%) with symptoms of preoperative obstruction 
received direct palliative surgery during DLS without any subsequent clinical 
improvement. In one morbidly obese patient, a widespread haematoma of the 
abdominal wall was infected after DLS and required surgical evacuation at three 
different time points. In the fifth patient, myocardial infarction was diagnosed 
immediately after DLS. Following percutaneous coronary intervention, the patient 
recovered successfully within 7 days.
Treatment strategies after diagnostic laparoscopy
The different treatments that patients received after DLS are presented in Tables 4 
and 5 according to suitability for CRS+HIPEC. Only 75 of the 91 patients (82%) deemed 
suitable for CRS+HIPEC eventually underwent the full procedure. The remaining 16 
patients (18%) had an open−close procedure after exploratory laparotomy (non−
therapeutic laparotomy), due to a high PCI (9 patients), excessive involvement of 
the small bowel (2 patients), unresectable primary tumour (4 patients) or liver 
metastases (1 patient). In retrospect, good or excellent laparoscopic evaluation of 
the abdominal cavity during DLS had been possible in 12 of these 16 patients. In 
the remaining four patients it was not possible to investigate all abdominopelvic 
regions but it was estimated that the PCI would probably be below 20.
In patients deemed unsuitable for CRS+HIPEC, treatment strategy depended on the 
perioperative reason(s) for exclusion (Table 5). Fourteen of the 29 patients (48%) 
who had a primary tumour in situ with no colorectal PM had surgery with curative 
intent. Most patients with no primary tumour in situ did not receive any additional 
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treatment (7 patients, 24%). During a median follow−up of 16 months (95% CI 
14−28 months), four of these 29 patients (14%) developed additional colorectal PM, 
diagnosed in only two patients (7%) within 6 months after DLS.
In the 54 patients unsuitable for CRS+HIPEC with signs of extensive disease, palliative 
treatment strategies consisted of comfort care (24%), palliative chemotherapy (37%), 
radiotherapy (4%) or a combination of treatments (17%).The majority of patients who 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4 | Treatment received after diagnostic laparoscopy in patients deemed suitable for 
CRS+HIPEC.
No. of patients (n = 91)
Type of HIPEC, n (%)
Open CRS+HIPEC 75 (82)
Open−close procedure 16 (18)
Reason for open−close procedure, n (%)
PCI too high 9 (56)
Small bowel involvement 2 (13)
Unresectable primary tumour 4 (25)
Liver metastases 1 (6)
No. of anatomical resections, median [IQR] 4 [2­7]







No. of anastomoses, n (%)
0 36 (40)
1 39 (43)
≥ 2 16 (18)
Stoma after HIPEC, n (%) 40 (44)
Stoma type, n (%)
Double−barrel ileostomy 2 (5)
Ileostomy 7 (18)
Double−barrel colonostomy 3 (8)
Colonostomy 28 (70)
Blood loss, mL, median [IQR] 600 [200−1188]
Duration of surgery, min, median [IQR] 471 [370−523]
CC score, n (%)
0 74 (81)
1 3 (3)
≥ 2 14 (15)
Length of hospital stay, days, median [IQR] 19 [13−27]
Clavien−Dindo complication rate, n (%)
No complications 29 (32)
I-II 31 (34)
≥ III 31 (34)
Reoperation, n (%) 16 (18)
Adjuvant chemotherapy, n (%) 26 (29)
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Table 5 | Treatments received after diagnostic laparoscopy in patients who were deemed 
unsuitable for CRS+HIPEC.
No. of patients (n = 93)
No indication for CRS+HIPEC (n = 29)
No/palliative treatment, n (%) 7 (24)
Systemic chemotherapy, n (%) 3 (10)
Combined treatments, n (%) 5 (17)
Curative surgery, n (%) 14 (48)
Not suitable for CRS+HIPEC due to extensive disease (n = 54)
No/palliative treatment, n (%) 13 (24)
Systemic chemotherapy, n (%) 20 (37)
Radiotherapy, n (%) 2 (4)
Combined treatments, n (%) 9 (17)
Unknown, n (%) 10 (19)
Not suitable for CRS+HIPEC for other reasons (n = 10)
No/palliative treatment, n (%) 4 (40)
Palliative surgery, n (%) 2 (20)
Systemic chemotherapy, n (%) 1 (10)
Combined treatments, n (%) 1 (10)
Unknown, n (%) 2 (20)
Survival outcomes
Figure 1 shows the median OS after DLS between patients who were suitable for 
CRS+HIPEC and those who were not suitable owing to the absence of colorectal PM, 
signs of extensive disease, or other reasons for perioperative exclusion. Median OS 
for patients deemed suitable for CRS+HIPEC was 36 months (95% CI 27−45 months), 
and that the three subgroups of patients deemed unsuitable was 49 months (95% 
CI 40−60 months), 14 months (95% Cl 10−18 months) and 24 months (95% Cl 9−38 




Figure 1 | Kaplan−Meier survival curves according to suitability and different reasons for 
perioperative exclusion for CRS+HIPEC.
DISCUSSION
In this observational study of 184 consecutive patients with suspected colorectal 
PM, routinely performed laparoscopic evaluation of the abdominal cavity was 
possible in the majority of the patients, with a low risk of major postoperative 
morbidity. The study demonstrates that patients with extensive disease can be 
spared an unnecessary laparotomy.
 
The extent of peritoneal disease (PCI) and the possibility of achieving a complete 
cytoreduction are the most powerful prognostic factors for survival after CRS+HIPEC, 
and as current preoperative imaging modalities fail to predict PCI and complete 
cytoreduction, direct visualisation of the abdominal cavity appears to be the only 
reliable way to assess both prognostic factors. To spare patients the morbidity of a 
laparotomy, the presence and resectability of colorectal PM could be evaluated by 
DLS as part of a two−step approach. In this study, good or excellent laparoscopic 
evaluation of the abdominal cavity was possible in 75% of patients with suspected 
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colorectal PM, despite the fact that 83.7% of these patients had a history of previous 
abdominal surgery. Major postoperative complications occurred in only five patients 
(2.7%), with no postoperative deaths.
Comparison of the main results of the present study with those from the seven 
previously published retrospective studies on the value of DLS in the preoperative 
workup for CRS+HIPEC is challenging.15-21 There are striking differences in patient 
populations, tumour types, definitions of a good laparoscopic evaluation of the 
abdominal cavity, and the indications for performing DLS or CRS+HIPEC. None of 
the other studies focused solely on patients with suspicion of PM of colorectal origin; 
three to nine primary tumour types were included per study. The number of patients 
with suspected colorectal PM in these studies ranged from 11 to 74. In most studies, 
it was not possible to subtract the data from patients with colorectal PM from the 
entire cohort. Only three studies made use of DLS as part of a two−step approach for 
CRS+HIPEC. 15,17,19 In these three studies, complete laparoscopic evaluation according 
to the PCI scoring system was possible in 73−86% of the patients with PM. DLS 
resulted in 28−57% of the patients being excluded for CRS+HIPEC. These results are 
in line with those of the present study. All studies used different definitions of a good 
laparoscopic evaluation of the abdominal cavity, and three studies gave no definition 
at all. Only von Breitenbuch and colleagues used a definition similar to that is used in 
the present study, resulting in a good laparoscopic evaluation in 88% of patients with 
no history of previous abdominal surgery and in 70% of those with such a history.20 
Postoperative complication rates from the seven retrospective studies ranged 
between 0 and 2%.15-21 These studies included only patients without palliative surgery 
during DLS, and for this specific group the results of the present study are comparable.
Another important finding of the present study was the unexpectedly high rate 
(50.5%) of patients who were potential candidates for CRS+HIPEC according to 
preoperative imaging, but were eventually deemed not suitable for CRS+HIPEC 
during DLS. On the one hand this reflects the low validity of imaging for colorectal 
PM to predict the presence and extent of peritoneal disease, and on the other hand 
it supports the added value of DLS before CRS+HIPEC; almost half of the patients 
with suspicion of colorectal PM were spared unnecessary laparotomy by performing 
a DLS. Findings in the present study were comparable to those of the other three 
studies that used DLS in a standardised way.15,17,19
A good laparoscopic evaluation of the abdominal cavity in patients with suspicion of 




likelihood of complete cytoreduction, thereby avoiding an unnecessary laparotomy, 
but also confers several other advantages. First, DLS allows tissue samples from 
suspicion lesions to be obtained for analysis or cytological examination. Cytological 
analysis is gaining in importance, as positive peritoneal cytology seems to be 
independently associated with a poor median OS compared with negative cytology.24 
Biopsies from suspicious lesions can confirm the presence or absence of peritoneal 
disease. For example, in the present study, biopsy prevented an unnecessary 
laparotomy in 34 patients without colorectal PM (37%). Furthermore, biopsies can 
provide additional information for future systemic therapy or identify a previously 
unknown primary tumour. Patients who are deemed unsuitable for CRS+HIPEC 
because of extensive disease can undergo additional systemic or palliative 
chemotherapy at an earlier stage than patients who are still recovering from a 
non−therapeutic laparotomy. In patients who seem suitable for CRS+HIPEC, DLS can 
provide more detailed information on the burden and location of disease before 
CRS+HIPEC. This can result in a better informed consent at the outpatient clinic, and 
may reduce patient anxiety regarding the exact extent of the procedure. Finally, it is 
also possible during DLS to identify patients who are not fit enough for major surgery.
The present study has some limitations owing to its retrospective design and 
the fact that all patients came from a single centre. It is possible that the positive 
results regarding the visibility of the abdominal cavity during DLS were due to 
extensive experience of the HIPEC surgeons in performing DLS in patients with a 
history of previous abdominal surgery, and may therefore not be extrapolated to 
all centres. No patient deemed unsuitable for CRS+HIPEC during DLS underwent 
an exploratory laparotomy to confirm this assumption. The authors suspect that 
DLS would understage rather than overstage the extent of peritoneal disease in 
patients with signs of extensive disease. Therefore, the assumption that a patient 
is deemed unsuitable for CRS+HIPEC due to extensive disease would probably not 
change during exploratory laparotomy. However, small peritoneal lesions might 
be missed during DLS, leading to a false−negative conclusion. In the present study, 
the likelihood of this appeared to be low, as only two of 29 patients (7%) developed 
colorectal PM within 6 months after a negative DLS.
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Preventing non−therapeutic laparotomies 
















To evaluate the introduction of diagnostic laparoscopy (DLS) in patients with 
colorectal peritoneal metastases (PM) to prevent non−therapeutic laparotomies 
during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy 
(CRS+HIPEC).
Methods
Patients with histologically proven colorectal PM who underwent a laparotomy 
for potential CRS+HIPEC from January 2006 to January 2019 were retrospectively 
identified from a prospectively maintained database. In 2012, DLS was introduced in 
the preoperative workup for CRS+HIPEC in our academic centre. The rates of non−
therapeutic laparotomies, major postoperative complications (Clavien−Dindo ≥III), 
and survival outcomes were investigated for patients who underwent a laparotomy 
before the introduction of DLS (cohort A) and patients who underwent a laparotomy 
after the introduction of DLS (cohort B). Reasons to refrain from DLS in cohort B 
were retrospectively explored from medical records.
Results
One hundred and seventy−two patients were included (cohort A, 48 patients [27.9%]; 
cohort B, 124 patients [72.1%]). A significant drop in the rate of non−therapeutic 
laparotomies occurred in cohort B compared to cohort A (21.0 vs 35.4%, p = 0.044, 
respectively), despite only 85 patients (68.5%) from cohort B undergoing DLS in our 
academic centre. The most important reason to refrain from DLS was a recently 
performed DLS or laparotomy in the referring hospital (48.7%). Major postoperative 
complications, in−hospital mortality, and survival outcomes were similar for both 
cohorts.
Conclusions
Performing DLS during the preoperative workup for CRS+HIPEC prevents non−
therapeutic laparotomies in patients with colorectal PM. We recommend performing 




Worldwide, carefully selected patients with limited and resectable colorectal 
peritoneal metastases (PM) are treated with cytoreductive surgery (CRS) followed by 
hyperthermic intraperitoneal chemotherapy (HIPEC) with the aim of achieving long−
term survival.1-5 Patients with low tumour burden, as expressed by the peritoneal 
cancer index (PCI), and in whom a complete cytoreduction of all macroscopic 
visible colorectal PM can be achieved (CC−0) benefit the most from this extensive 
surgical procedure in terms of survival.5-9 Therefore, CRS+HIPEC for patients with 
colorectal PM is restricted to those with a PCI ≤20, in whom a complete macroscopic 
cytoreduction can be reached.8-11
Today, surgical oncologists are still discovering the real extent and potential 
resectability of colorectal PM at the time of operative exploration, as current 
imaging modalities underestimate both important prognostic factors.12-14 
Unfortunately, 20–40% of these patients are excluded for CRS+HIPEC directly after 
exploratory laparotomy, resulting in an open−close procedure (i.e., non−therapeutic 
laparotomy).15,16 For patients, this is a very undesirable postoperative outcome, as 
it is not only associated with a significant risk of postoperative complications and 
a diminished quality of life (QoL) in the short term but also delays enrolment into 
other therapies. From a healthcare perspective, an aborted CRS+HIPEC procedure 
is expensive and lead to a longer wait list.
Suggestions have been made to use diagnostic laparoscopy (DLS) in the 
preoperative workup for CRS+HIPEC to prevent non−therapeutic laparotomies 
during cytoreductive surgery in patients with colorectal PM.17,18 Several studies show 
that DLS is an accurate and safe staging tool in patients with peritoneal disease.16,18-23 
However, the limitations of these studies are the variety of primary tumours that 
are included and the highly selected way a DLS is used. Since 2012, HIPEC surgeons 
from our academic centre have introduced DLS as part of the preoperative workup 
for CRS+HIPEC to prevent unnecessary laparotomies. This provides the opportunity 
to compare a historical cohort of patients with colorectal PM who were scheduled 
for CRS+HIPEC before the introduction of DLS to those with colorectal PM who 
were scheduled for CRS+HIPEC after DLS was part of the preoperative workup. 
Our aim was to evaluate the implementation of DLS in the preoperative workup 






Design, setting, and participants
All consecutive patients with histologically proven colorectal PM who underwent 
an exploratory laparotomy for potential CRS+HIPEC from January 2006 to January 
2019 were retrospectively identified from a prospectively maintained institutional 
database. Patients were divided into two different cohorts according to their 
operation date to evaluate the implementation and impact of performing DLS 
during the preoperative workup for CRS+HIPEC to prevent non−therapeutic 
laparotomies. Study cohort A consisted of a historical group of patients with 
colorectal PM who underwent an exploratory laparotomy for potential CRS+HIPEC 
before the introduction of DLS in the preoperative workup for CRS+HIPEC ( January 
2006 to December 2011), and study cohort B consisted of patients with colorectal 
PM who underwent an exploratory laparotomy for potential CRS+HIPEC after the 
introduction of DLS in the preoperative workup for CRS+HIPEC ( January 2012 to 
January 2019). The Ethics Committee of the University Medical Center Groningen 
approved this study (METc 201800395).
Primary and secondary outcomes
The primary outcome was the rate of non−therapeutic laparotomies during 
cytoreductive surgery for cohorts A and B. Secondary outcomes were major 
postoperative complications, in−hospital mortality, disease−free survival (DFS), and 
overall survival (OS). Furthermore, to evaluate the implementation of DLS in the 
preoperative workup, we calculated the number of patients who did not undergo 
DLS in our academic centre after the introduction of DLS in the preoperative workup 
for CRS+HIPEC (i.e., cohort B). Reasons for refraining from DLS were retrospectively 
explored from digital medical records.
Major postoperative complications are defined as grade 3 or higher according 
to the Clavien−Dindo classification system and registered up to 90 days after 
surgery.24 These types of complications require endoscopic, radiologic, or surgical 
interventions or admission to the intensive care unit. Postoperative mortality is 
defined as death within 30 days after surgery. OS is defined as the time between the 
initial exploratory laparotomy and death or date of last follow−up in censored cases. 
DFS was defined as the time between CRS+HIPEC and the date of first recurrence 
or last follow−up in censored cases.
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Preoperative evaluation and staging
All referred patients with colorectal PM underwent a standardised preoperative 
evaluation to investigate the extent and resectability of the peritoneal disease 
and rule out other distant metastases. All patients were staged with a computed 
tomography (CT) of thorax, abdomen, and pelvis. Since 2012, laparoscopic evaluation 
in our academic centre has been part of the preoperative workup for CRS+HIPEC 
to further assess the extent of colorectal PM and the possibility of performing a 
complete cytoreduction. Patients with an absolute contra−indication for CRS+HIPEC 
on imaging (i.e., extra−abdominal metastases or more than three liver metastases) 
were directly referred to a medical oncologist and did not undergo DLS. These patients 
are not represented in this manuscript as they were not scheduled for CRS+HIPEC.
Every laparoscopic evaluation was performed under general anaesthesia and 
a pneumoperitoneum was established by using an optical trocar. In all cases, 
a 30° laparoscope was used and introduced through an umbilical port. One or 
two additional trocars were placed under direct vision according to the surgeon’s 
discretion. All thirteen abdominopelvic regions of the peritoneal cavity were 
systematically reviewed and adhesiolysis was only performed when deemed 
necessary. The laparoscopic PCI was calculated and the possibility to perform a 
complete cytoreduction during an exploratory laparotomy was estimated. The 
visibility of each abdominopelvic region, the laparoscopic PCI, and the possibility 
to achieve a complete cytoreduction were all recorded in the operation report. 
Cytology samples and biopsies were only taken as indicated. During several expert 
sessions with our four HIPEC surgeons we created a 4−point scale for the degree 
of visibility of the abdominal cavity during DLS (i.e., grade I; visibility of two or less 
abdominopelvic regions, grade II; visibility of three to eight abdominopelvic regions, 
grade III; visibility of at least diaphragm regions, pelvis region and small bowel 
regions , and grade IV; visibility of all thirteen abdominopelvic regions).
Hereafter, during a weekly multidisciplinary meeting, eligibility for CRS+HIPEC 
was determined by an experienced team consisting of medical oncologists, 
gastroenterologists, radiologists, and oncologic surgeons. In general, patients with 
colorectal PM were considered eligible for CRS+HIPEC when they met the following 
criteria: (I) PCI ≤ 20; (II) resectable primary tumour; (III) absence of extra−abdominal 
metastases; (IV) absence of massive peritoneal disease involvement of the small 
bowel or its mesentery; (V) Eastern Cooperative Oncology Group (ECOG) performance 
status ≤3; and (VI) American Society of Anaesthesiologists (ASA) <3. Up to three 




Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
CRS+HIPEC was performed according to the Dutch protocol.3 In summary, CRS was 
performed only in patients with completely resectable colorectal PM, and HIPEC 
was performed only after reaching a complete or nearly complete cytoreduction.
Each procedure started with an exploratory laparotomy to calculate the PCI score 
and judge resectability of the colorectal PM. The procedure was terminated in cases 
where the patient was deemed not suitable for CRS+HIPEC, and palliative surgery 
was performed only according to the surgeon’s discretion (i.e., non−therapeutic 
laparotomy). Patients with resectable colorectal PM underwent CRS with the aim of 
removing all visible tumour tissue. The resection status after CRS was judged with 
the completeness of cytoreduction score (CC−score).25 CC−0 indicates no visible or 
palpable residual tumour tissue in the peritoneal cavity; CC−1 indicates residual 
tumour deposits <2.5 mm; CC−2 indicates residual tumour deposits between 2.5 
mm and 2.5 cm; and CC−3 indicates residual tumour deposits >2.5 cm or confluence 
of unresectable tumour deposits at any site within the abdomen or pelvis.
HIPEC was performed in the case of a complete (CC−0) or nearly complete (CC−1) 
cytoreduction, whereby the abdominal cavity was perfused with mitomycin C (35 mg/
m2) according to the open Coliseum technique, with a temperature of 40−41 °C for 90 
min.26 After HIPEC, reconstruction surgery including bowel anastomoses, and if deemed 
necessary a colostomy, was performed. All patients were admitted to the intensive care 
unit for at least one postoperative day until cardiac and pulmonary functions were normal.
Follow up
Clinical follow−up occurred within one month after surgery and thereafter on a 
quarterly basis for a minimum of 5 years. In the case of suspected recurrence based 
on clinical symptoms or an increase in carcinoembryonic antigen (CEA) level, a CT 
of the thorax and abdomen was performed.
Data collection
Relevant data were prospectively collected in an institutional database and 
consisted of patient characteristics, tumour characteristics, extent of peritoneal 
disease, previous treatments, operative characteristics, postoperative mortality 
and morbidity, and short− and long−term survival outcomes.
Reasons to refrain from DLS after the introduction in 2012 were retrospectively 




All statistical analyses were conducted using SPSS® Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA). Categorical variables are reported as number 
(n) and percentages (%) and were analysed using the χ2 test or Fisher’s exact test. 
Continuous variables are reported as median (interquartile range [IQR]) or mean 
± standard deviation (SD) and were analysed using a Student’s t test or the Mann–
Whitney U test. Kaplan–Meier survival analyses were performed to describe DFS 
and OS for study cohorts A and B. All tests were performed two−sided, and a p value 
below 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
One hundred seventy−two patients with histologically proven colorectal PM 
underwent an exploratory laparotomy for potential CRS+HIPEC in our academic 
centre between January 2006 and January 2019. Forty−eight patients (27.9%) 
underwent an exploratory laparotomy before the introduction of DLS in the 
preoperative workup for CRS+HIPEC (i.e., cohort A), whereas 124 patients (72.1%) 
underwent an exploratory laparotomy after the introduction of DLS in the 
preoperative workup for CRS+HIPEC (i.e., cohort B). Table 1 shows a comparison 
of patient characteristics and tumour characteristics between cohorts A and B. 
Patients from cohort B were on average older (62 vs 55 years, p < 0.002) and had a 
higher body mass index (BMI) (26.6 vs 23.4 kg/m2, p < 0.001). Furthermore, they were 
less frequently diagnosed with an N2 (41.1 vs 45.8%, p = 0.024) or M1 status (50.0 
vs 77.1%, p = 0.004), and were less frequently treated with adjuvant chemotherapy 
(25.0 vs 41.7%, p = 0.001). On the other hand, patients from cohort B were more 
frequently diagnosed with metachronous onset of colorectal PM (54.0 vs 33.3%, 




Table 1 | Baseline characteristics from all patients with colorectal PM who underwent an 
exploratory laparotomy for potential CRS+HIPEC stratified by the operation date (cohort A, 







Age, years, mean ± SD 55.0 ± 9.7 62 ± 9.9 0.002
Gender, female, n (%) 22 (45.8) 60 (48.4) 0.764
BMI, kg/m2, mean ± SD 23.4 ± 4.7 26.6 ± 4.7 <0.001
ASA, n (%) 0.871
1 6 (12.5) 19 (15.3)
2 37 (77.1) 91 (73.4)
3 5 (10.4) 14 (11.3)
4 0 (0.0) 0 (0.0)
Comorbidity, n (%)
Diabetes mellitus 4 (8.3) 11 (8.9) 0.379
Hypertension 7 (14.6) 26 (21.0) 0.256
Cardiac comorbidity 7 (14.6) 12 (9.7) 0.878
Lung comorbidity 7 (14.6) 13 (10.5) 0.206
Tumour characteristics
Primary tumour location, n (%) 0.455
Right colon 23 (47.9) 41 (33.1)
Transverse colon 2 (4.2) 10 (8.1)
Left colon 4 (8.3) 15 (12.1)
Sigmoid 13 (27.1) 40 (32.3)
Rectum 6 (12.5) 18 (14.5)
Signet cell histology, n (%) 4 (8.3) 12 (9.7) 0.759
T stage primary tumour, n (%) 0.087
≤3 18 (37.5) 56 (45.2)
4 25 (52.1) 66 (53.2)
N status primary tumour, n (%) 0.024
0 7 (14.6) 35 (28.2)
1 14 (29.2) 36 (29.0)
2 22 (45.8) 51 (41.1)
M status primary tumour, n (%)
0 9 (18.8) 57 (46.0) 0.004
1 37 (77.1) 62 (50.0)
Onset of colorectal PM, n (%)
Synchronous 32 (66.7) 57 (46.0) 0.015
Metachronous 16 (33.3) 67 (54.0)
Synchronous liver metastases, n (%) 4 (8.3) 12 (9.7) 0.785
Prior CRC treatments
Prior CRC surgery, n (%) 42 (87.5) 112 (90.3) 0.588
Prior chemotherapy, n (%) 14 (29.2) 48 (38.7) 0.360
Neoadjuvant chemotherapy, n (%) 4 (8.4) 24 (19.4) 0.568
Adjuvant chemotherapy, n (%) 20 (41.7) 31 (25.0) 0.001
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Table 2 | Treatment characteristics from all patients with colorectal PM who underwent an 
exploratory laparotomy for potential CRS+HIPEC stratified by the operation date (cohort A, 






DLS routinely performed, yes, n (%) 0 (0.0) 85 (68.5) <0.001
HIPEC type, n (%) 0.044
Open CRS+HIPEC 31 (64.6) 98 (79.0)
Open−close procedure 17 (35.4) 26 (21.0)
Main reason open−close procedure, n (%) 0.496
PCI>20 8 (47.1)¥ 13 (50.0)
Too much small bowel involvement₪ 4 (23.5) 4 (15.4)
Irresectable primary tumour∆ 2 (11.8) 7 (26.9)
Irresectable liver metastases 3 (17.6) 2 (7.7)
PCI at HIPEC, n (%) 0.121
0−5 4 (36.4) 34 (28.8)
6−10 2 (18.2) 26 (22.0)
11−15 0 (0.0) 20 (16.9)
16−20 0 (0.0) 16 (15.0)
21−25 3 (27.3) 13 (11.0)
>25 2 (18.2) 9 (7.6)
Total anatomic resections, median [IQR] 4 [1−6] 4 [2−7] 0.410
Anastomoses, n (%) 0.161
0 31 (64.6) 57 (46.0)
1 12 (25.0) 44 (35.5)
≥2 5 (10.5) 23 (18.5)
Stoma post−HIPEC, n (%) 21 (43.8) 63 (50.8) 0.406
Operation time, min, median [IQR] 493 [364−614] 471 [352−538] 0.217
Blood loss, mL, median [IQR] 700 [475−1325] 750 [500−1500] 0.790
Resection status, n (%) 0.126
CC−0 or CC−1 31 (64.6) 98 (79.0)
≥ CC−2 17 (35.4) 26 (21.0)
Length of hospital stay, days, median [IQR] 15 [10−21] 16 [12−24] 0.239
Reoperation, n (%) 4 (8.3) 15 (12.1) 0.480
In hospital mortality, n (%) 1 (2.1) 2 (1.6) 0.833
Complication rate, Clavien−Dindo, n (%) 0.424
Grade I 4 (8.3) 10 (8.1)
Grade II 14 (29.2) 40 (32.3)
Grade III 7 (14.6) 23 (18.5)
Grade IV 7 (14.6) 6 (4.8)
¥ During study period A (2006­2011) the PCI classification system was not used systematically 
in the Netherlands. In five patients with an open−close procedure from cohort A we concluded 
that the PCI would most likely have been above 20 based on the information from the 
operation report (i.e., extensive disease involvement of all nine abdominal regions).
₪ Massive peritoneal disease involvement of the small bowel or its mesentery, whereby 
removal very likely will lead to short bowel syndrome.





Table 2 presents the surgical characteristics of the exploratory laparotomy and 
postoperative morbidity rates for cohorts A and B.
None of the patients from cohort A underwent DLS during the preoperative workup 
for CRS+HIPEC, as it was not common clinical practice between 2006 and 2011. An 
unexpectedly low number of 85 patients (68.5%) underwent DLS in our academic 
centre after the introduction of DLS in the preoperative workup for CRS+HIPEC The 
number of non−therapeutic laparotomies for the entire cohort was 43 (25.0%). A 
non−therapeutic laparotomy occurred less frequently in cohort B when compared 
to historical cohort A (21.0 vs 35.4%, p = 0.044). Causes for the occurrence of a non−
therapeutic laparotomy did not differ between both cohorts (p = 0.496).
As the number of patients who underwent DLS in cohort B was unexpectedly low, 
additional analyses were performed to identify the direct effect of DLS on the 
prevention of non−therapeutic laparotomies. In this specific case, patients were 
no longer divided by their operation date (i.e., cohort A or B) but by whether they 
underwent DLS (n = 89) or not (n = 83). Non−therapeutic laparotomies occurred 
less frequently in patients who underwent DLS compared to patients who did not 
undergo DLS (18.0 vs 32.5%, respectively, p = 0.028).
Reasons to refrain from DLS
An overview of the reasons to refrain from DLS for patients in cohort B after the 
introduction of the preoperative workup for CRS+HIPEC is presented in Table 3a. 
Refraining from DLS in our academic centre was most frequently caused by the 
fact that the patient recently underwent a laparotomy (30.8%) or DLS (17.9%) in the 
referring hospital or a laparotomy in our own academic centre (17.9%). For these 
patients, in the decision−making process additional DLS in our academic centre after 
recent abdominal surgery was not considered useful. Furthermore, DLS was not 
performed in seven patients (17.9%) who showed a clear response to neoadjuvant 
chemotherapy on CT imaging. In six patients (15.4%), reasons to refrain from DLS 
could not be identified from the digital medical records.
Interestingly, in patients who did not undergo DLS after its introduction in the 
preoperative workup for CRS+HIPEC, a non­therapeutic laparotomy occurred in 
11 patients (28.2%). The specific reason for refraining from DLS was not predictive 
of an occurrence of a non−therapeutic laparotomy (p = 0.437) [data not shown]. 
There seemed to be a trend toward an increase in non−therapeutic laparotomies 
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in patients from cohort B who did not undergo DLS compared to patients from 
the same cohort who underwent DLS in the preoperative workup (28.2 vs 17.6%, 
respectively), but this trend did not reach significance (p = 0.107).
Laparoscopic evaluation
Table 3b presents the surgical characteristics of the DLS and postoperative 
morbidity rates of the 85 patients (68.5%) from cohort B who underwent DLS prior 
to exploratory laparotomy. Good laparoscopic evaluation of the abdominal cavity 
(i.e., grade ≥III) was possible in 64 patients (74.1%). The conversion rate during DLS 
amounted to 21.2%, and no reoperations occurred. The postoperative complication 
rate was low (3.5%) and consisted only of Clavien–Dindo grade II complications 
(i.e., urinary tract infection and bacteraemia). In patients who underwent DLS in 
the preoperative workup for CRS+HIPEC, only 15 non−therapeutic laparotomies 
(17.6%) occurred.
Surgical morbidity and mortality
Table 2 presents the surgical characteristics of the exploratory laparotomy and 
the postoperative morbidity rates for cohorts A and B. One hundred and twenty−
nine patients (75.0%) underwent CRS+HIPEC during an exploratory laparotomy. 
Treatment characteristics, consisting of the number of anatomic resections, PCI 
score, operating time, blood loss, and resection status, were similar for both cohorts.
Major postoperative complications after exploratory laparotomy occurred in 14 
patients (29.2%) from cohort A and in 29 patients (23.4%) from cohort B (p = 0.424). 
Relaparotomy was necessary in 4 (8.3%) and 15 patients (12.1%), respectively 





Table 3a | Reasons for not performing a DLS routinely in patients with colorectal PM from 
cohort B (n = 39).
Reasons for not performing DLS routinely, n (%)
Recent laparotomy in other hospital (<4 weeks) 12 (30.8)
Recent DLS in other hospital (<4 weeks) 7 (17.9)
Recent laparotomy in our academic centre (<4 weeks) 7 (17.9)
Clear response on neoadjuvant therapy on imaging 7 (17.9)
Unknown 6 (15.4)
Impact on open−close procedures
HIPEC type, n (%)
Open CRS+HIPEC 28 (71.8)
Open−close procedure 11 (28.2)
Main reason open−close procedure, n (%)
PCI>20 5 (45.5)
Too much small bowel involvement₪ 2 (18.2)
Irresectable primary tumour 3 (27.3)
Irresectable liver metastases 1 (9.1)
₪ Massive peritoneal disease involvement of the small bowel or its mesentery, whereby 
removal very likely will lead to short bowel syndrome.
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Table 3b | Visibility and postoperative morbidity of the DLS in patients with colorectal PM 
from cohort B (n = 85).
Time intervals
Interval colorectal PM to DLS, months, median [IQR] 1 [0−2]
Interval colorectal PM to HIPEC, months, median [IQR] 2 [2−4]
Visibility during DLS
Grade of visibility, n (%)*
I (very poor) 11 (12.9)
II (poor) 8 (9.4)
III (good) 11 (12.9)
IV (excellent) 53 (62.4)
Conversion rate, n (%) 18 (21.2)








Length of hospital stay, days, median [IQR] 2 [2−3]
Reoperation, n (%) 0 (0.0)
Complication rate, Clavien−Dindo, n (%)
Grade I 0 (0.0)
Grade II 3 (3.5)
Grade III 0 (0.0)
Grade IV 0 (0.0)
Complication type, n (%)
Urinary tract infection 2 (2.4)
Bacteraemia with unknown cause 1 (1.2)
Impact on open−close procedures
HIPEC type, n (%)
Open CRS+HIPEC 70 (82.4)
Open−close procedure 15 (17.6)
* Grade I visibility of two or less abdominopelvic regions, grade II visibility of three to eight 
abdominopelvic regions, grade III visibility of at least diaphragm regions, pelvis region, and 





The mean OS for the entire group of patients was 30.1 months (95% CI 26.0–34.2 
months). The mean OS was similar for cohorts A and B (25.9 months [95% CI 19.5–
32.3] vs 29.5 months [95% CI 25.9–33.1 months], respectively, p = 0.132).
For additional analyses of overall and disease−free survival after CRS+HIPEC, 
patients with a non−therapeutic laparotomy were excluded (n = 43). The mean OS 
for patients after CRS+HIPEC was 36.4 months (95% CI 31.6–41.2 months). The mean 
OS was similar for cohorts A and B (34 months [95% CI 25.9–42.1 months] vs 34 
months [95% CI 30.2–37.8 months], respectively, p = 0.523). The mean DFS for the 
entire cohort of patients was 20.7 months (95% CI 16.1–25.2 months). The mean 
DFS was similar between cohorts A and B (20.9 months [95% CI 13.2–28.7 months] 
vs 18.5 months [95% CI 14.7–22.4 months], respectively, p = 0.706).
DISCUSSION
In this observational study, consisting of 172 consecutive patients with colorectal 
PM, we demonstrated that non−therapeutic laparotomies during cytoreductive 
surgery occurred less frequently after the introduction of DLS as part of the 
preoperative workup for CRS+HIPEC.
Proper selection of patients with colorectal PM for CRS+HIPEC is a known challenge, 
as possible survival gain is difficult to weigh against treatment−related morbidity and 
mortality. From this perspective, for patients and clinicians, the most disappointing 
outcome after this major procedure is a non−therapeutic laparotomy, as it is 
associated with an increased risk of postoperative morbidity and a diminished 
QoL without providing any improvement in survival. These days, up to 40% of 
patients with PM are still confronted with a non−therapeutic laparotomy during 
cytoreductive surgery.15,16 Previous research showed that DLS is an accurate and safe 
staging tool in patients with PM and might prevent non−therapeutic laparotomies 
in patients with extensive disease. 16,18-23 In this study, we showed that the rate of 
non−therapeutic laparotomies significantly dropped from 35.4 to 21.0% after the 
introduction of DLS in our preoperative workup, despite the fact that only 68.5% 
of the patients underwent DLS in our academic centre after this introduction. In 
the group of patients who underwent DLS, a trend towards an ever−lower rate 
of non−therapeutic laparotomies was found (17.6%). Additional analyses showed 
that recent abdominal surgery in two out of three patients was the main reason to 
refrain from DLS in our academic centre, resulting in an unexpectedly higher rate 
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of non−therapeutic laparotomies (28.2%) in these patients. An explanation for this 
phenomenon might be the fact that surgeons from the referral centres in most 
cases were confronted unexpectedly with colorectal PM during a primary tumour 
resection. At that moment, the focus would be on referring the patient to a highly 
experienced HIPEC centre as quickly as possible, and therefore less attention might 
be paid to the true extent of the peritoneal disease.
In our current study some significant differences in baseline characteristics were 
found between patients who underwent an exploratory laparotomy for potential 
CRS+HIPEC before and after the introduction of DLS in the preoperative workup 
for CRS+HIPEC (i.e., cohort A and B, respectively). Patients from cohort B were 
on average older and had a higher BMI, which can be explained by the increase 
of the global average life expectancy and the increase in rates of obesity during 
the past 20 years. Age and BMI are both not considered a contraindication for 
CRS+HIPEC in our academic centre. Patients from cohort B were also less frequently 
treated with adjuvant chemotherapy. Due to a lack of scientific evidence there is 
no worldwide consensus about the use and timing of perioperative chemotherapy. 
Over the years, we have become more careful in applying adjuvant chemotherapy 
to patients after CRS+HIPEC, because of the increase in morbidity and temporally 
decrease in QoL that are both associated with chemotherapy. It is very unlikely that 
these differences in age, BMI, and the use of adjuvant chemotherapy could explain 
the rate drop of non−therapeutic laparotomies in cohort B. Furthermore, patients 
from cohort B were also more frequently diagnosed with metachronous onset of 
colorectal PM. The most likely explanation for this phenomenon seems the shift 
towards an increased awareness about CRS+HIPEC among surgeons from regional 
hospitals. In the past, especially patients with metachronous colorectal PM were 
frequently referred to a medical oncologist for palliative treatment options instead 
of an experienced HIPEC centre. These days, patients are referred to our academic 
centre in a low−threshold way, resulting in the treatment of more patients with 
metachronous onset of colorectal PM. To the best of our knowledge, there are no 
scientific publications about the impact of onset of colorectal PM on the rate of 
non−therapeutic laparotomies during CRS+HIPEC.
Overall, six other studies have reported data about the impact of DLS on preventing 
non−therapeutic laparotomies in patients with PM during cytoreductive surgery.16,19-23 
It should be noted that none of these studies focused only on patients with colorectal 
PM; a variation of three up to eleven primary tumour types were included per study. 




patients who underwent DLS ranged from 12.5 to 37.0%. In most studies, DLS was used 
in only highly selected patients.19,21,22 When DLS was routinely performed in all patients 
with PM, low rates of non−therapeutic laparotomies during cytoreductive surgery 
were reported (ranging from 15.2 to 17.0%).20,23 In only three studies was it possible 
to compare rates of non−therapeutic laparotomies between patients who underwent 
DLS and patients who did not undergo DLS prior to cytoreductive surgery.16,19,22 
These studies all reported a significant drop in the rate of non−therapeutic 
laparotomies in patients who underwent DLS when compared to patients who did 
not undergo DLS prior to cytoreductive surgery. However, it remains challenging to 
compare the results from our present study with the current literature because of 
differences in patient populations, tumour types, and indications to perform DLS.
In the Netherlands, HIPEC procedures are performed only in highly experienced 
tertiary referral centres by a dedicated team of surgeons. As mentioned before, 
most surgeons from referral centres have less experience in reporting the extent of 
colorectal PM according to the PCI score and therefore might under stage the extent 
of disease and overestimate the possibility to achieve a complete cytoreduction. 
With this obtained knowledge, we are paying more attention to early detection 
and referring of patients with colorectal PM to our academic centre. Patients will 
undergo laparoscopic evaluation by one of our HIPEC surgeons to investigate the 
extent and resectability of the colorectal PM, independently of prior abdominal 
surgery performed at the referral centre. With these adjustments, we suspect that 
the rate of non−therapeutic laparotomies in patients with colorectal PM will drop 
even further in our academic centre in the following years.
In the near future, it is possible that DLS will play a smaller role in patient selection 
because detection rates of PM from current preoperative imaging modalities are 
improving.27,28 In a recent study consisting of 49 patients with colorectal PM, MRI 
PCI was strongly correlated with the surgical PCI.28 Two radiologists with extensive 
experience in detecting colorectal PM could identify all patients with resectable 
disease based on a PCI below 21. Larger series are still necessary to provide more 
evidence of the accuracy of detection and staging of colorectal PM. DLS in the 
preoperative workup for CRS+HIPEC will not be easily curbed, as other advantages 
remain, such as taking biopsies to confirm the presence or absence of peritoneal 
disease and provide additional information for future systemic therapies.
This study has certain strengths and limitations. To the best of our knowledge, 
this is the first study that specifically describes the impact of DLS to prevent non−
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therapeutic laparotomies in a large cohort of patients with colorectal PM. Another 
strength of the current study is the presence of an adequate comparison group; 
a historical cohort of all consecutive patients who underwent an exploratory 
laparotomy for potential CRS+HIPEC before DLS was introduced in our academic 
centre. Gathered knowledge from this study provided crucial information about 
our daily practice to further improve the implementation of DLS in the preoperative 
workup for CRS+HIPEC. On the other hand, our study has some limitations due 
to the retrospective design and the single−centre approach. Selection bias might 
have occurred, although most data were obtained from a prospectively maintained 
institutional database and reasons to refrain from DLS in a subset of patients were 
further investigated. Although our HIPEC surgeons are extensively trained to perform 
CRS+HIPEC procedures and already had extensive experience in gastrointestinal 
surgery, study results may also have been influenced by their learning curves in 
the beginning of this study period. Learning curves from our academic centre and 
other Dutch hospitals have already been published elsewhere.29
CONCLUSIONS
Non−therapeutic laparotomies during cytoreductive surgery (i.e., open−close 
procedures) are prevented in patients with colorectal PM when DLS is performed 
during the preoperative workup for this major abdominal procedure. We recommend 
that only HIPEC surgeons perform this laparoscopic evaluation to ensure adequate 
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The peritoneal cancer index (PCI) calculated during exploratory laparotomy 
is a strong prognostic factor for overall survival (OS) in patients with colorectal 
peritoneal metastases (PM) who undergo cytoreductive surgery with hyperthermic 
intraperitoneal chemotherapy (CRS+HIPEC). Progression of the PCI between 
diagnostic laparoscopy (DLS) and potential CRS+HIPEC (∆PCI) might be a more 
dynamic prognostic factor for OS after CRS+HIPEC.
Methods
Between 2012 and 2018, all colorectal PM patients who underwent an exploratory 
laparotomy for potential CRS+HIPEC after DLS were retrospectively identified from a 
prospectively maintained database. Patients were divided into stable disease (∆PCI 
0–3), mild progression (∆PCI 4–9), or severe progression (∆PCI ≥10). Kaplan–Meier 
analysis and a multivariate Cox regression were performed.
Results
Eighty−four patients (∆PCI 0–3, n = 35; ∆PCI 4–9, n = 34; and ∆PCI ≥10, n = 15) were 
analysed. Median OS after CRS+HIPEC was significantly decreased in patients with a 
∆PCI of 4–9 (35.1 months [95% CI 25.5−44.6 months]) or ∆PCI ≥10 (24.1 months [95% 
CI 11.7−36.5 months]) compared to patients with a ∆PCI of 0–3 (47.9 months [95% CI 
40.0−55.7 months], p = 0.004). In multivariate regression analysis, ∆PCI remained 
an independent risk factor for OS: ∆PCI 4–9 HR 3.1 (95% CI 1.4−7.2, p = 0.007) and 
∆PCI ≥10 HR 4.4 (95% CI 1.5−13.1, p = 0.007).
Conclusions
A high ∆PCI is an independent dynamic prognostic factor for OS and might reflect 
a more aggressive tumour biology in patients with colorectal PM. HIPEC surgeons 
should be aware of a high−∆PCI−associated diminished prognosis and should 
reconsider CRS+HIPEC when confronted with a ∆PCI ≥10.
95
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INTRODUCTION
Colorectal cancer is the third most commonly diagnosed cancer worldwide.1 Up to 
40% of patients with colorectal cancer develop peritoneal metastases (PM) during 
the course of the disease, whereby the median overall survival (OS) with systemic 
therapy regimens ranges from 12 to 24 months.2-4
These days, carefully selected patients with resectable and limited colorectal 
PM can be treated with curative intent by cytoreductive surgery combined with 
hyperthermic intraperitoneal chemotherapy (CRS+HIPEC).5-8 During cytoreductive 
surgery, all macroscopically visible tumour tissue in the abdominal cavity will be 
removed, followed by perfusion with heated chemotherapy to eliminate remaining 
microscopic disease.9-11 In highly selected patients with colorectal PM, the survival 
gain due to CRS+HIPEC can be up to five years.7,12,13 However, CRS+HIPEC is associated 
with substantial morbidity and mortality and a decline in quality of life (QoL) in the 
first year after treatment.15-18 Thus, one of the major challenges is to adequately 
select patients who will benefit most from this treatment with acceptable treatment−
related morbidity and mortality in terms of OS and QoL.
Understandably, oncologists and surgeons are very interested in prognostic 
indicators that can be used in the selection process. According to the available 
literature, the extent of peritoneal disease, completeness of the performed 
cytoreduction, and signet ring cell histology especially have a great influence on the 
survival outcomes after CRS+HIPEC.6,19-24 The resectability of the peritoneal disease 
and thus the possibility to achieve a complete cytoreduction, is determined by 
various factors, such as the extent of the peritoneal disease, disease involvement 
of the small bowel, the deep mesenteric root, or the hepatic hilus. The extent of 
peritoneal disease is scored by the peritoneal cancer index (PCI), which combines 
peritoneal lesions sizes with the exact distribution over 13 abdominopelvic regions. 
The PCI score ranges from 0 to 39 points; a higher score indicates a more extensive 
tumour burden. Most HIPEC teams perform CRS+HIPEC only in patients with 
colorectal PM with a PCI <20 with the possibility to perform a (nearly) complete 
cytoreduction.
Pre−operative assessment of the PCI score remains challenging, as current 
radiological imaging techniques have limited sensitivity and resolution in detecting 
PM.25-27 As such, several institutions worldwide perform a diagnostic laparoscopy 




PM.28-30 At this moment, the PCI scoring system is predominantly used as a static 
single−time−point scoring system during an exploratory laparotomy for potential 
CRS+HIPEC, and as such does not include disease progression over time. Recently, 
the Sydney CRS+HIPEC research group created a more dynamic prognostic factor 
in 182 HIPEC patients with metachronous colorectal PM by combining tumour 
volume (i.e., laparotomy−PCI) with the time period over which the extent of disease 
developed (i.e., time between primary tumour resection and CRS+HIPEC).31 Patients 
with a high volume−time−index had a significantly decreased median OS compared 
to patients with a low volume−time−index (23 vs 44 months, p = 0.002). Although 
PCI has been repeatedly identified as one of the most important independent 
prognostic factors for survival, the score lacks information about the time frame 
over which peritoneal disease develops.
Laparoscopic evaluation is part of our standardised preoperative workup for 
CRS+HIPEC to assess the extent and resectability of colorectal PM, and therefore 
the opportunity arose to investigate the impact of an increase in PCI in a short−time 
frame on survival outcomes after CRS+HIPEC. We hypothesised that an increase in 
PCI score within a relatively short timeframe might reflect a more aggressive tumour 
biology with a worse prognosis even when the PCI score is still below 20 and might 
differentiate patients with a less favourable outcome despite CRS+HIPEC. Thus, the 
aim of the current study is to identify the impact of an increase in PCI from DLS to 
CRS+HIPEC on OS in patients with colorectal PM.
METHODS
Design, setting, and participants
Between 2012 and 2018, all consecutive patients with histologically proven colorectal 
PM who had undergone DLS and an exploratory laparotomy for potential CRS+HIPEC 
were retrospectively identified from a prospectively maintained institutional 
database. The study protocol was approved by the Medical Ethical Committee of 
the University Medical Center Groningen (protocol number 201800395).
From all included patients, the difference in PCI score between DLS and exploratory 
laparotomy for potential CRS+HIPEC (i.e., ∆PCI) was calculated. Patients were divided 
into three groups according to the ∆PCI score: ∆PCI 0–3, ∆PCI 4–9, and ∆PCI ≥10. This 
group classification was determined by our research group in advance with the 
analyses to distinguish between clinically stable disease (∆PCI 0–3), mild progression 
of disease (∆PCI 4–9), or severe progression of disease (∆PCI ≥10).
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Primary and secondary outcomes
The primary outcome was OS after exploratory laparotomy for potential 
CRS+HIPEC, calculated from the operation date until the date of death or last 
follow−up in censored cases. Secondary outcomes were disease−free survival (DFS), 
postoperative complications (according to the Clavien–Dindo classification system32), 
and the rate of non−therapeutic laparotomies during exploratory laparotomy (i.e., 
open–close procedures). DFS was calculated from the date of CRS+HIPEC to the date 
of first recurrence or last follow−up in censored cases.
Preoperative evaluation and staging for CRS+HIPEC
All referred patients with colorectal PM for evaluation of potential candidates for 
CRS+HIPEC underwent a standardised preoperative screening. This screening 
consisted of reviewing previous operation and pathology reports; a clinical 
examination; carcinoembryonic antigen (CEA) measurement; CT of the chest, 
abdomen, and pelvis; and colonoscopy if not already performed within the previous 
6 months.
DLS was also included in this standardised evaluation. During DLS, a 12 mm trocar 
with the use of a 30° camera and at least one 5 mm trocar were placed in the 
midline for visualisation of the abdominal cavity. The operating table was placed 
sequentially into Trendelenburg, anti−Trendelenburg, and right and left tilt positions 
to systematically assess the abdominal cavity. The extent of colorectal PM was 
calculated according to the standard PCI score; lesion sizes (from 0 to 3 points) 
and distribution of peritoneal deposits were measured in nine abdominopelvic 
regions and four small bowel segments. If deemed necessary, minor adhesiolysis 
was performed to reduce the risk of bowel injury. DLS evaluations were performed 
or supervised by one of the five experienced HIPEC surgeons. Clinically suspected 
lesions were biopsied for pathological confirmation of colorectal PM.
During several expert sessions with our four HIPEC surgeons we created a 4−point 
scale for the degree of visibility of the abdominal cavity during DLS (i.e., grade I; 
visibility of two or less abdominopelvic regions, grade II; visibility of three to eight 
abdominopelvic regions, grade III; visibility of at least diaphragm regions, pelvis 
region and small bowel regions , and grade IV; visibility of all 13 abdominopelvic 
regions). A score of three or higher was deemed required for adequate judgement of 
the extent of disease. Conversion from DLS to an exploratory laparotomy in case of 
poor visibility only occurred in patients without previous pathological confirmation of 




A multidisciplinary team comprising surgeon oncologists, medical oncologists, 
radiologists, and pathologists reviewed the preoperative screening and judged if 
the patient was a suitable candidate for CRS+HIPEC, aiming to achieve complete 
cytoreduction with acceptable treatment−related morbidity and mortality. Patients 
who were deemed unsuitable for CRS+HIPEC during this multidisciplinary oncology 
team meeting were excluded from the current study. Absolute contra−indications 
for CRS+HIPEC were moderate or severe co−morbidity (American Society of 
Anaesthesiologists [ASA] score above III), extraperitoneal disease, extensive disease 
with involvement of the small bowel, or a PCI score ≥20 during DLS. The presence 
of hepatic metastases was not a contraindication as long as there were only up to 
three resectable lesions.17
Patients with a good or excellent visibility during DLS with a borderline DLS−PCI (i.e., 
DLS−PCI 15−20) were offered rapid CRS+HIPEC within two weeks to prevent further 
spreading of the disease. Patients with poor visibility during DLS with a borderline 
DLS−PCI were referred for palliative treatment options, as the PCI during laparotomy 
would have been above our national PCI cut−off value of 20. Patients with poor 
visibility during DLS without a borderline DLS−PCI were given the benefit of doubt 
and were scheduled for CRS+HIPEC.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Our institute performed all CRS+HIPEC procedures according to the standardised 
Dutch HIPEC protocol.17 In summary, CRS was performed only when the colorectal 
PM were deemed to be completely resectable and HIPEC was performed only after 
a (nearly) complete cytoreduction.
Each CRS+HIPEC procedure was initiated with an exploratory laparotomy to 
recalculate the PCI score in an open setting. The laparotomy PCI was calculated 
in a similar fashion as described before. In patients who were deemed not 
eligible for CRS+HIPEC during exploratory laparotomy because of extensive or 
not resectable disease, the procedure was terminated without further treatment 
(i.e., open–close procedure). If the patient was deemed eligible for CRS+HIPEC, all 
macroscopically visible disease was resected. After completion of the cytoreduction, 
the completeness of cytoreduction score was determined.33 CC−0 indicated that 
no residual tumour was visible or palpable in the peritoneal cavity; CC−1 indicated 
residual tumour deposits smaller than 2.5 mm; CC−2 indicated residual tumour 
between 2.5 mm and 2.5 cm; and CC−3 indicated residual tumour larger than 2.5 
cm or a confluence of nodules.
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The HIPEC procedure was then performed by using the open Coliseum technique.34 
In this open technique, the abdominal wall is pulled upward and a closed circuit 
is created using inflow and outflow drains attached to a pump and a heating unit 
is set up. Mitomycin C (35 mg/m2) was circulated in the abdominal cavity with a 
temperature of 41–42⁰C for 90 min. Afterwards, reconstruction surgery including 
bowel anastomoses with or without a colostomy was performed. All patients were 
admitted to the intensive care unit for at least one postoperative day.
Follow−up
Clinical follow−up of each patient occurred within one month after surgery and 
thereafter on a 3–6 month basis for a minimum of five years. Follow−up included 
clinical examination and CEA measurements. A CT scan of the thorax and abdomen 
was performed in cases of suspected recurrence of the disease by the presence of 
clinical symptoms or an increase in CEA levels.
Data collection
Data on patient and tumour characteristics, operative characteristics, postoperative 
outcome, survival, and recurrence were collected prospectively. Postoperative 
complications were collected up to 60 days after surgery and registered according 
to the Clavien–Dindo classification system.32
Statistical analyses
All statistical analyses were performed with SPSS® Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA.). All tests of statistical significance were two−sided. 
P < 0.05 was considered statistically significant. Quantitative variables are presented 
as mean (± SD) or median (interquartile range, IQR) and qualitative variables 
are presented as count (percentage). Patient and tumour characteristics were 
compared using a Chi square or Fisher’s exact test. OS between the ∆PCI groups 
was assessed and calculated according to the Kaplan–Meier method and Log-rank 
Test. Subsequently, a multivariable Cox regression analysis was performed to 
examine the association of ∆PCI with the risk of death after adjustment for potential 
confounders. Potential confounders were identified from the current literature or 
identified in the univariate survival analysis (p < 0.20). Results from the univariate 






One hundred and sixty−four patients with colorectal PM underwent an exploratory 
laparotomy for potential CRS+HIPEC during the inclusion period (Figure 1). Sixty−two 
patients (37.8%) were excluded from the analysis because no DLS was performed 
during the preoperative workup, and 18 patients (11.0%) were excluded because one 
or two PCI scores from the surgical procedures were missing. Eighty−four patients 
(51.2%) were included for further analyses. ∆PCI was calculated for all included 
patients. Patients were divided into three subgroups according to ∆PCI: ∆PCI 0–3 
(n = 35), ∆PCI 4–9 (n = 34), and ∆PCI ≥10 (n = 15).
Figure 1 | Flow chart of the patient selection process.
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Patient and tumour characteristics
Table 1 shows that there were no significant differences at baseline in patient and 
tumour characteristics between the different ∆PCI groups.
Table 2 presents the treatment characteristics of the DLS and the exploratory 
laparotomy for the different ∆PCI groups. There were no significant differences in the 
treatment characteristics for the DLS between the ∆PCI groups. In the entire cohort, 
good laparoscopic evaluation of the abdominal cavity (i.e., visibility grade ≥III) was 
possible in 62 patients (73.8%), resulting in conversion to an open procedure in 20 
patients (23.8%). Postoperative complications occurred in three patients (3.6%) and 
consisted of a prolonged gastroparesis postoperatively (grade II), fever without a 
specific focus (grade II), and a small bowel perforation (grade III).
The median time between DLS and exploratory laparotomy was 1 month (IQR 
1−2) and was comparable between the ∆PCI groups (p = 0.938). The median PCI 
significantly increased from 4 at DLS to 10 at exploratory laparotomy (p < 0.0001). 
Seventy−one patients (84.5%) underwent CRS+HIPEC during the exploratory 
laparotomy and 13 patients (15.5%) had a non−therapeutic laparotomy, because 
of a PCI >20 (nine patients), too much small bowel involvement (one patient), more 
than three liver metastases (one patient), or an irresectable primary tumour (two 
patients). The PCI score during the exploratory laparotomy was as expected higher 
in the ∆PCI 4–9 and ∆PCI ≥10 groups compared to the ∆PCI 0–3 group (p < 0.0001). 
In addition, non−therapeutic laparotomies occurred more frequently in patients 
with a ∆PCI 4–9 (20.6%) or ∆PCI ≥10 (33.3%) compared to patients with a ∆PCI 0–3 
(2.9%) (p = 0.014).
Overall and disease−free survival
The median OS after exploratory laparotomy for the entire cohort was 36.2 months 
(95% CI 30.1−42.2 months). Figure 2 shows that the median OS after exploratory 
laparotomy was significantly decreased in patients with a ∆PCI of 4–9 (30.6 months 
[95% CI 21.9−39.2 months]) or ∆PCI ≥10 (21 months [95% CI 10.3−31.7 months]) 
compared to patients with a ∆PCI of 0–3 (46.8 months [95% CI 38.9−54.7 months], p 
< 0.0001). Figure 3 shows the same significant trend within the group of 71 patients 
who underwent CRS+HIPEC. Median OS after CRS+HIPEC was significantly decreased 
in patients with a ∆PCI of 4–9 (35.1 months [95% CI 25.5−44.6 months]) or ∆PCI ≥10 
(24.1 months [95% CI 11.7−36.5 months]) compared to patients with a ∆PCI of 0–3 




Additional analyses were performed within the subgroup of 43 patients (51.2%) 
in whom an excellent laparoscopic view on all 13 abdominopelvic regions could 
be achieved to rule out the possibility of an increase in PCI over time caused by 
inadequate assessment of the DLS­PCI. The median OS after exploratory laparotomy 
was also in this subgroup of patients significantly decreased in patients with a ∆PCI 
of 4–9 (19.0 months [95% CI 7.7−30.3 months]) or ∆PCI ≥10 (22.6 months [95% CI 
6.4−38.8 months]) compared to patients with a ∆PCI of 0–3 (54.1 months [95% CI 
45.3−63.0 months], p = 0.004). For the subgroup of 36 patients who successfully 
underwent CRS+HIPEC, median OS was also significantly decreased in patients with 
a ∆PCI of 4–9 (31.5 months [95% CI 22.0−41.1 months]) or ∆PCI ≥10 (23.2 months 
[95% CI 5.8−40.5 months]) compared to patients with a ∆PCI of 0–3 (54.1 months 
[95% CI 45.3−63.0 months], p = 0.014).
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Figure 2 | Kaplan–Meier survival curves for all 84 patients who underwent an exploratory 
laparotomy for potential CRS+HIPEC divided into the three different ∆PCI groups.
Figure 3 | Kaplan–Meier survival curves for all 71 patients who underwent CRS+HIPEC dived 

































































































































































































































































































































































































































































































































































































































































































A multivariable Cox regression analysis was performed to examine the direct 
association of ∆PCI with the risk of death after adjustment for potential confounders. 
In univariate analysis, the PCI during laparotomy (p < 0.001), the CC−score (p < 0.001), 
and a ∆PCI of 4–9 (p = 0.007) or ∆PCI ≥10 (p < 0.001) were significant prognostic 
factors (Table 3). Other potential important prognostic factors identified from the 
current literature were the primary tumour site and the presence of signet cell 
histology. In a multivariate regression analysis, correcting for all previous mentioned 
potential confounders, ∆PCI remained an independent risk factor for OS: ∆PCI 4–9 
HR 3.1 (95% CI 1.4−7.2, p = 0.007) and ∆PCI ≥10 HR 4.4 (95% CI 1.5−13.1, p = 0.007).
The median DFS for all patients who underwent CRS+HIPEC was 22.4 months (95% 
CI 16.5−28.4 months). There was no significant difference in median DFS between 
the three ∆PCI groups (29.5, 18.2, and 11.1 months for ∆PCI 0–3, ∆PCI 4–9, and ∆PCI 
≥10, respectively, p = 0.139).
Postoperative complications
Table 2 also provides an overview of the postoperative morbidity after exploratory 
laparotomy, divided by ∆PCI group and severity of the complication according to 
the Clavien–Dindo classification system. Major postoperative complications (i.e., 
Clavien­Dindo grade ≥III) occurred in 28 patients (33.3%) and did not differ between 
the three ∆PCI groups (p = 0.134). Two patients (2.4%) died within the first 30 days 
after CRS+HIPEC. An asystole occurred in one patient 10 days after surgery without 
successful resuscitation (∆PCI 0–3 group), and multi­organ failure occurred in one 
patient after multiple laparotomies because of intra­abdominal abscesses (∆PCI 
4–9 group).
DISCUSSION
In this observational study, consisting of 84 patients with histologically proven 
colorectal PM, we demonstrated that ∆PCI might be a novel, more dynamic 
prognostic factor for OS after CRS+HIPEC. We found that a higher ∆PCI was clearly 
associated with a decreased OS. As such, we postulate that ∆PCI reflects a more 
aggressive tumour biology and disease progression in patients with colorectal PM 
and might serve as an adjunct tool for intraoperative clinical decision making beyond 
static PCI scoring at the time of exploratory laparotomy for potential CRS+HIPEC.
Worldwide, authors agree that one of the key independent prognostic factors for 
survival after CRS+HIPEC in patients with colorectal PM is the PCI score during 
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exploratory laparotomy.19,22,35-38 This concept of tumour burden expressed by the PCI 
score does not take the dynamic aspect of the biological behaviour of the tumour 
into account, whether it is slow or fast growing. In our clinic, patients with a PCI score 
<20 during DLS were deemed eligible for CRS+HIPEC according to common practice. 
Unfortunately, in our series, cases had been seen where the HIPEC surgeons were 
confronted with a rapid increase in PCI score of more than 5 points in a few weeks’ 
time, but with a PCI still below 20. Consequently, according to the current guidelines, 
CRS+HIPEC was executed. Intuitively, this increased tumour burden over a short 
time period should have been taken into account as a negative prognostic indicator. 
To the best of our knowledge, there are no previous data on this topic to confirm 
the clinical observation. As such, we have translated this into the development 
of a new prognostic parameter, ∆PCI, which is able to stratify three groups of 
rate progression. We have shown that a rapid increase in ∆PCI is an independent 
risk factor for OS in patients with colorectal PM and should be considered as an 
additional clinical decision−making tool prior to execution of CRS+HIPEC.
Other possible explanations, rather than purely tumour biology, were also 
investigated for the increase in PCI within the short−time frame between DLS and 
laparotomy. An underestimation of the DLS−PCI will automatically lead to a higher 
∆PCI due to better access and staging of disease during laparotomy. In our subgroup 
of 43 patients (51.2%) with excellent laparoscopic view on all abdominopelvic 
regions the same significant trend was observed between the ∆PCI and the survival 
outcomes after laparotomy. In addition, in 12 out of 15 patients (80.0%) with a 
∆PCI ≥10 a good laparoscopic evaluation was possible during DLS. Progression of 
disease during the waiting period between DLS and CRS+HIPEC might also be found 
more frequently in this study population as systemic treatment regimens are not 
considered standard therapy in the Netherlands. Despite the widespread use of 
perioperative systemic chemotherapy, a recent systematic review showed that there 
is not enough evidence to draw conclusions on the benefit of perioperative systemic 
therapy for patients with isolated resectable colorectal PM who are candidates 
for CRS+HIPEC.39 The CAIRO 6 trial, a multicentre, open−label, Phase II−III RCT, will 
provide some answers as to the oncological efficacy of perioperative systemic 
therapy and CRS+HIPEC vs upfront CRS+HIPEC (control arm) for isolated resectable 
colorectal PM (NCT02758951).
Patients with colorectal PM should undergo DLS routinely prior to exploratory 
laparotomy for potential CRS+HIPEC to allow calculation of a ∆PCI score. These days, 




studies showed that DLS is a safe, accurate, and feasible staging tool in patients 
with PM from various tumours and might prevent non−therapeutic laparotomies in 
patients with extensive disease.28-30,40-43 However, incidental complications such as 
small bowel perforation or abrasions have been described in the past. For patients 
who are eligible for CRS+HIPEC, such complications can be of great impact or even 
fatal, leading to a high chance of excluding a potential curative treatment. Therefore, 
DLS should be performed without extensive adhesiolysis and with great caution to 
minimise this risk. Conversion to an open−procedure in case of poor visibility during 
DLS is only indicated for very specific indications such as the need to create a stoma 
because of severe obstruction symptoms. In other cases of poor visibility, patients 
can be given the benefit of doubt after good clinical counselling and be scheduled 
for CRS+HIPEC with an increased risk of the occurrence of an open−close procedure.
Differences in ∆PCI seem to be a reflection of subtypes of disease. We postulate 
that future research for colorectal PM should focus on molecular characteristics 
of tumour lesions that distinguish somnolent from a more aggressive tumour 
phenotype in patients with colorectal PM. At this moment, several studies have 
identified four molecular subtypes in colorectal tumours (consensus molecular 
subtypes, CMS1 to CMS4).44-47 Guinney et al. showed that 60% of primary colorectal 
tumours and 75% of colorectal PM belong to the CMS4 subtype.48 CMS4, also known 
as the mesenchymal subtype, represents a particular class of highly aggressive 
tumours that seems to be associated with worse DFS and OS and a poorer response 
to anticancer therapy.48-51 For example, patients with stage III colorectal CMS4 
tumours did not benefit from systemic adjuvant oxaliplatin treatment as compared 
to the other subtypes. Strikingly, oxaliplatin is a commonly used chemotherapeutic 
agent in HIPEC procedures, so identification of the molecular subtype of colorectal 
PM can have therapeutic consequences.51 In the future, we will attempt to identify 
the molecular subtypes associated with the degree of change of ∆PCI and as such 
the underlying mechanisms for each subgroup.
This retrospective study has potential limitations. The patient cohort was taken from 
a single institution over a long period of seven years. We can hypothesise that over 
time patients are diagnosed with colorectal PM at an earlier stage with less disease 
progression. However, this seems unlikely, as accurate diagnostic staging tools for 
colorectal PM are still lacking and peritoneal tumour deposits are still difficult to 
detect with currently available imaging techniques. Also there is no worldwide 
consensus about the true PCI cut−off value in patients with colorectal PM in which 
CRS+HIPEC should be contra−indicated. Patients from this cohort were all treated 
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according to our national Dutch HIPEC protocol, where CRS+HIPEC is only performed 
in patients with a PCI ≤20. Thus, results from our current study might not be fully 
generalisable to other highly experienced HIPEC centres worldwide. Although we 
reported one of the largest series of patients with colorectal PM who underwent DLS 
with an attempt at undergoing CRS+HIPEC, the number of patients is still insufficient 
to perform various sub−analysis in the different ∆PCI groups.
CONCLUSIONS
∆PCI seems to be a new, more dynamic prognostic factor for OS after CRS+HIPEC 
in patients with colorectal PM. This prognostic factor appears to reflect on a 
more aggressive tumour biology and disease progression. When confronted 
intraoperatively with a high ∆PCI of ≥10, HIPEC surgeons should be aware of a more 
aggressive tumour type and therefore diminished prognosis and reconsider the 
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The extent of surgery (ES) during cytoreductive surgery with hyperthermic 
intraperitoneal chemotherapy (CRS+HIPEC) is a well−known risk factor for major 
postoperative morbidity. Interestingly, the reliability of surgeons to predict the ES 
prior to CRS+HIPEC is unknown.
Methods
In this prospective, observational cohort study, five surgeons predicted the ES prior 
to surgery in all consecutive patients with peritoneal metastases (PM) who were 
scheduled for CRS+HIPEC between March 2018 and May 2019. After the preoperative 
workup for CRS+HIPEC was completed, all surgeons independently predicted for 
each individual patient the resection or preservation of 22 different anatomical 
structures and the presence of a stoma post−HIPEC according to a standardised ES 
form. The actual ES during CRS+HIPEC was extracted from the surgical procedure 
report and compared with the predicted ES. Overall and individual positive and 
negative predictive values (i.e., PPV and NPV) for each anatomical structure were 
calculated.
Results
One hundred and thirty−one ES forms were collected from 32 patients who 
successfully underwent CRS+HIPEC. The number of resections was predicted 
correctly 24 times (18.3%), overestimated 57 times (43.5%), and underestimated 50 
times (38.2%). Overall PPVs for the different anatomical structures ranged between 
33.3 and 87.8%. Overall NPVs ranged between 54.9 and 100%, and an NPV greater 
than 90% was observed for 12 anatomical structures.
Conclusions
Experienced surgeons seem to be able to predict better the anatomical structures 
that remain in situ after CRS+HIPEC, rather than predict the resections that were 
necessary to achieve a complete cytoreduction.
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INTRODUCTION
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy 
(CRS+HIPEC) is used in highly selected patients with peritoneal metastases (PM) from 
gastrointestinal, gynaecological, or primary peritoneal cancers.1–4 This treatment 
strategy combines the surgical removal of all macroscopically visible disease 
with perfusion of the abdominal cavity with heated chemotherapy to eradicate 
residual microscopic disease. Cumulative scientific evidence shows an important 
improvement in survival outcomes compared to systemic chemotherapy alone.5–7
CRS+HIPEC is accompanied by a high treatment−related mortality rate of 0–8% 
and grade 3–4 morbidity rate of 18–52% in experienced centres.8–14 In addition, 
CRS+HIPEC negatively impacts the quality of life (QoL) up to one year after 
surgery.15,16 For clinicians and patients, it remains a challenge to weigh the potential 
survival benefit from CRS+HIPEC against the risk of substantial treatment−related 
morbidity, mortality, and potentially diminished QoL.
The extent of surgery (ES) has been identified as an independent risk factor for 
treatment−related morbidity and mortality.17–20 The ES during CRS obviously depends 
on the extent of involved organs because of metastases or close relation with 
metastases, which makes it surgically mandatory to remove the affected anatomical 
structures. The extent of peritoneal disease widely varies between patients. To predict 
postoperative outcomes prior to surgery, it is pivotal for every surgeon to appreciate 
the ES before deciding in a patient−shared decision to proceed with CRS+HIPEC.
However, the correlation between the predicted ES by experienced surgeons in 
advance with the actual ES during CRS is unknown. As such, the aim of the present 
study is to determine the correlation between the predicted ES with the actual ES 
during CRS.
METHODS
Design, setting, and participants
In this prospective, observational cohort study, five surgeons from one Dutch 
tertiary referral centre (University Medical Center Groningen) predicted the ES 
prior to surgery in all consecutive patients with histologically proven PM of any 
origin who were scheduled for CRS+HIPEC. Surgeons with extensive experience in 




this study. The learning curve from these surgeons has been studied before and 
was published by the Dutch Peritoneal Oncology Group (DPOG) elsewere.21 Data on 
patient and tumour characteristics, operative and postoperative characteristics were 
collected prospectively and stored in our institutional database in compliance with 
the Declaration of Helsinki.22 The Institutional Ethics Committee of the University 
Medical Center Groningen approved the study protocol (METc201800157). Written 
informed consent was obtained from all patients.
Every surgeon predicted the ES before each CRS+HIPEC procedure based on the 
information from our standardised preoperative workup for CRS+HIPEC and after our 
weekly multidisciplinary oncology meeting, which are described later. Each surgeon 
predicted the ES for every patient undergoing CRS+HIPEC irrespective of being the 
operating surgeon of the case. The surgeons anonymously filled in the ‘Extent of 
Surgery’ form to ensure a standardised way of estimating the ES (Appendix 1). In 
summary, this ES form included 22 anatomical structures that might be resected 
during CRS+HIPEC and a separate question about the presence of a stoma post−
HIPEC. The surgeons were instructed to predict the resection or preservation of 
each anatomical structure and to predict the presence or absence of a stoma post−
HIPEC. In cases in which an open–close procedure (i.e., non−therapeutic laparotomy) 
was expected by the surgeon, he indicated this on the ES form and did not make 
any predictions regarding the anatomical structures or the presence of a stoma.
After surgery, the ES forms were compared to the actual ES during CRS+HIPEC 
retrieved from the surgical procedure report. For every anatomical structure, 
four scenarios could occur: (I) the surgeon predicted correctly that an anatomical 
structure would be resected during CRS+HIPEC; (II) the surgeon predicted correctly 
that an anatomical structure would remain in situ after CRS+HIPEC; (III) the surgeon 
predicted incorrectly that an anatomical structure would be resected during 
CRS+HIPEC; or (IV) the surgeon predicted incorrectly that an anatomical structure 
would remain in situ after CRS+HIPEC. Because our study aimed to correlate the 
predicted ES to the actual ES, only fully completed ES forms from patients who 
underwent complete CRS+HIPEC were included in the final analyses.
Primary and secondary outcomes
The primary outcome was the overall ability of the surgeons to predict the ES prior 
to CRS+HIPEC. The primary outcome was divided into overall positive and negative 
predictive values per anatomical structure (PPV and NPV, respectively). A high PPV 
suggests that the surgeon is well able to predict if the anatomical structure will be 
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resected, whereas a high NPV indicates that the surgeon is well able to predict if 
the anatomical structure will remain in situ. Secondary outcomes included overall 
and individual PPVs and NPVs for the presence of a stoma post−HIPEC, individual 
PPVs and NPVs per anatomical structure, overall sensitivity and specificity per 
anatomical structure, and the occurrence of major postoperative complications. 
Major postoperative complications were defined as grade ≥III according to the 
Clavien–Dindo classification system.23




Preoperative evaluation and staging for CRS+HIPEC
All referred patients with PM underwent a standardised preoperative workup for 
CRS+HIPEC consisting of a clinical examination, laboratory testing, and a thoracic, 
abdominal, and pelvic computed tomography (CT) to quantify the extent and 
resectability of peritoneal disease and to rule out other distant metastases. If deemed 
necessary, additional magnetic resonance imaging (MRI) was performed to further 
investigate the extent of PM. In patients with colorectal PM, diagnostic laparoscopy 
(DLS) was routinely performed by one of our HIPEC surgeons to pathologically 
confirm the presence of PM and to systematically assess the extent and resectability 
of peritoneal disease according to the peritoneal cancer index (i.e., DLS PCI).24
Afterwards, during a weekly multidisciplinary oncology meeting, results from all 
patients were discussed and eligibility for CRS+HIPEC was determined. In general, 
patients who were candidates for CRS+HIPEC had limited and resectable PM with no 
evidence of extra−abdominal disease and were deemed fit for extensive abdominal 
surgery. Up to three resectable liver metastases were not considered as absolute 
contra−indication. Extensive small bowel resection resulting in a short bowel 
syndrome was an absolute contra−indication. No definite PCI limitations were used 
in patients with PM from pseudomyxoma peritonei (PMP), low−grade appendiceal 
mucinous neoplasm (LAMN), or mesothelioma. The absolute PCI cut off point to 
perform CRS+HIPEC in patients with colorectal PM was 20.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Every CRS+HIPEC procedure was performed by two HIPEC surgeons according to our 
standardised Dutch HIPEC protocol.25 CRS was performed only in patients whereby 
both surgeons judged the PM as completely resectable. In addition, HIPEC was 
performed only after a complete cytoreduction was achieved.
Each procedure started with an exploratory laparotomy to assess the extent of 
peritoneal disease in an open setting (i.e., laparotomy PCI). In cases of extensive 
or not−resectable PM, the procedure was prematurely terminated (i.e., open–close 
procedure). When the patient was deemed eligible for CRS+HIPEC, all macroscopically 
visible disease was removed by performing peritonectomies and organ resections. 
The completeness of cytoreduction score (CC−score) was determined at the end of 
the cytoreduction.24 The cytoreduction was considered complete if a CC−score of 0 
or 1 was established (i.e., no residual tumour or residual tumours deposits smaller 
than 2.5mm, respectively).
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When complete cytoreduction was achieved, HIPEC was performed for 90 min at 
a temperature of 41−42 °C by using the open Coliseum technique. Mitomycin C 
(35mg/m2) was used in patients with colorectal PM, LAMN, PMP, and small bowel 
carcinoma. A combination of cisplatin (50 mg/m2) with doxorubicin (15 mg/m2) was 
used in patients with mesothelioma.
Hereafter, the fluid was evacuated from the abdominal cavity and reconstruction 
surgery including bowel anastomoses with or without a stoma was performed. 
Patients were admitted to the intensive care unit for strict monitoring for at least 
one day. Patients were transferred to the nursing ward when cardiac and pulmonary 
functions were stable.
Data collection
Relevant data on patient characteristics, tumour characteristics, operative 
characteristics and postoperative morbidity, and mortality were extracted 
from a merged prospectively maintained institutional database. Postoperative 
complications within 90 days after surgery were registered according to the Clavien–
Dindo classification system.23 Operative details including the anatomical resections, 
the presence of a stoma post−HIPEC, the operation time, and total blood loss were 
retrospectively extracted from the surgical procedure reports.
All fully completed ES forms from patients who underwent complete CRS+HIPEC 
were registered per surgeon and compared to the actual ES. For every anatomical 
structure, the four previously described possible scenarios were identified and 
registered.
Statistical analyses
Categorical variables are reported as number (n) and percentages (%) and 
continuous variables are reported as median (interquartile range [IQR]). The PPV, 
NPV, sensitivity, and specificity for each anatomical structure and the presence 
of a stoma post−HIPEC were calculated in total and per surgeon. In addition, the 
prevalence of all resections during CRS+HIPEC was determined according to all ES 
forms. For example, when only one patient underwent a stomach resection during 
CRS+HIPEC, the total prevalence to correctly predict a stomach resection in this 
study cohort was five, as five surgeons filled in an ES form.
Thereafter, three categories were created to further classify the surgeon’s ability to 




three categories consisted of (I) good PPV/NPV (i.e., >80%), (II) moderate PPV/NPV 
(i.e., 50–80%), and (III) poor PPV/NPV (i.e., <50%). The prevalence of each anatomical 
resection was taken into account when these categories were interpreted. All 
statistical analyses were conducted using SPSS® Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA).
RESULTS
Thirty−eight consecutive patients underwent an exploratory laparotomy for 
potential CRS+HIPEC in our academic centre between March 2018 and May 2019. 
One−hundred fifty−six ES forms were completed during this study period. Because 
of the aim of the study, not all completed ES forms could be used for final analyses. 
Figure 1 provides a structured flow chart explaining this selection process. In six 
patients (15.8%), it was not possible to correlate the corresponding 24 ES forms 
(15.4%) to the actual ES, as an open–close procedure occurred. Interestingly, in only 
2 out of these 24 ES forms (8.3%) was an open–close procedure correctly predicted 
in advance. In addition, 1 out of the remaining 132 ES forms was also excluded 
for analyses, as the surgeon incorrectly predicted an open–close procedure 
and therefore did not make any predictions about the resection of the different 
anatomical structures. In summary, the data presented in this manuscript are based 
on 131 ES forms from 32 patients who successfully underwent CRS+HIPEC.
Patient and tumour characteristics
Table 1 provides an overview of the baseline characteristics. The majority of the 
patients had already undergone abdominal surgery in the past (90.6%) and were 
diagnosed with a metachronous onset of PM (56.3%) The most commonly treated 
tumour types were colorectal (77.4%) and appendiceal (12.9%) cancer. In all patients, 
radiological examinations were performed during the preoperative evaluation for 
CRS+HIPEC to assess the extent of disease and included CT for 32 patients (100%), 
MRI for 10 patients (31.3%), and PET­CT for 12 patients (37.5%). Median time between 
CT and CRS+HIPEC was 4 weeks (IQR 1−6 weeks) and median time between MRI 
and CRS+HIPEC was 3 weeks (IQR 1−6 weeks). Furthermore, half of the patients 
underwent DLS in our centre to pathologically confirm the presence of PM and to 
systematically assess the extent and resectability of peritoneal disease according 
to the PCI. DLS was refrained in the other half of the patients, because a DLS or 
exploratory laparotomy was recently performed to confirm the presence of PM and 
to investigate the extent of peritoneal disease.
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The intra−operative outcomes including the anatomical resections are listed in Table 
2. The median PCI was 5 (IQR 3−11), the median operation time was 468 min (IQR 
368−599), and the median amount of intraoperative blood loss was 800 mL (IQR 
350−2100). In all patients, a complete cytoreduction (i.e., CC−0 or CC−1) was achieved. 
During CRS, a median of four anatomical structures were resected, and the most 
common resections were omentum (96.9%), small bowel (68.8%), rectum (56.3%), 
sigmoid (50.0%), and ovaries (28.1%). A stoma was created in 19 patients (59.4%).
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Table 1 | Baseline characteristics from all 32 patients who successfully underwent CRS+HIPEC.
Patient characteristics
Age, years, median [IQR] 59 [53­71]
Gender, male, n (%) 13 (40.6)





Prior CRC surgery, n (%) 29 (90.6)
Prior chemotherapy, n (%) 10 (31.3)
Tumour characteristics
Primary tumour, n (%)
Appendix 5 (15.6)
Right colon 7 (21.9)
Transverse colon 1 (3.1)
Left colon 3 (9.4)
Sigmoid 8 (25.0)
Rectum 6 (18.8)
Small bowel 1 (3.1)
Signet cell histology, n (%) 5 (15.6)
T stage of primary tumour, n (%)
≤3 9 (34.6)
4 17 (65.4)




M stage of primary tumour, n (%)
0 15 (55.6)
1 12 (44.4)
Onset of PM, n (%)
Synchronous 14 (43.8)
Metachronous 18 (56.3)
Synchronous liver metastases, n (%) 2 (6.3)
Primary tumour in situ, n (%) 6 (18.8)
Presence of a stoma pre-HIPEC, n (%) 6 (18.8)
Preoperative evaluation for CRS+HIPEC
HIPEC indication, n (%)




Small bowel carcinoma 1 (3.2)
Preoperative imaging, n (%)
CT scan 32 (100)
MRI scan 10 (31.3)
PET scan 12 (37.5)




Table 2 | Treatment characteristics from all 32 patients who successfully underwent 
CRS+HIPEC.
CRS+HIPEC procedure
PCI at HIPEC, median [IQR] 5 [3−11]
Total anatomic resections, median [IQR] 4 [4−6]
Stomach, n (%) 1 (3.1)
Jejunum, n (%) 5 (15.6)
Ileum, n (%) 9 (28.1)
Ileocecal, n (%) 8 (25.0)
Appendix, n (%) 4 (12.5)
Right colon, n (%) 5 (15.6)
Transverse colon, n (%) 1 (3.1)
Left colon, n (%) 7 (21.9)
Sigmoid, n (%) 16 (50.0)
Rectum, n (%) 18 (56.3)
Omentum, n (%) 31 (96.9)
Right diaphragm, n (%) 5 (15.6)
Left diaphragm, n (%) 3 (9.4)
Right peritoneum, n (%) 6 (18.8)
Left peritoneum, n (%) 5 (15.6)
Lymph nodes, n (%) 5 (15.6)
Spleen, n (%) 2 (6.3)
Gallbladder, n (%) 6 (18.8)
Bladder, n (%) 2 (6.3)
Urether, n (%) 4 (12.5)
Uterus, n (%) 5 (15.6)




≥ 2 9 (28.1)
Stoma post−HIPEC, n (%) 19 (59.4)
Operation time, min, median [IQR] 468 [368−599]
Blood loss, mL, median [IQR] 800 [350−2100]




Length of hospital stay, days, median [IQR] 17 [13−24]
Reoperation, n (%) 7 (21.9)
In-hospital mortality, n (%) 1 (3.1)
Complication rate, Clavien−Dindo, n (%)
Grade I−II 10 (31.2)
Grade III−IV 12 (37.5)
Complication type grade ≥ III, n (%)
Anastomotic leakage 2 (6.3)
Postoperative bleeding 1 (3.1)
Intra−abdominal abscess 5 (15.6)
Wound infection 5 (15.6)
Wound dehiscence 3 (9.4)
Fistula formation 2 (6.3)
Urinoma 1 (3.1)
Electrolyte disorder 1 (3.1)
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Overall ability to predict the extent of surgery
The number of resections necessary to achieve a complete cytoreduction 
were predicted correctly 24 times (18.3%), overestimated 57 times (43.5%), and 
underestimated 50 times (38.2%).
The overall PPV for the different anatomical structures ranged between 33.3 and 
87.8% (Table 3a and b, Figure 2). The anatomical sites in which the surgeon predicted 
reasonably well where the appendix (100%), rectum (87.8%), and sigmoid (81.3%). 
On the other hand, to predict a resection of especially the bladder (41.7%), jejunum 
(40.0%), peritoneum (34.2%), transverse colon (33.3%), or lymph nodes (32.1%) 
turned out to be very difficult. In contrast, the overall PPV for the presence of a 
stoma post−HIPEC was overall high (88.1%). In the 24 ES forms including the patients 
in whom a stoma was already present prior to CRS+HIPEC, a PPV of 100% was found.
The overall NPV for the different anatomical structures ranged between 54.9 and 
100%, including 12 anatomical structures with an NPV greater than 90%. The lowest 
scores were found for the rectum (54.9%) and sigmoid (59.0%). In addition, the 
NPV for the absence of a stoma post−HIPEC was 56.2%. This means that surgeons 
incorrectly predicted the absence of a stoma in 56.2% of the cases, as in these 
patients a stoma was created during CRS+HIPEC. In the 24 ES forms including the 
patients in whom a stoma was already present prior to CRS+HIPEC, a NPV of 62.5% 
was found.
The sensitivity for resection of the different gastrointestinal anatomical structures 
was overall low with a range of 0.0 to 85.0%. Especially, overall sensitivity for the 
small bowel resections (i.e., jejunum, ileum, and ileocecal) was only 28.6, 40.7, and 
21.9%, respectively. For the other anatomical structures sensitivity was the highest 
for the left peritoneum (96.2%) and the right peritoneum (73.3%). Overall sensitivity 
for the presence of a stoma post−HIPEC was found to be 51.3%.
The specificity for the preservation of the different anatomical structures was overall 
high and ranged from 75.5 to 100%.
Individual ability to predict the extent of surgery
The individual ability to predict the ES is outlined in Supplementary Table 1 and 
2. Major differences in PPVs between the surgeons were observed for most of 
the anatomical structures, with exception of the appendix. For nine anatomical 




ileum, left colon, transverse colon, spleen, gallbladder, bladder, lymph nodes, and 
uterus). The largest differences were observed for the transverse colon (range 
100%), uterus (range 87.5%), and ileum (range 83.3%).
In contrast, the NPVs for the majority of the anatomical structures were similar 
between surgeons and differences ranged between 1.5 and 66.7%. The largest 
difference was observed for the sigmoid (range 31.8%).
Impact of radiological examinations on the ability to predict the extent 
of surgery
According to the preoperative evaluation for CRS+HIPEC, 87 ES forms (66.4%) 
included patients in whom only CT was performed and 44 ES forms (33.6%) 
included patients in whom both CT and MRI were performed. Combining CT with 
MRI significantly improved the overall PPV for the sigmoid (85.2 vs 76.2%, p < 0.0001), 
rectum (100 vs 73.9%, p < 0.0001), and ureter (100 vs 40.0%, p = 0.024), and the 
overall NPV for the jejunum (100 vs 85.4%, p = 0.001). For the other anatomical 
structures no significant differences were found for the overall PPV and overall NPV.
Postoperative morbidity and mortality
Major postoperative complications (i.e., grades III–IV) occurred in 12 patients 
(37.5%) (Table 2). The most common surgical complications in these patients were 
intra−abdominal abscesses (15.6%) and wound infections (15.6%). Reoperation was 
necessary in seven patients (21.9%). The overall 90−days postoperative mortality 
rate (i.e., grade V) was 3.1%.
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Surgeons’ ability to predict the extent of surgery
Figure 2 | Overall positive and negative predictive values for all anatomical structures divided 
into good PPV/NPV (i.e., >80%), moderate PPV/NPV (i.e., 50−80%), and poor PPV/NPV (i.e., <50%)
DISCUSSION
In this prospective observational cohort study, consisting of 131 ES forms, the 
surgeons’ ability to predict the ES prior to CRS+HIPEC was evaluated for the first 
time. Overall, the surgeons seemed to be able to predict better the anatomical 
structures that remain in situ after CRS+HIPEC, rather than predict the resections 
that were necessary to achieve a complete cytoreduction with an underestimation 
of the ES in almost 40% of the cases.
Over the past decades, CRS+HIPEC has improved survival outcomes for patients 
with PM from various primary tumours.1–7 This potential survival benefit needs 




mortality. HIPEC surgeons attempt to make this estimation for their patients in 
advance of planning an CRS+HIPEC procedure, but the complex interplay of patient 
characteristics, tumour characteristics, and treatment−related characteristics makes 
this task almost impossible. In recent years, various risk factors for the occurrence 
of major postoperative complications after CRS+HIPEC (i.e., grades III–V) have 
been identified.17,20,26,27 The ES—including the number of resected anatomical 
structures—has repeatedly been described as an independent risk factor for 
treatment−related morbidity.20,26,27 A surgeon’s ability to correctly predict the ES 
in advance of CRS+HIPEC seems to be one of the key elements to estimating the 
individual risk for treatment−related morbidity, which is of importance for informing 
patients in the outpatient clinic and patient−shared decision making. In our current 
study, we show that surgeons—despite the presence of different state−of−the−art 
imaging modalities such as multidetector CT, PET−imaging, and MRI—predicted the 
number of resections correctly in only 18.3% of the cases. Furthermore, in 38.2%, 
an underestimation of the number of anatomical resections occurred, subsequently 
the associated risk for treatment−related morbidity might also be underestimated 
prior to surgery. The high PPV for the presence of a stoma (88.1%) and the low NPV 
for the absence of a stoma (56.2%) post−HIPEC supports our protocol with stoma 
counselling and education for every patient prior to CRS+HIPEC.
To our knowledge, no previous studies have reported on surgeon’s ability to predict 
the ES prior to CRS+HIPEC. However, the large number of publications about the 
limitations of current imaging modalities in detecting PM and the occurrence of an 
open–close procedure in up to 50% of the patients, confirm that in most patients 
surgeons despite having performed extensive imaging will only discover the true 
extent of peritoneal disease during the exploratory laparotomy itself.28–35 This has 
major logistical consequences as for instance an open−close procedure is not only 
a patient tragedy, but also a drawback for the other patients waiting on the list. 
This is also reflected by our current study showing both an overestimation and 
underestimation of the number of resected anatomical structures during CRS+HIPEC 
in 43.5 and 38.2% of the cases, respectively.
Interestingly, for some specific anatomical structures we found high PPVs for 
each of the individual surgeons. For the appendix, this might be explained by the 
clear indication to remove this organ during CRS+HIPEC standardly. The PPVs for 
sigmoid and rectum were also high, which might be explained by the relatively high 
number of patients with synchronous onset of colorectal PM from sigmoid or rectal 
cancer (25.0 and 18.8%, respectively), and where the surgeon knows in advance 
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that this part of the colon will have to be removed. Overall, NPVs for the different 
anatomical structures were higher and showed less variation between surgeons 
compared to the PPVs. This suggests that surgeons were better able to predict 
the anatomical structures that remained in situ after CRS+HIPEC than to predict 
the anatomical structures that would be resected during CRS+HIPEC to achieve a 
complete cytoreduction.
From a clinical perspective, PPVs and NPVs are the most interesting outcomes 
reflecting the ability to predict the ES according to our daily practice. The ES that 
seems to be necessary to achieve a complete cytoreduction plays a crucial role in 
the selection process for CRS+HIPEC. This estimation per anatomical structure in 
advance is expressed by the PPV and NPV. However, our study results should be 
interpreted with some caution, as from a statistical point of view it is known that 
both values are influenced by the prevalence of the performed resections during 
CRS+HIPEC. For example, in our study cohort, there is a relatively high number 
of patients with rectal cancer, making it easier for surgeons to predict a rectum 
resection, resulting in a higher PPV. On the other hand, it is more difficult to predict 
the preservation of the rectum resulting in a lower NPV. In summary, the PPVs and 
NPVs provide specific information about the ability from our surgeons to predict 
the ES in this specific study population.
This study has certain strengths and limitations. This is the first study that describes 
the ability of experienced surgeons to predict the ES prior to CRS+HIPEC. These 
results have been collected in a way that fully reflects our daily clinical practice 
by having only experienced surgeons complete the standardised ES forms prior 
to surgery for a group of patients who represent our average HIPEC population. 
Gathered knowledge from this study made us aware of the still−existing challenge 
of predicting the ES, and future research should focus on optimising the detection 
of PM during the preoperative workup. There is not one CRS+HIPEC procedure; 
these procedures are very different in extent and burden and thus outcomes and a 
better estimation of the ES prior to surgery will improve our preoperative decision 
making especially when we are dealing with patients that are older or have extensive 
comorbidity. Our study has some limitations due to the single−centre approach and 
the already−mentioned limitations of the PPV and NPV from a statistical point of 
view. Our surgeons are extensively trained to perform gastrointestinal procedures 
and CRS+HIPEC procedures and therefore these results might not be extrapolated 
to all centres, although most CRS+HIPEC procedures are performed in highly 




by also presenting the sensitivity and the specificity for the different anatomical 
structures, as these outcomes are not influenced by the number of resections. 
However, sensitivity and specificity seems less useful for surgeons because they 
do not reflect daily practice, as the predictions for the ES are always made prior to 
surgery.
CONCLUSIONS
The ES during CRS+HIPEC is a well−known risk factor for the occurrence of major 
postoperative morbidity, and therefore essential to know prior to surgery. Surgeons 
with extensive experience in performing these procedures have the ability to predict 
in advance which of the anatomical structures can be preserved during CRS+HIPEC 
but in most cases fail to predict the actual ES, including the resections that are 
necessary to achieve a complete cytoreduction. This phenomenon has not been 
described before and emphasises that future research should focus even more on 
optimising the detection of the extent of disease prior to surgery.
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NEW AVENUES FOR RESEARCH

7
Impact and risk factors for clinically relevant 
surgery−related muscle loss in patients 
after major abdominal cancer surgery
















Surgery−related muscle loss (SRML) occurs in at least one out of three cancer 
patients within one week after major surgery. Though, this important phenomenon 
has hardly been investigated.
Methods
The MUSCLE POWER is a prospective, observational cohort study that investigates 
the presence, impact, and predictors for clinically relevant SRML in 178 cancer 
patients after major abdominal surgery using ultrasound measurements, squeeze 
and force measurements, and QoL questionnaires. Primary endpoint is the 
proportion of patients with clinically relevant SRML defined as ≥5% muscle loss 
within one week after surgery, measured by the cross−sectional area (CSA) of three 
different muscles: m. biceps brachii, m. rectus femoris, and m. vastus intermedius. 
Possible correlation with QoL and fatigue up to six months after surgery will be 
investigated. Daily physical activity during hospital stay will be monitored by 
a motility tracker, and protein intake will be monitored by a dietician. Possible 
predictors for clinically relevant SRML—consisting of age ≥65 years, preoperative 
diabetes, preoperative sarcopenia, major postoperative complications (Clavien−
Dindo ≥III), insufficient physical activity, and insufficient postoperative protein 
intake—will be investigated with a multivariable logistic regression analyses with a 
backward stepwise approach. Variables with a p < 0.05 will be retrained in the final 
multivariable model.
Discussion
The MUSCLE POWER investigates the presence and impact of clinically relevant 
SRML in cancer patients after major abdominal surgery. Crucial information 
regarding possible predictors for clinically relevant SRML can be used in future 
intervention studies to prevent postoperative muscle loss and subsequently 
improve postoperative outcome and QoL.
Trial registration
Medical Ethics Committee of the University Medical Center Groningen, the 
Netherlands (METc2018/361, version 3.0, January 21, 2019), and Netherlands Trial 
Register ([NTR], NTR NL7505, version 1.0, February 7, 2019).
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INTRODUCTION
Acute muscle loss has been studied extensively in critically ill patients in the 
intensive care unit (ICU) and is recognized as a common problem.1-7 At least 25% of 
the patients will develop ICU−acquired paresis, which is associated with significant 
mortality and morbidity and predicts long−term functional disability.5-9
In contrast to the growing amount of knowledge about the impact of muscle loss in 
ICU patients, there have been only a few studies reporting the amount of muscle 
loss in patients after major surgery.10-13 In patients who underwent elective high−
risk cardiothoracic surgery, 55% developed quadriceps atrophy seven days after 
surgery.10 In another study, one out of three cancer patients developed clinically 
relevant surgery−related muscle loss (SRML) within one week after curative gastric 
cancer surgery.11 Clinically relevant SRML was associated with postoperative 
complications and a longer length of hospital stay. These findings were also 
confirmed in a study including 254 patients who underwent major hepatectomies 
with extrahepatic bile duct resections.12 In this study, patients with clinically 
relevant SRML within one week after surgery had a significantly higher rate of 
major postoperative complications and an increased surgery−related mortality 
risk. Quality of life (QoL) and fatigue were decreased up to three months after 
surgery. Postoperative fatigue is one of the main complaints after surgery and its 
presence prevents patients from returning to work. Only one study investigated 
and identified two independent predictors for clinically relevant SRML (age ≥65 
years and preoperative diabetes).11 These few studies demonstrate that clinically 
relevant SRML might be a major problem for our current healthcare system based 
on its impact on several short−term postoperative problems and its postoperative 
impact on QoL and fatigue.
Prevention of clinically relevant SRML can be a promising strategy to improve 
morbidity and mortality and increase QoL after major surgery. Unfortunately, these 
days, there is still a lack of scientific knowledge regarding this topic. Therefore, we 
made the design of the MUSCLE POWER study to further investigate the presence, 
impact, and possible predictors for clinically relevant SRML in cancer patients who 
underwent major abdominal cancer surgery. With this obtained knowledge, future 
intervention studies can focus on the prevention of postoperative muscle loss and 






The MUSCLE POWER study is an observational single−centre prospective cohort 
study in an academic setting that evaluates the proportion of cancer patients with 
clinically relevant SRML after major abdominal cancer surgery by using bedside 
ultrasound measurements of the arms and legs. Clinically relevant SRML is 
defined as ≥5% muscle loss within one week after surgery measured by the cross−
sectional area (CSA) of the different muscles. In addition, we explore the effects of 
clinically relevant SRML on different life domains of QoL and fatigue after surgery. 
Furthermore, we investigate six possible predictors for clinically relevant SRML, 
identified by current literature or expert opinion, to provide essential information 
for future intervention studies to prevent clinically relevant SRML and reduce the 
possible associated impact on short− and long−term outcomes after surgery. We 
hypothesize that 50% of our patient population will have clinically relevant SRML 
within one week after major abdominal cancer surgery. Predictors for developing 
clinically relevant SRML will be preoperative sarcopenia, preoperative diabetes, age 
≥65 years, occurrence of major postoperative complications, insufficient physical 
activity, and insufficient protein intake during the first week after surgery. Clinically 
relevant SRML will also be associated with fatigue and a reduced QoL three and six 
months after surgery.
This trial will run in the University Medical Center Groningen (UMCG) from April 
2019 until the target sample size of 178 patients has been reached (probably at the 
end of 2020). Other hospitals might be invited to collaborate, depending on the 
recruitment rate during the first year of patient inclusion.
Patient selection
Adult patients scheduled for major abdominal cancer surgery based on an underlying 
malignancy of the liver, pancreas, bile duct, colon, rectum, or pseudomyxoma 
peritonei are eligible for this study. Potential eligible patients will be identified at 
the weekly multidisciplinary oncology meeting and screened and informed about 
the study by their surgeon in the outpatient clinic during standard preoperative 
visits. Patients who meet the inclusion and exclusion criteria and are interested to 
participate in the study will receive a patient information letter describing the aims, 
content, duration, and objections of the study as well as the risks of participating. 
The investigator will contact these patients within one week by telephone to provide 
further information and answer remaining questions. After this conversation, 
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patients have two weeks to decide whether they would like to participate. For 
patients who want to participate, an informed consent form has to be signed prior 
to the surgical procedure. During the study period, patients can leave the study at 
any time for any reason without any consequences. The investigator can decide to 
withdraw a patient from the study for urgent medical reasons.
Inclusion criteria
To be eligible to participate in this study, a patient must meet all of the following 
inclusion criteria:
• Age ≥18 years;
• Able to read and understand the Dutch language;
• Diagnosed with or suspicion of a liver tumour (primary cancer or colorectal 
liver metastases), pancreatic malignancy, bile duct malignancy, colon tumour, 
rectum tumour, or pseudomyxoma peritonei;
• Scheduled for open major abdominal cancer surgery at UMCG, consisting of 
the following surgical procedures:
 o cytoreductive surgery combined with hyperthermic intraperitoneal 
intraoperative chemotherapy (CRS+HIPEC);
 o (sub)total pelvic exenteration;
 o (sub)total colon resection;
 o pylorus preserving pancreaticoduodenectomy (PPPD);
 o whipple procedure (classic pancreaticoduodenectomy);
 o (sub)total pancreatectomy;
 o major liver resection defined as ≥3 liver segments.
• Undergone a preoperative computed tomography (CT) of the abdomen to 
determine preoperative sarcopenia;
• Given written informed consent to participate in the study.
Exclusion criteria
A potential eligible patient who meets any of the following exclusion cannot 
participate in this study: scheduled to undergo emergency resection; scheduled to 
undergo laparoscopic surgery; scheduled to undergo robotic surgery; and unable 
to co−operate and give informed consent.
Study endpoints
The primary endpoint of this study is the proportion of patients who have clinically 




by the CSA of the different muscles with bedside ultrasound measurements. The 
secondary endpoints are related to the amount of loss of muscle mass per day 
after surgery and during hospital stay and to the amount of decrease in muscle 
strength per day after surgery and during hospital stay. Six possible predictors 
for clinically relevant SRML—consisting of age ≥65 years, preoperative diabetes, 
preoperative sarcopenia, major postoperative complications (Clavien−Dindo ≥III), 
insufficient physical activity, and postoperative protein intake—will be explored. 
In addition, we will evaluated the amount of unplanned readmissions within 30 
days after discharge, and the QoL and fatigue three and six months after surgery 
between patients with and without clinically relevant SRML.
Sample size calculation
The sample size calculation is based on the primary endpoint, the proportion of 
patients with clinically relevant SRML defined as ≥5% muscle loss within one week 
after surgery measured by the CSA of the different muscles. To determine the 
appropriate sample size (SS) for estimating the proportion of patients with clinically 
relevant SRML, we used the following formula:
SS = (Z−score)2*proportion*(1 – proportion)/(margin of error)2
For a confidence level of 95%, α is 0.05 and the corresponding Z−value is 1.96. 
The sample proportion is unknown. We chose the number 0.50 (50%) because it 
takes the maximum spread into account. Consensus about the margin of error was 
achieved by joint discussion of the research group; a margin error of 0.075 (7.5%) 
was accepted. In total, 178 patients will be enrolled in the study to reach the target 
sample size.
Measurements
Figure 1 shows an overview of the different types of measurements during the study 
period.
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Baseline muscle mass for each patient will be measured by the investigator one 
day prior to surgery with a hand−held ultrasound system (Philips FUS6882 Lumify 
L12−4) and consist of ultrasound measurements of the following four muscles: m. 
biceps brachii, m. rectus abdominis, m. rectus femoris, and m. vastus intermedius. 
For each muscle, the cross­section (anterior−posterior diameter) and the CSA will 
be measured bilaterally three times. Patients will be positioned supine on the bed 
with arm and leg muscles relaxed. The transducer will be placed perpendicular to 
the long axis of the different muscles (i.e., perpendicular to the major axis of the 
limb). The location of the measurement of the arm will be at two−thirds of the 
length between the tip of the acromion and elbow fold with the elbow extended 
and the forearm in supine position. In the leg, the measurement will be at one−half 
the distance between spina iliaca anterior superior and the proximal border of the 
patella. The rectus will be measured halfway between the xiphoid and umbilicus 
on both sides of the abdomen. These different measuring points will be marked 
with a waterproof marker to ensure fixed points during the rest of the study period.
The muscle ultrasound measurements will be repeated on the third, seventh, and tenth 
day after surgery and on the day of discharge, with exception of the m. rectus abdominis, 
because of the laparotomy wound that will occur after surgery. Baseline measurements 
and measurements obtained on the seventh day after surgery will be used to 
investigate the primary endpoint. Other measurements will be used to investigate 
the amount of loss of muscle mass per day after surgery and during hospital stay.
Muscle strength
Squeeze and force measurements will be performed on the same days as the 
ultrasound measurements: one day prior to surgery; third, seventh, and tenth day 
after surgery; and on the day of discharge.
Isometric muscle force from grip strength of the hand, elbow flexion and extension, 
and knee flexion and extension will be measured with a hand−held dynamometer 
(HHD) using different break tests. A description of the body positions of the HHD 
and the patient during different measurements is described in Table 1 and shown 
in Figure 2 (A and B) and Figure 3 (A and B). Patients will receive the instruction 
to build up maximal strength in one to two seconds. The researcher will gradually 
overcome the muscle force and stop at the moment the extremity gives away. Each 
measurement will be carried out three times in series with 20 seconds intervals 
between the contractions. This is a standardised method for performing a break test.14
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By using multiple squeeze and force measurements at different time points, we 
can analyse the amount of decrease in muscle strength per day, discover specific 
patterns of decrease in muscle strength, and calculate the total amount of decrease 
in muscle strength during the hospital stay.
Table 1 | Body position of the hand−held dynamometer and the patient during different 
break tests.
Joint/limb position Localisation HHD Position patient
Elbow flexion Neutral shoulder, elbow 
flexed 90⁰, upper arm 
against trunk
Just proximal to styloid 
process of radius
Lying supine
Elbow extension Same as in flexion Just proximal to ulnar head Same as in flexion
Knee flexion Hip and knee flexed 90⁰ Just proximal to calcaneus Sitting in a chair
Knee extension Same as in flexion Just proximal to talis Same as in flexion
Physical activity
Insufficient physical activity post operation might be a possible predictor for 
clinically relevant SRML. Therefore, each patient will wear a motility tracker 
(Actigraph wGT3X−BT [Actigraph, Pensacola, FL, USA]) during the first week after 
surgery except on the day of operation and during water−based activities. The 
Actigraph WGT3X−BT is a small and lightweight device that will be worn on the 
left or right ankle with an elastic belt to prevent discomfort for the patient and to 
measure physical activity data as reliably as possible. The device does not provide 
direct feedback to the patient.
The Actigraph provides high raw acceleration data to capture physical activity 
intensity, activity bouts, and sedentary bouts. The information from the activity 
tracker will be downloaded to ActiLife. This program automatically provides total 
activity counts and time per intensity level per day. Existing cut−off points for 
moderate (2020−5999 counts/min) and vigorous intensity physical activity (>5999 
counts/min) will be used. A valid monitoring day will be defined as having 10 or more 
hours of monitor wear. Wear time is determined by subtracting non−wear time from 
24 hours. Non−wear time is as defined by an interval of at least 60 consecutive min 






Figure 2 | Positions of the hand−held dynamometer for elbow flexion and extension.
(A) Elbow flexion. (B) Elbow extension.
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A
B
Figure 3 | Positions of the hand−held dynamometer for knee flexion and extension.




The total amount of moderate and vigorous intensity physical activity in the first 
seven days after surgery will be calculated. If a patient’s activity is less than 150 
min of moderate/vigorous intensity physical activity within the first week after 
surgery, it will be registered as ‘insufficient physical activity’. We will than investigate 
if insufficient physical activity is associated with clinically relevant SRML.
Protein intake
We suspect that malnutrition prior to surgery and insufficient protein intake during 
the first week after surgery might be possible predictors for clinically relevant SRML. 
According to the European Society for Clinical Nutrition and Metabolism guidelines, 
surgical patients need 1.5 g/kg protein per day after major surgery.15 Patients will 
fill in the patient−generated subjective global assessment (PG−SGA) questionnaire 
one day prior to surgery. This validated questionnaire for nutritional assessment 
focuses on four elements: (1) dietary intake change, (2) gastrointestinal symptoms, 
(3) short−term weight loss, and (4) changes in functional capacity.16 Each element 
can be scored from zero to four. The higher the total score from the PG−SGA, the 
greater the risk for malnutrition, in which a score of nine or higher indicates a critical 
need for nutritional interventions.
The first seven days after surgery, daily protein and energy intake will measured by 
a dietician by using a nutrition dairy. The intake on the day of the surgical procedure 
itself will be excluded. Afterwards, we will calculate the number of days that the 
protein intake was not adequate (e.g., <1.5 g/kg). We will register the protein intake 
as ‘insufficient’ if the patient received less than 1.5 g/kg for two or more days within 
the first week after surgery. Next we investigate if an insufficient amount of protein 
intake during the first week after surgery is associated with clinically relevant SRML.
Sarcopenia preoperatively
We suspect that preoperative sarcopenia might be a possible predictor for clinically 
relevant SRML. The presence of preoperative sarcopenia will be measured on 
preoperative workup CT scans by an experienced musculoskeletal radiologist. 
Cross−sectional skeletal muscle surface (cm2) will be assessed at the level of the third 
lumbar vertebra (L3) to determine the sarcopenia index. Measurements of the psoas 
and abdominal wall will be obtained and compared. Skeletal muscle cut−off values 
for sarcopenia will be corrected for height, age, and ethnic group according to the 
consensus diagnostic criteria for sarcopenia, developed by the European Working 
Group on Sarcopenia in Older People (EWGSOP).17 These measurements will be used 
to investigate if preoperative sarcopenia is associated with clinically relevant SRML.
159
The MUSCLE POWER study 
Other possible predictors
In addition to the presence of insufficient physical activity, insufficient protein 
intake, and preoperative sarcopenia, we identified three other possible predictors 
for clinically relevant SRML: age ≥65 years, preoperative diabetes, and occurrence 
of major postoperative complications. Data about these possible predictors will be 
collected from digital patient records. Postoperative complications will be registered 
using the Clavien−Dindo classification system.18 Major postoperative complications 
are defined as Clavien−Dindo ≥III. All possible predictors will be dichotomized 
(presence or absence of the predictor) for further analyses.
Urine collection
Urinary creatinine excretion rate (CER) measured from a 24−hour sample is an 
established non−invasive marker of total body muscle mass and seems to predict 
long−term outcomes in patients after liver transplantation.19 We suspect that CER 
might be an interesting marker in predicting clinically relevant SRML. Therefore, 
collection of 24−hour urine samples will take place at baseline and be repeated on 
the seventh day after surgery.
Questionnaires
Patients will receive three different questionnaires at baseline and three and six months 
after surgery to compare scores over time to identify the impact of clinically relevant 
SRML on QoL and fatigue. Patients will receive the questionnaires by e−mail or on paper.
The WHOQOL−Bref (version 1.0, December 1996) and RAND−36 (version 2.0, 2007) 
will be used to assess QoL. The WHOQOL−Bref contains a total of 26 questions 
including the following four domains: physical health, psychological, social 
relationships, and environment.20,21 The RAND−36 Item Health Survey cover eight 
concepts: physical functioning, bodily pain, role limitations due to physical health 
problems, role limitations due to personal or emotional problems, role emotional 
well−being, social functioning, energy/fatigue, and general health perceptions.22 It 
also includes a single item that provides an indication of perceived change in health. 
Both questionnaires are available in Dutch.
The multidimensional fatigue inventory (Dutch version MFI−20, 2003) will be used 
to assess fatigue. The MFI−20 is a 20−item self−report instrument designed to 
measure fatigue and is well−established in cancer patients.23 It covers the following 






All data will be handled confidentially and stored in an electronic case record form 
designed in the software program Open Clinica (TRAIT BV, the Netherlands), a 
program especially designed for clinical trial data recording and monitoring. Only 
the principal investigators will have access to the stored data.
Data analysis plan
All statistical analyses will be conducted using SPSS® Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA). Continuous variables will be expressed as mean 
± standard deviation (SD) or median with interquartile range (IQR) and categorical 
variables will be described as count (n) and percentage (%) with 95% confidence 
intervals (CI). Patient characteristics will be compared using the student t−test or 
Mann Whitney U−test for continuous variables and differences between nominal 
variables will be determined using Pearson chi−square test or Fisher’s exact test. 
Distribution will be assessed with the Shapiro−Wilk normality test.
The different possible predictors for clinically relevant SRML will be investigated 
with a multivariable logistic regression analyses to calculate odds ratios (ORs) 
with 95% Cl. A backwards stepwise selection methodology will be used to identify 
independent predictors for clinically relevant SRML. Variables with p < 0.1 in the 
univariate analysis will be included in the multivariate analysis, and variables 
significant at p < 0.050 will be retrained in the final multivariable model. All tests 
will be two−sided and p ≤ 0.05 will be considered statistically significant.
Dissemination policy
Both positive and negative research results will be disclosed and submitted to peer−
reviewed scientific journals. The principal investigator and steering committee will 
prepare the manuscripts together with the statistician and other active writing 
committee members. Co−authorship is reserved for all investigators and in addition 
to those who constructively contributed to the study at the discretion of the project 
leader and steering committee. Finally, disputes on the interpretation of the results 
may not lead to an unnecessary delay in publication.
DISCUSSION
The results from the MUSCLE POWER study will provide important clinical knowledge 
on the presence, impact, and possible predictors for clinically relevant SRML after 
major abdominal cancer surgery. This obtained scientific knowledge, will fill in 
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important gaps in the current literature and may give leads how to prevent clinically 
relevant SRML and improve morbidity and mortality and QoL after surgery in this 
vulnerable patient population.
The primary aim of this study is to identify the proportion of patients who have 
clinically relevant SRML, defined in this study as ≥5% muscle loss within one week 
after surgery measured by the CSA of three different muscles by ultrasound. Our 
primary endpoint is clear and relatively easy to measure, although there is currently 
no global consensus about what amount of muscle loss is clinically relevant (e.g., 
harmful for the patient). The definition of clinically relevant SRML is therefore based 
on combining data from three previous published studies that examined acute 
muscle loss in surgical patients.10-12
In most previous clinical studies, changes in skeletal muscle mass were investigated 
by CT scans at different time points.3,4,11,12 In the meantime, muscle ultrasound 
has emerged as a common, inexpensive, reliable, and valid imaging technique 
for measuring skeletal muscle at the bedside in patients with different clinical 
conditions, without exposing patients to harmful ionizing radiation.1,9,24-27 Therefore, 
in the present study, we will investigate changes in skeletal muscle mass by using 
bedside ultrasound measurements instead of routinely performing additional CT 
scans at different time points.
In the MUSCLE POWER study, additional important information about two factors 
that may extensively influence skeletal muscle loss will be collected as well. To 
maintain skeletal muscle tissue, food intake and muscle contraction are crucial.28 
Previous published papers show that in the majority of patients after surgery, 
daily protein intake is much lower than the recommended guidelines of 1.5 g/kg/
day.13,17,18,29 In the present study, protein intake will be monitored daily by a dietician 
during the first week after surgery to explore its impact on clinically relevant SRML. 
Additionally, all patients will wear a motility tracker to calculate daily moderate and 
vigorous physical activity, as hospitalisation is known to be associated with reduced 
levels of physical activity. Recent studies with older patients show that nutritional 
and physical interventions should be combined to minimise loss of muscle mass 
and muscle strength.30-32 To the best of our knowledge, continuous monitoring of 
both factors in patients in the first week after abdominal cancer surgery has not 
yet been performed. We suspect that in the near future, data from the MUSCLE 
POWER study may play an important role in the development of new nutritional 




Of course, our study protocol may bear some limitations. First of all, the sample 
size calculation was based on the scarcely available scientific data about clinically 
relevant SRML.10-12 Our hypothesis that 50% of our patient population will have 
clinically relevant SRML after major abdominal cancer surgery will take the limited 
amount of previous available data and the maximum spread into account. Despite 
this, the present study may not be powered enough to investigate all six possible 
predictors for clinically relevant SRML that were identified by current literature or 
expert opinion. Another limitation is the fact that we do not perform echo−intensity 
assessments of the different muscles to investigate muscle quality. Specific trainings 
are necessary to reliably reproduce these measurements and software that is 
necessary for echogenicity analysis is not available on our ultrasound system.33,34 
To partially solve this problem, we will perform squeeze and force measurements 
to obtain some information about muscle function (e.g., muscle strength).
DECLARATIONS
Funding
This work is supported by a grant from the UMCG Cancer Research Foundation 
(Institutional Foundation for Cancer Research and Development). The study protocol 
has not undergone any peer−review by this funding body, nor will they play a role 
in the analysis and interpretation of the data.
Ethical approval
The study protocol has been approved by the Medical Ethics Committee of the 
University Medical Center Groningen, the Netherlands (METc2018/361, version 3.0, 
January 21, 2019), and the study protocol was registered with the Netherlands Trial 
Register ([NTR], NTR NL7505, version 1.0, February 7, 2019).
163
The MUSCLE POWER study 
REFERENCES
1. Puthucheary ZA, Rawal J, McPhail M, et al. 
Acute skeletal muscle wasting in critical 
illness. JAMA. 2013;310:1591−600.
2. Campbell IT, Watt T, Withers D, et al. Muscle 
thickness, measured with ultrasound, 
may be an indicator of lean tissue wast-
ing in multiple organ failure in presence 
of edema. Am J Clin Nutr. 1995;62:533−539.
3. Weijs PJ, Looijaard WG, Dekker IM, et 
al. Low skeletal muscle area is a risk 
factor for mortality in mechanically 
ventilated critically ill patients. Crit Care. 
2014;18:R12.
4. Moisey LL, Mourtzakis M, Cotton BA, 
et al. Skeletal muscle predicts ventila-
tor−free days, ICU−free days, and mor-
tality in elderly ICU patients. Crit Care. 
2013;17:R206.
5. de Jonghe B, Sharshar T, Lefaucheur JP, et 
al. Paresis acquired in the intensive care 
unit: a prospective multicenter study. 
JAMA. 2002;288:2859−2867.
6. Chambers MA, Moylan JS, Reid MB. 
Physical inactivity and muscle weak-
ness in the critically ill. Crit Care Med. 
2009;37:337−346.
7. Latronico N, Bolton CF. Critical illness 
polyneuropathy and myopathy: a major 
cause of muscle weakness and paralysis. 
Lancet Neurol. 2011;10:931−941.
8. Baldwin CE, Bersten AD. Alterations in 
respiratory and limb muscle strength 
and size in patients with sepsis who 
are mechanically ventilated. Phys ther. 
2014;94:68−82.
9. Dos Santos C, Hussain SN, Mathur S, et 
al. Mechanism of chronic muscle wasting 
and dysfunction after an intensive care 
unit stay: a pilot study. Am J Respir Crit 
Care Med. 2016;194:821−830.
10. Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp 
PR, Griffiths MJ. Sustained elevation of 
circulating growth and differentiation 
factor−15 and a dynamic imbalance in 
mediators of muscle homeostasis are as-
sociated with the development of acute 
muscle wasting following cardiac surgery. 
Crit Care Med. 2013;41:982−989.
11.  Huang DD, Ji YB, Zhou DL, et al. Effect of 
surgery−induced acute muscle wasting 
on postoperative outcomes and quality 
of life. J Surg Res. 2017;218:58−66.
12. Otsuji H, Yokoyama Y, Ebata T, et al. Sur-
gery−related muscle loss and its associ-
ation with postoperative complications 
after major hepatectomy with extrahe-
patic bile duct resection. World J Surg. 
2017;41:498−507.
13. Kouw IWK, Groen BBL, Smeets JSJ, et al. 
One week of hospitalization following 
elective hip surgery induces substantial 
muscle atrophy in older patients. JAMA. 
2019;20:35−42.
14. Douma RKW, Soer R, Krijnen WP, Reneman 
M, van der Schans CP. Reference values for 
isometric muscle force among workers for 
the Netherlands: a comparison of refer-
ence values. BMC Sports Science Medicine 
and Rehabilitation. 2014;6:10.
15. Singer P, Reintam Blaser A, Berger MM, et 
al. ESPEN guideline on clinical nutrition in 
the intensive care unit. Clinical Nutrition. 
2019;38:48−79.
16. Ottery D. Patient Generated Subjective 
Global Assessment. In: McCallum P, 
Polisena C, Ed. The clinical guide to oncol-
ogy nutrition, The American Dietetic Asso-
ciation, Chicago, 11−23.
17. Cruz­Jentoft AJ, Baeyens JP, Bauer JM, 
et al. Sarcopenia: European consensus 
on definition and diagnosis: report of 
the European Working Group on Sarco-
penia in Older People. Age and Ageing. 
2010;39:412−423.
18. Clavien PA, Barkun J, de Oliveira ML, Vau-
they JN, et al. The Clavien−Dindo classifi-
cation of surgical complications: five−year 
experience. Ann Surg. 2009;250:187−196.
19. Stam SP, Osté MCJ, Eisenga MF, et al. Post-
transplant muscle mass measured by uri-
nary creatinine excretion rate predicts 
long−term outcomes after liver transplan-




20. The WHOQOL group. Development of the 
World Health Organization WHOQOL−
BREF quality of life assessment. Psychol 
Med. 1998;28:551−558.
21. Skevington SM, Lotfy M, O’Connell KA, 
WHOQOL group. The World Health Or-
ganization’s WHOQOL−BREF quality of 
life assessment: psychometric properties 
and results of the international field trial. 
A report from the WHOQOL group. Qual 
Life Res. 2004;13:299−310.
22. Van der Zee K, Sanderman R, Heyink JW, 
de Haes H. Psychometric qualities of the 
RAND 36−item Health Survey 1.0: a mul-
tidimensional measure of general health 
status. Int J Behav Med. 1996;3:104−122.
23. Smets EM, Garssen B, Bonke B, De Haes 
JC. The Multidimensional Fatigue Inven-
tory (MFI) psychometric qualities of an 
instrument to assess fatigue. J Psychosom 
Res. 1995;39:315−325.
24. Bunnell A, Ney J, Gellhorn A, Hough CL. 
Quantitative neuromuscular ultrasound 
in intensive care unit−acquired weak-
ness: a systematic review. Muscle Nerve. 
2015;52:701−708.
25. Connolly B, MacBean V, Crowley C, et al. 
Ultrasound for the assessment of periph-
eral skeletal muscle architecture in criti-
cal illness: a systematic review. Crit Care 
Med. 2014;7:1−10.
26. Sabatino A, Regolisti G, Bozzoli I, et al. Re-
liability of bedside ultrasound for mea-
surement of quadriceps muscle thickness 
in critically ill patients with acute kidney 
injury. Clin Nutr. 2017;36:1710−1715.
27. Parry SM, El­Ansary D, Cartwright MS, et 
al. Ultrasonography in the intensive care 
setting can be used to detect changes in 
the quality and quantity of muscle and is 
related to muscle strength and function. 
J Crit Care. 2015;30:1151.
28. Koopman R, van Loon LJ. Aging, exercise, 
and muscle protein metabolism. J Appl 
Physiol. 2009;106:2040−2048.
29. Gillis C, Nguyen TH, Liberman AS, Carli 
F. Nutrition adequacy in enhanced re-
covery after surgery: a single academ-
ic center experience. Nutr Clin Pract. 
2015;30:414−419.
30. English KL, Paddon-Jones D. Protecting 
muscle mass and function in older adults 
during bed rest. Curr Opin Clin Nutr Metab 
Care. 2010;13:34−39.
31. Paddon-Jones D, Sheffield-Moore M, 
Urban RJ, et al. Essential amino acid and 
carbohydrate supplementation ame-
liorates muscle protein loss in humans 
during 28 days bedrest. J Clin Endocrinol 
Metab. 2004;89:4351−4358.
32. Wall BT, van Loon LJC. Nutritional strate-
gies to attenuate muscle disease atrophy. 
Nutr Rev. 2013;71:195−208.
33. Ticinesi A, Meschi T, Narici MV, Lauren-
tani F, Maggio M. Muscle ultrasound 
and sarcopenia in older individuals: a 
clinical perspective. J Am Med Dir Assoc. 
2017;18:290−300.
34. Berger J, Bunout D, Barrera G, et al. 
Rectus femoris (RF) ultrasound for the as-
sessment of muscle mass in older people. 










W.Y. van der Plas
G.M. van Dam
S. Kruijff
* These authors contributed equally




Patients with peritoneal carcinomatosis (PC) from colorectal origin may undergo 
cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy 
(HIPEC) as a curative approach. One major prognostic factor that affects survival is 
completeness of cytoreduction. Molecular fluorescence guided surgery (MFGS) is a 
novel intraoperative imaging technique that may improve tumour identification in 
the future, preventing over− and under−treatment in these patients. This narrative 
review outlines a chronological overview of MFGS development in patients with PC 
of colorectal origin.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers worldwide, with an 
incidence of 40 patients per 100.000 population and a mortality rate of 15 per 100.000 
persons.1,2 Of these patients, 8−25% develop peritoneal carcinomatosis (PC).3-6 Over the 
past decades, the treatment of PC of colorectal origin has evolved considerably, from 
palliative care towards a more successful treatment approach with curative intent.7,8 In 
particular, the introduction of cytoreductive surgery (CRS) combined with hyperthermic 
intraperitoneal chemotherapy (HIPEC) has contributed significantly to this change.9,10 
After surgical cytoreduction of all macroscopic tumour tissue, the abdominal cavity 
is perfused with heated chemotherapy in order to eliminate remaining microscopic 
disease. Up to date, only one randomised clinical trial has been performed studying 
patients with PC of colorectal origin. A median overall survival of 22 months was seen 
for patients after undergoing CRS in combination with HIPEC, compared to 13 months 
for patients receiving only systemic chemotherapy with or without palliative surgery.11,12 
The authors report a 5−years survival of 43% for patients in whom all macroscopic 
tumour was removed, compared to 0% for patients in whom residual lesions of 
more than 2.5 mm were left behind.11 These findings emphasize the importance of 
patient selection and a macroscopically complete cytoreduction, mainly because 
incomplete cytoreduction followed by HIPEC does not contribute to a prolonged 
survival, but potentially does introduce a high risk of postoperative complications, 
an extensive rehabilitation period and subsequently decreased quality of life.12-15
 Although the technical quality of the complete CRS+HIPEC procedure has improved, 
still up to 88% of the patients undergoing CRS+HIPEC for PC of CRC develop 
recurrent disease within 2 years.16 Currently, many imaging modalities are available 
for preoperative staging, such as ultrasonography, computed tomography (CT), 
magnetic resonance imaging (MRI) or positron emission tomography (PET) scans. 
Unfortunately, all of these imaging modalities are insufficient for the preoperative 
assessment of tumour load, or determination of a preoperative peritoneal cancer 
index (PCI), the most important staging system in PC. CT, MRI and fluorodeoxyglucose 
(FDG−) PET scans have a poor sensitivity and specificity to estimate PCI by detection 
of individual tumour deposits, due to the limited spatial resolution.17 For example, 
the detection of individual peritoneal deposits using a CT−scan varies from 9.1 to 
24.3% for tumor sizes <1 cm, to up to 59.3−66.7% for tumour size of over 5 cm.18 
These results are in accordance with other previous studies.19-21 Current hybrid PET/
CT scanners have a limited spatial resolution of 5−8 mm, whereas MRI seems to be 




For intraoperative differentiation between benign and malignant lesions, surgeons 
currently depend on visual and tactile inspection only. Unfortunately, the human 
eye and palpation are not competent enough to detect molecular changes in 
intra−abdominal lesions that have the same colour and physical properties, or 
to distinguish tumour lesions from benign scar tissue originating from previous 
surgery. Today, to the best of our knowledge, no intraoperative imaging modalities 
provided by the more classical modalities like PET, are available to assist in the 
real−time identification of peritoneal cancer deposits, loco−regional metastases 
and tumor−positive resection margins.
Considering the high tumour recurrence rates after the CRS+HIPEC procedure, there 
is a clear need for an imaging modality that can aid the oncological surgeon in 
the differentiation between tumour and benign tissue intraoperatively. In recent 
years, optical molecular imaging using tumour−targeted fluorescence tracers has 
emerged as a promising imaging technique for real−time guidance in oncological 
surgery.24-26 This technique can be applied intraoperatively to serve as a ‘red−flag’ 
imaging technique to assist in optimal tumour identification. Improved detection 
of tumour tissue could not only help attain a more complete cytoreduction, but 
might also facilitate tailored surgery, avoiding unnecessary resections of benign 
lesions and organs.
This narrative review explains the principles of intraoperative optical molecular 
imaging and provides a chronological overview of the development of molecular 
fluorescence guided surgery (MFGS) in patients with PC of colorectal origin.
PRINCIPLES OF INTRAOPERATIVE OPTICAL MOLECULAR IMAGING
In colorectal surgery, as in surgical oncology in general, radical surgery and 
tumour−free resection margins are essential for optimising patient prognosis. 
Optical molecular imaging using fluorescence imaging agents can provide real−time 
intraoperative feedback with high resolution, that is in concordance with the natural 
surgical field of view of a surgeon and based on the molecular characteristics of the 
tissue (Figure 1). The technique makes use of non−ionising imaging agents and can 
be implemented relatively easily in the current surgical workflow.
Over the past decades, there has been an increased interest in the clinical application 
of optical molecular imaging using fluorescence imaging agents. Fluorescence 
occurs when a photon or fluorescent dye absorbs light at a certain wavelength, 
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subsequently triggering the release of a photon with a longer wavelength.27 The 
quality of fluorescence imaging is influenced by different factors such as changes in 
photon directions (i.e., scattering) and absorption of photons by the tissue. Multiple 
tissue components play an important role in fluorophore absorption, with the most 
relevant being haemoglobin, water, and lipids. As the scattering and absorption 
properties of tissue are lower in light with longer wavelengths, the near−infrared 
(NIR) light spectrum (700–900 nm) is considered the optimal clinical diagnostic 
window for fluorescence imaging.28
Figure 1 | Concept of molecular fluorescence guided surgery (MFGS).
(A) Prior to surgery a fluorescent target tracer is injected intravenously. (B) During the operation 
the surgeon will receive real−time feedback by a molecular fluorescence camera in the detection of 
tumour tissue. Unpublished figure from previously published study Harlaar et al.107
These characteristics result in deeper penetration depths of up to one to three 
centimetres that can be obtained in the NIR light spectrum, leading to higher signal−
to−background (SBR) ratios compared to the visible light spectrum (i.e., red−green−
blue white−light, 380–700 nm).29,30
NIR fluorescence light is invisible to the human eye and therefore special imaging 
devices are required to visualise fluorescence during surgery. In general, these 
camera systems are equipped with two different light sources: a white−light source 
and a NIR fluorescence light source. Due to the use of a dichroic mirror and specific 
filters installed in the camera system itself, the visible light derived from the tissue 




of both visible and NIR fluorescence light. Next to that, an overlay of fluorescence 
signals can be projected on the ‘normal’ white−light images by use of computer 
software.27 In the operating theatre, all three images can be displayed on monitors 
at the same time, providing real−time imaging related to the natural surgical field of 
view (Figure 2). Currently, there are several different intraoperative NIR fluorescence 
imaging devices available for research and clinical use.31-38
Fluorescence signals in tissue arise by either an endogenous tissue component (i.e., 
autofluorescence), or an intravenously administered exogenous optical contrast 
agent. At present, various types of optical contrast agents are available enabling 
intraoperative imaging, which can roughly be divided into non−targeted and 
targeted imaging agents.
The effect of non−targeted imaging agents is mainly based on vascularisation 
and perfusion (i.e., also the so−called enhanced permeability and retention [EPR] 
effect), whereas targeted imaging agents specifically bind to a receptor or protein 
that is present in a tumour cell. Due to genetic alterations that occur in cancer 
development, various receptors and proteins become upregulated, which can 
potentially be used as targets for imaging purposes.39 Prior to developing such 
targeted imaging agents, it is essential to identify which genes or proteins become 
upregulated for each specific tumour type.40,41
UPREGULATED GENES AND PROTEINS RELATED TO CRC
The potential application of targeted imaging agents for intraoperative tumour 
visualisation is dependent on the expression levels of biomarkers. A biomarker is a 
specific component present on or secreted by the tumour cell itself.
Most colorectal cancers are thought to develop via the ‘adenoma−to−carcinoma 
sequence’, arising from normal cells through the stepwise asset of different genetic 
alterations.42,43 In these expressed genes different functional categories can be 
identified: genes related to proliferation and metabolic rates, to cell adhesion and 
communication, to transcription and mitosis regulation, or to apoptosis.44,45 Knowing 
which biomarkers are encoded by which genes is important when searching for 
which target to develop a fluorescence imaging agent for.
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Figure 2 | Intraoperative imaging with white−light, NIR fluorescence and the overlay of both.
Intraoperative imaging of a patient with PC of colorectal origin following intravenous administration 
of 4.5 mg of the fluorescent tracer bevacizumab−800CW targeting VEGF−A. A white−light image 
(A), NIR fluorescence image (B) and overlay of both (C) clearly show fluorescent signals at the 
location of a clinically suspect peritoneal lesion. Back−table imaging directly after surgery of a 
different peritoneal lesion of the same patient is depicted (D−F). Both peritoneal lesions proved to 
be tumour metastasis upon final histopathology. Unpublished figures from previously published 
study Harlaar et al.107
Cardoso et al. presented a list of 128 different genes that were found to be 
upregulated in CRC compared to normal colorectal tissue.44 Since protein 
expression is not always synchronously upregulated, not all of these genes result 
in overexpression of the related proteins or receptors. Previously, an extensive 
literature search has been performed on this specific list of genes, in order to identify 
which genes gave an upregulation of the related proteins or receptors as confirmed 
by immunohistochemical analysis.46 As a result, 29 targets were identified, that could 
be used for imaging purposes during surgery.
TARGET SELECTION CRITERIA (TASC)
To select the most optimal target for imaging purposes from this large set of 
upregulated biomarkers, the TArget Selection Criteria (TASC) scoring system 
was developed.46 The aim of the TASC was to improve the selection of suitable 
biomarkers for tumour−targeted imaging of all types of cancer. Seven of the 
most relevant target characteristics were identified based on literature, that each 
could be scored with 0–6 points. The following characteristics were identified by 




the cell membrane or in close proximity of the tumour cell; II) expression pattern; 
III) tumour−to−healthy tissue ratio (T/N); IV) percentage of positive tumours; V) 
reported successful use of the biomarker in in vivo imaging studies; VI) enzymatic 
activity; and VII) internalisation.46 Based on extensive testing of the TASC on a variety 
of biomarkers, cut−off values were determined for target selection. A total score of 
18 or more indicates that a biomarker can be considered a potential candidate for 
tumour−targeted imaging.
As mentioned before, 29 targets were identified that may be used as potential targets 
for intraoperative imaging of CRC.46 Using the TASC−scoring system, six biomarkers 
were considered the most promising: Epithelial Cell Adhesion Molecule (EpCAM), 
CXC Chemokine Receptor 4 (CXCR4), Mucin 1 (Muc1), Matrix MetalloProteinases 
(MMPs), Epidermal Growth Factor Receptor (EGFR), and Carcino­Embryonic Antigen 
(CEA). Although the Vascular Endothelial Growth Factor−A (VEGF−A) scored a total 
of 17 points, it was still considered a suitable potential target as well, given the 
extensive experience there already is in VEGF−A targeted imaging. For the clinical 
translation of these seven suitable biomarkers, specific fluorescence imaging agents 
need to be available to facilitate MFGS of CRC and PC of colorectal origin.
FLUORESCENCE IMAGING ANGENTS
As stated before, fluorescence imaging agents or probes that can be used for MFGS 
can roughly be divided into two categories: non−targeted fluorescent probes and 
targeted fluorescent probes. The main difference between these two categories is 
based on their mechanism of action (MOA).
Non−targeted fluorescent probes
Non−targeted fluorescent probes accumulate ‘passively’ in solid tumours due to 
physiological properties such as increased angiogenesis, pressure differences 
and high metabolic activity (Figure 3A). It is commonly known that the majority 
of solid tumour cells stimulate angiogenesis and therefore are highly vascularised. 
This feature combined with the lack of efficient lymphatic drainage results in more 
accumulation in tumour tissue compared to normal surrounding tissue, thereby 
enhancing contrast and enabling a differentiation between the tumour and 
surrounding tissue. This phenomenon is also known as the enhanced permeability 
and retention (EPR) effect.
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Many non−targeted fluorescent probes have already been used in humans to 
enhance contrast during surgery in a variety of different indications, such as for 
example fluorescein for retinal fluorescein angiography, indocyanine green (ICG) 
for liver perfusion and lymph node detection, or methylene blue for sentinel lymph 
node detection in breast cancer patients.47-53
ICG is the most commonly known fluorescent probe, which was already approved by 
the Food and Drug Administration (FDA) back in 1959. ICG has several advantages 
over to fluorescein as it only fluoresces in the NIR light spectrum (instead of the 
visible light spectrum) and therefore is less influenced by tissue optical properties 
such as scattering and absorption. As ICG binds to plasma proteins, it has a negligible 
toxicity and is excreted rapidly by the liver into the bile, with a plasma half−life 
of only 3−4 min.54-55 These features make ICG a very attractive contrast agent for 
assessment of macro− and micro−circulatory status of different organs based on 
its intravascular distribution.56
Ever since its first clinical application in hepatology for liver condition monitoring in 
1957, it has been widely applied and studied to visualise perfusion in ophthalmology 
for identification of retinal blood vessels, in cardiac bypass surgery for evaluation 
of anastomoses and for monitoring cardiac output.57-62 More recent studies have 
reported the potential application of ICG for intraoperative fluorescence angiography 
in a broad range of other indications such as neuro−, coronary−, reconstructive− , 




Figure 3 | Fluorescence imaging probes. Overview of fluorescent imaging probes with different 
mechanisms of action.
The effect of non−targeted fluorescent probes is based on tissue distribution by perfusion (A), 
whereas antibody−based (B), peptide−based (C) and small molecule−based (D) imaging enables 
targeted fluorescence imaging through binding to specific receptors or proteins overexpressed by 
the tumour. Smart activatable fluorescent probes are activated upon cleavage by specific enzymes 
or proteases secreted by the tumour (E), whereas pH activated probes becomes fluorescent through 
a change in molecular structure due to the characteristic acidotic environment of a tumour (F).
The first potential application of ICG−based fluorescence imaging in patients with 
peritoneal metastases of colorectal origin was demonstrated in 2016.71 In this study, 
peritoneal metastases from non−mucinous adenocarcinoma were accurately 
identified following the intravenous administration of free ICG during surgery, 
leading to an adjustment in clinical decision making in 29% of patients. However, 
the benefit was minimal in patients with mucinous adenocarcinoma. Despite the 
positive results demonstrated in this study, the main disadvantage still lies in the 
fact it is not tumour−specific and therefore leads to a low sensitivity and specificity.
Targeted fluorescent probes
Due to the low sensitivity and specificity of non−targeted fluorescence probes, 
its application in surgical oncology is still limited. Therefore, to increase contrast, 
this resulted in a shift towards the development and clinical translation of 
targeted optical imaging agents enhancing surgical vision based on the molecular 
characteristics of cancer cells.
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The MOA of targeted fluorescent probes is based on the concept of a carrier 
molecule that is conjugated to a fluorescent dye, specifically binding to a certain 
tumour target. Carrier molecules can either be monoclonal antibodies, (small) 
peptides, small molecules or other molecules that specifically target certain cell 
surface markers that become overexpressed due to genetic variances that occur 
in every tumour (Figure 3B).72 Moreover, the increased metabolic activity that 
characterises certain tumour types can be used as a target.40
Besides a suitable carrier molecule, the fluorescent dye itself also plays an important 
role. The development of new fluorescence probes is challenging since each agent 
needs separate regulatory approval, which is an expensive and time−consuming 
process.73 As mentioned before, fluorescent dyes that emit light in the NIR light 
spectrum provide several advantages over dyes that emit light in the visible 
light spectrum. Although there is a wide variety of fluorescent dyes available for 
conjugation to carrier molecules, the most preclinical and clinical experience has 
been obtained with the NIR fluorescent dye IRDye800CW, developed by LI­COR 
Biosciences Inc. (Lincoln, NE, USA). The IRDye800CW has a peak emission wavelength 
at 794 nm and is ideal for protein and antibody labelling, as conjugation to a carrier 
molecule is relatively easy and extensive toxicity studies have been performed.74
The increasing clinical application of therapeutic monoclonal antibodies 
specifically targeting certain biomarkers of cancer is an interesting development 
in the perspective of optical molecular imaging. Targeting certain tumour−specific 
receptors with fluorescently labelled antibodies seems to have great potential for 
visualisation of cancer during interventions, also in CRC.72,75-78 Multiple targeted 
probes have already been testes successfully in several preclinical studies.75,77-84
The first in−human proof−or−principle of targeted optical molecular imaging using 
a fluorescent probe was provided by van Dam et al. in 2011, demonstrating the 
potential of MFGS in patients with PC originating from ovarian cancer using the 
fluorescent tracer folate−FITC, targeting the folate receptor a.24 Ever since, targeted 




POTENTIAL FLUORESCENCE IMAGING AGENTS FOR DETECTION 
OF COLORECTAL CANCER
As mentioned before, using the TASC scoring system, seven potential targets for 
optical molecular imaging of PC of colorectal origin have been identified: CXCR4, 
EpCAM, EGFR, CEA, Muc1, MMPs and VEGF−A.46 The specifics of these proteins 
and receptors are summarised in Table 1.85-109 Several fluorescent imaging probes 
targeting these biomarkers have already been investigated in humans in a broad 
variety of indications.
For example, the NIR fluorescent tracer cetuximab−800CW targeting EGFR has 
been applied in humans for surgical navigation in head−and−neck squamous cell 
carcinoma.92 Moreover, cetuximab­800CW is being used in a phase−I clinical trial in 
the University Medical Center Groningen in patients with head and neck squamous 
cell carcinoma (NCT03134846).
Besides, the NIR fluorescent tracer bevacizumab−800CW targeting VEGF−A has 
been applied for detection of a variety of different tumour types, among which 
locally advanced rectal cancer (NCT01972373), pancreatic cancer (NCT02743975), 
breast cancer (NCT02583568) and oesophageal cancer.108,109 The feasibility of MFGS 
using bevacizumab−800CW is also being investigated for intraoperative guidance in 
benign diseases such as endometriosis (NCT02975219) or for endoscopic detection 
of familial adenomatous polyposis (NCT02113202).
In CRC and specifically peritoneal metastases of colorectal origin, so far two phase−I 
feasibility studies have been performed in humans.
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FEASABILITY STUDIES IN PC OF COLORECTAL ORIGIN
In 2016, Harlaar et al. used the NIR fluorescent tracer bevacizumab−IRDye800CW 
targeting VEGF−A for MFGS in seven patients with PC from CRC origin, that were 
scheduled to undergo CRS+HIPEC.107 Intravenous administration of bevacizumab­
800CW 3 days prior to surgery proved to be safe, as no (serious) adverse events that 
were related to tracer administration occurred in any of the patients. Fluorescence 
signals were observed in all patients during surgery. Additional tumor tissue that 
had not been identified by the surgeons using only visual and tactile inspection was 
detected in two patients using fluorescence imaging. The fresh surgical specimens 
were imaged back−table at the operating theatre. A total of 80 peritoneal areas were 
imaged using the intraoperative camera system and analysed by a pathologist. All 
29 resected, but non−fluorescent areas proved to be benign on final histopathology, 
thus potentially indicating a sensitivity of 100%. In 27 out of 57 fluorescent areas 
in the fresh surgical specimen, tumour tissue was identified. Although the authors 
state that their study was not powered to investigate the sensitivity and specificity, 
the results are very promising. In conclusion, in this study MFGS using bevacizumab­
800CW was safe and feasible and could potentially improve CRS and patient 
selection.
The second feasibility study was performed in 2018 by Boogerd et al., in which 
SGM−101, a fluorescent anti−CEA monoclonal antibody, was administered 
intravenously 2−4 days before surgery, to investigate the feasibility of MFGS in 
CRC and PC of colorectal origin.96 Patients with PC of colorectal origin that were 
scheduled for open surgical removal were included. First, a dose−finding study 
was performed in the first nine patients. Subsequently, the most optimal dose of 
SGM−101 was investigated in another 17 patients. SGM−101 showed no treatment−
related (serious) adverse events. However, a total of eight possibly related mild 
adverse events occurred throughout the study. Using MFGS, in six patients a total 
of 19 additional peritoneal lesions were identified as potentially tumour−positive, 
and therefore treatment strategies were changed. The authors report a sensitivity 
of 98% and a specificity of 62%.
Interestingly, although both studies used different fluorescent tracers, more or less 
the same conclusions were drawn. Most importantly, both bevacizumab−800CW 
and SGM−101 were deemed safe in combination with MFGS. Moreover, it appeared 
that with both fluorescent tracers, a very high sensitivity could be obtained. If these 
results are validated in a larger patient cohort and indeed clinically suspect, but 
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non−fluorescent lesions turn out to be benign, non−fluorescent lesions may be 
left in situ in the future and subsequently decrease morbidity. Interestingly, this 
might also imply that currently visual and tactile inspection−based surgery leads to 
unnecessary resections when compared to MFGS. The majority of complications and 
revalidation time is probably related to the extent of the cytoreduction itself. This 
might also improve the current morbidity of 22−34% and mortality of 0.8−4.1%.110-115
The specificity in these two feasibility studies appears to be relatively low, with 
a substantial amount of false positive lesions when applying intraoperative 
fluorescence imaging. This might be due to technical limitations of the fluorescence 
camera system that still need to be improved, such as the multispectral substration 
techniques. Currently, quantification of fluorescence with most of the present 
generation of clinically approved fluorescence camera systems is still limited, making 
the interpretation of fluorescence signals subjective. If a threshold could be set to 
give the surgeon a ‘yes’ or ‘no’ answer to the question whether a peritoneal lesion 
is tumour−positive with a certain sensitivity and specificity, this could potentially 
improve interpretation of fluorescence signals. Last, for some tracers, the optimal 
dose might still needs further optimisation.107
Additional research and studies need to be performed to investigate novel 
fluorescence imaging agents in humans for MFGS of PC of colorectal origin. 
Theoretically, multiple fluorescence imaging agents can be intravenously 
administered to the same patients simultaneously, a so−called “tracer cocktail”, in 
order to improve sensitivity and specificity. Therefore, novel fluorescence imaging 
agents need to be validated in a standardised way, with the emphasis on the 
determination of the safety, feasibility, optimal agent dose, and optimal timing for 
surgical intervention in phase−I feasibility studies.
FUTURE PERSPECTIVES
Target selection for MFGS
Currently, there are many carrier molecules that seem promising for potential 
validation in phase−I feasibility studies according to the TASC scoring system.46 
Additionally, new strategies have been developed recently to identity biomarkers 
that are upregulated in cancer development, such as functional genomic mRNA 
(FGM) profiling.116 This method corrects expression data of numerous genes for 
relevant non−genetic variables. It is likely that in the near future new promising 
targets will be identified by this gene expression analysis, that may be used as 




Novel fluorescence imaging probes
Next to the validation of potential targets for imaging, novel fluorescent probes 
are being developed.72,117 Different types of carrier molecules have different 
pharmacokinetics. The substantial molecular weight of monoclonal antibodies 
(generally ± 150 kDa, Figure 3B) results in a relatively long blood circulation time 
of several days up to weeks. Although there is extensive experience with the 
use of monoclonal antibodies, even smaller molecules may provide favourable 
pharmacokinetic properties, such as nanobodies.118 A faster clearance from 
background tissue results in sufficient signal−to−background ratios that occur within 
a much shorter period of time. Therefore, peptides or small molecules might be 
logistically favourable compared to antibodies for MFGS (Figure 3C and D).118 On 
the other hand, smaller molecules are in general more difficult to conjugate to a 
fluorescence dye, as even small structural changes can influence pharmacokinetics 
and binding efficacy significantly.118,119
Another subgroup of imaging probes has come forward in recent years: targeted 
smart−activatable probes (Figure 3E).119 The working mechanism of these probes is 
based on the principle of photochemical quenching or ligand−targeted activation. 
Smart activatable probes only fluoresce when bound to the tumour or cleaved by 
specific proteases or peptidases excreted by the tumour, which improves signal−
to−background ratios due to limited background fluorescence.118,120 The first clinical 
studies to investigate smart activatable probes have been performed already.117 
However, to the best of our knowledge, this has not yet been done for intraoperative 
imaging of CRC or PC of colorectal origin.
A similar ‘on−or−off’ concept has been applied in the development of a pH−
activatable fluorescent probe. This probe becomes activated upon contact with 
a certain threshold pH (pH ≤ 6.9), as the majority of solid tumours are acidotic. 
Although this probe does not target a tumour biomarker, it is still highly specific due 
to the pH transistor concept.121 The benefit of such a probe is that it can be applied 
in a broad range of oncological indications. However, the first proof−of−concept in 
human study using a pH−activated probe still needs to be conducted.
Phase II/III clinical studies
Although different fluorescent probes are being developed, so far only two phase−I 
feasibility studies have been finalised in relatively small numbers of patients with 
PC of colorectal origin.96,107 The ability of fluorescence imaging to detect peritoneal 
metastases that are missed by visual and tactile inspection and to aid in the 
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differentiation between malignant and benign tissue, may have the potential to 
change clinical decision making. Although these results seem promising, further 
validation in phase−II clinical studies is required, with larger patient cohorts that 
are sufficiently powered to estimate the diagnostic accuracy. Eventually, in phase−III 
studies, the impact of MFGS in CRS+HIPEC surgery on clinical endpoints such as 
progression−free and overall survival need to be evaluated, hoping to improve the 
current median progression−free survival of only 12.6 months.11
Photodynamic therapy
Although current clinical studies are mainly aimed to investigate the feasibility 
of optical imaging for cancer detection, in the future intraoperative imaging may 
also be used as a therapeutic modality. Carrier molecules that specifically target 
the tumour can also be labelled to a photoactive dye (i.e., photosensitiser), to 
allow targeted photodynamic therapy (tPDT). When excited with light of a specific 
wavelength, photosensitisers not only fluoresce, but also form reactive oxygen 
species that oxidise the cells they target, thereby killing them.122 Potentially, tPDT 
may be applied after CRS, to assist in the elimination of microscopic peritoneal 
lesions. As there is only superficial activation of the targeted photosensitisers, 
side−effects are estimated to be limited. The first clinical trials have already been 
performed to investigate the safety and feasibility of tPDT using a variety of 
different photosensitisers. Phase I and II clinical trials have been conducted for 
treatment of colorectal cancer, pelvic recurrence of CRC, colorectal liver metastases 
(NCT00068068), and locally advanced rectal cancer.123-126 Moreover, tPDT has also 
been applied for the treatment of peritoneal metastases originating from ovarian 
cancer and sarcomas, and different gastrointestinal tumours with promising 
results.127,128 These studies demonstrate that tPDT could potentially be used as an 
effective treatment for both CRC and PC. However, future studies are required to 
determine the effect on PC of colorectal origin, when combined with MFGS.
CONCLUSION
In conclusion, treatment of PC of colorectal origin with curative intent consists of 
CRS followed by HIPEC. Up to date, surgeons still rely on visual and tactile inspection 
for intraoperative differentiation between tumour and benign tissue. The ultimate 
goal during cytoreduction is to obtain a macroscopically complete cytoreduction by 
resecting malignant tissue only. Therefore, there is a clear need for an intraoperative 
imaging technique improving tumour detection. The first phase−I clinical trials 




PC of colorectal origin. Even though no conclusions can be drawn with regard to 
the impact of these studies on clinical decision making, it appears MFGS has the 
potential to improve both cytoreduction and patient selection, facilitating patient−
tailored surgery. However, to reliably determine the sensitivity and specificity of 
MFGS during CRS+HIPEC, subsequent phase−II studies are required.
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Challenges in patient selection for CRS+HIPEC
In Chapter 1, the rationale behind this thesis was outlined. Carefully selected 
patients with limited and resectable colorectal peritoneal metastases (PM) can be 
treated with curative intent by combining cytoreductive surgery with hyperthermic 
intraperitoneal chemotherapy (CRS+HIPEC). This complex abdominal procedure 
is accompanied by substantial treatment−related morbidity and mortality, a 
diminished quality of life (QoL) up to one year after surgery, and high rates of early 
recurrence of disease. A complex interplay of patient, tumour, and treatment−
related factors determines these postoperative outcomes. For clinicians and 
patients, it remains a serious challenge to weigh the potential survival benefit 
from this extensive treatment against the risk of substantial treatment−related 
morbidity, mortality, and potential diminished QoL and functional status. According 
to the available literature, the extent of peritoneal disease (i.e., peritoneal cancer 
index [PCI]), completeness of the performed cytoreduction (i.e., completeness of 
cytoreduction score [CC−score]), and signet ring cell histology especially have a great 
influence on the survival outcomes after CRS+HIPEC. These powerful prognostic 
factors for survival after CRS+HIPEC are determined at the time or even after the 
operative exploration rather than in a preoperative setting. The aim of this thesis 
is to identify new and promising preoperative factors in patients with colorectal 
PM to predict postoperative morbidity and survival outcomes after CRS+HIPEC in 
an earlier stage.
Part I – Biological and clinical prognostic factors to further optimise 
patient selection for CRS+HIPEC.
In Chapter 2, we investigated the impact of the time−of−onset of colorectal PM 
(synchronous or metachronous) on surgical morbidity and survival outcomes after 
CRS+HIPEC. For this chapter, the most common definitions used in the scientific 
literature for synchronous and metachronous colorectal PM were selected, as 
there is no worldwide consensus regarding this matter. Patients with synchronous 
colorectal PM were diagnosed with colorectal cancer at the time of presentation. 
Patients with metachronous colorectal PM developed colorectal PM after an initial 
‘curative’ colorectal resection. The results from this multicentre observational cohort 
study—consisting of 433 consecutive patients who underwent CRS+HIPEC between 
February 2006 and December 2017 in two Dutch tertiary referral hospitals—showed 
that metachronous onset of colorectal PM was associated with early recurrence after 
CRS+HIPEC when compared to synchronous onset of colorectal PM. Remarkably, 
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overall survival (OS) and surgical morbidity were similar between both groups. 
Additional analyses revealed that especially patients with metachronous colorectal 
PM with a PCI above 10 had a markedly worse OS and disease−free survival (DFS) 
after CRS+HIPEC when compared to the other patients. Therefore, we recommend 
being extra careful in selecting patients with metachronous colorectal PM with a 
PCI above 10 for CRS+HIPEC.
The diagnostic laparoscopy (DLS) has been implemented in the preoperative 
workup for CRS+HIPEC in patients with suspicion of colorectal PM to prevent non−
therapeutic laparotomies (i.e., open−close procedures) at the University Medical 
Center Groningen (UMCG). Chapter 3 describes the feasibility and safety of routinely 
performing DLS in 184 consecutive patients with suspicion of colorectal PM. Good 
laparoscopic evaluation was possible in 75% of the patients, despite the fact that 
84% of these patients had a history of prior abdominal surgery. Major postoperative 
complications occurred in only five patients (2.7%), who were all deemed not suitable 
for CRS+HIPEC, with no postoperative deaths. Another important finding was the 
unexpectedly high rate of 50.5% of patients who were potential candidates for 
CRS+HIPEC according to preoperative imaging but in the end were deemed not 
suitable for CRS+HIPEC during DLS. On the one hand, this reflects the low validity of 
imaging for colorectal PM to predict the presence and extent of peritoneal disease, 
and on the other hand, it supports the added value of DLS prior to CRS+HIPEC; 
almost half of the patients with suspicion of colorectal PM avoided a laparotomy 
by having a DLS performed.
Chapter 4 focuses on the evaluation of the implementation of DLS in the 
preoperative workup for CRS+HIPEC and the impact on preventing non−therapeutic 
laparotomies. DLS was introduced in 2012 for this specific indication; this provided 
the opportunity to compare a historical cohort of 48 consecutive patients with 
colorectal PM who were scheduled for CRS+HIPEC before the introduction of DLS 
to 124 consecutive patients with colorectal PM who were scheduled for CRS+HIPEC 
after DLS was part of the preoperative workup. The rate of non−therapeutic 
laparotomies significantly dropped from 35.4 to 21.0% after the introduction of 
DLS in our preoperative workup, despite the fact that only 68.5% of the patients 
underwent DLS in our academic centre after this introduction. In cases where 
surgeons refrained from performing DLS, in two out of three patients this was 
due to the patient having recently underwent abdominal surgery in the referring 
centre, resulting in an unexpectedly higher rate of non−therapeutic laparotomies 




understage the extent of colorectal PM and overestimate the possibility of achieving 
a complete cytoreduction, because they have less experience in reporting these 
prognostic factors. With this obtained knowledge, we are paying more attention 
to early detection and referring of patients with colorectal PM to our academic 
centre. Patients will undergo laparoscopic evaluation by one of our HIPEC surgeons 
to investigate the extent and resectability of the colorectal PM, independently of 
prior abdominal surgery performed at the referral centre. With these adjustments, 
we suspect that the rate of non−therapeutic laparotomies in patients with colorectal 
PM will drop even further in our academic centre in the following years.
At this moment, the PCI scoring system is predominantly used worldwide as a static 
single−time−point scoring system during an exploratory laparotomy for potential 
CRS+HIPEC and as such does not include disease progression over time. With the 
introduction of DLS in our preoperative workup for CRS+HIPEC, the opportunity 
arose to investigate the impact of an increase in PCI in a short−time frame on 
survival outcomes after CRS+HIPEC. In Chapter 5, we developed the ∆PCI as an 
independent, more dynamic prognostic factor for OS in patients with colorectal PM. 
In our prospectively maintained institutional database, we identified 84 patients 
who underwent DLS and an exploratory laparotomy for potential CRS+HIPEC 
between 2012 and 2018, with the PCI being known for both procedures. The 
difference in PCI score between DLS and exploratory laparotomy (i.e., ∆PCI) was 
calculated. Patients were divided into three groups of rate progression: stable 
disease (∆PCI 0–3), mild progression of disease (∆PCI 4–9), or severe progression of 
disease (∆PCI ≥10). The median OS after CRS+HIPEC was significantly decreased in 
patients with a ∆PCI of 4–9 (35.1 months) or ∆PCI ≥10 (24.1 months) when compared 
to patients with a ∆PCI of 0–3 (47.9 months). In multivariate regression analysis, 
∆PCI remained an independent risk factor for OS. This prognostic factor appears 
to reflect on a more aggressive tumour biology and might serve as an adjunct 
tool for intraoperative clinical decision making beyond static PCI scoring at the 
time of exploratory laparotomy for potential CRS+HIPEC. HIPEC surgeons should 
be aware of a high−∆PCI−associated diminished prognosis and should reconsider 
the execution of the CRS+HIPEC procedure when confronted with a high ∆PCI of 
≥10 intraoperatively.
The extent of surgery (ES) during CRS+HIPEC is a well−known risk factor for the 
occurrence of major postoperative morbidity and is essential to know prior to 
surgery. Potential survival benefit from the CRS+HIPEC needs to be in balance with 
the associated risks of treatment−related morbidity and mortality. Every day, HIPEC 
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surgeons attempt to make this estimation for their patients in advance of planning 
a CRS+HIPEC procedure. Chapter 6 describes a prospective, observational cohort 
study that investigated surgeons’ abilities to correctly predict the ES in advance of 
CRS+HIPEC. Five surgeons with extensive experience in gastrointestinal surgery 
and CRS+HIPEC procedures predicted the ES prior to surgery. For each individual 
patient, all surgeons independently predicted the resection or preservation of 22 
different anatomical structures according to a standardised ES form. The actual ES 
during CRS+HIPEC was extracted from the surgical procedure report and compared 
with the predicted ES. One hundred and thirty−one ES forms were collected from 32 
patients who successfully underwent CRS+HIPEC. Positive and negative predictive 
values per anatomical structure (PPV and NPV, respectively) were calculated. A high 
PPV suggests that the surgeon is well able to predict if the anatomical structure 
will be resected, whereas a high NPV indicates that the surgeon is well able to 
predict if the anatomical structure will be preserved. The number of resections 
necessary to achieve a complete cytoreduction was predicted correctly 24 times 
(18.3%), overestimated 57 times (43.5%), and underestimated 50 times (38.2%). 
Overall, NPVs for the different anatomical structures were higher and showed less 
variation between surgeons compared to the PPVs. This suggests that surgeons with 
extensive experience in performing these procedures have the ability to predict in 
advance which of the anatomical structures can be preserved during CRS+HIPEC but 
in most cases fail to predict the resections that are necessary to achieve a complete 
cytoreduction with an underestimation of the ES in almost 40% of the cases. This 
phenomenon has not been described before and emphasises that future research 
should focus even more on optimising the detection of the extent of disease prior 
to surgery.
Part II – New avenues for research.
Surgery−related muscle loss (SRML) occurs in at least one out of three cancer 
patients within one week after major surgery. Prevention of clinically relevant 
SRML in cancer patients can be a promising strategy to improve morbidity and 
mortality and increase QoL after major surgery. These days, there is still a lack of 
scientific knowledge regarding this topic. Chapter 7 extensively describes the design 
of the MUSCLE POWER study, an observational single−centre prospective cohort 
study that currently is investigating the presence, impact, and possible predictors 
for clinically relevant SRML in 178 cancer patients after major abdominal surgery 
using ultrasound measurements, squeeze and force measurements, and QoL 
questionnaires. Daily physical activity during the hospital stay is monitored by a 




regarding possible predictors for clinically relevant SRML can be used in future 
intervention studies to prevent postoperative muscle loss and minimise its impact 
on different postoperative outcomes and QoL in the long term. The MUSCLE POWER 
study is open for inclusion and more than 50 patients have been enrolled over the 
past four months. Final results can be expected at the end of 2020.
Chapter 8 explains the principles of intraoperative optical molecular imaging and 
provides a chronological overview on molecular fluorescence guided surgery (MFGS) 
development in patients with colorectal PM. For intraoperative differentiation 
between benign and malignant lesions, surgeons currently depend on visual 
and tactile inspection only. Considering the high tumour recurrence rates after 
CRS+HIPEC, there is a clear need for an imaging modality that can aid the oncological 
surgeon in the differentiation between tumour and benign tissue intraoperatively. 
In recent years, MFGS has emerged as a promising real−time intraoperative imaging 
technique to improve tumour detection by using tumour−targeted fluorescence 
tracers. A tumour−targeted fluorescence tracer is based on the concept of a carrier 
molecule that is conjugated to a fluorescent dye, specifically binding to a certain 
tumour target. This technique can be applied intraoperatively to serve as a ‘red−flag’ 
imaging technique to assist in optimal tumour identification, thereby potentially 
enhancing surgical vision for the detection of small tumour deposits and enabling 
differentiation between benign and malignant tissue during surgery. Bevacizumab­
IRDye800CW, one of the promising tumour−targeted fluorescence tracers targeting 
the vascular endothelial growth factor (VEGF), will be used in the near future for a 
new phase I trial at the UMCG to detect tumour tissue from colorectal PM during 
DLS (i.e., the SELECT trial). If bevacizumab­IRDye800CW is also feasible during DLS, 
it might provide a more accurate investigation of the extent of peritoneal disease 
at an earlier stage. Ultimately, these new strategies may reduce overtreatment, 
morbidity, and costs while maintaining the same or better effectiveness with a 
lower recurrence rate and improved QoL.
FUTURE PERSPECTIVES
There is no doubt that adequate patient selection for the treatment of colorectal 
PM is the main challenge in the field of CRS+HIPEC. The potential survival benefit 
must be in balance with the treatment−related morbidity, mortality, and impact 
on QoL. Hopefully, the results presented in this thesis will contribute to further 
understanding of the complex interplay of patient, tumour, and treatment−related 
factors that determines these postoperative outcomes. Improvement of the 
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preoperative selection of patients for CRS+HIPEC—including a more tumour− and 
patient−tailored approach—is crucial to gaining further progression in the field of 
CRS+HIPEC.
Tumour biology
Tumour biology is very likely to play an important role in the outcome after 
CRS+HIPEC, as we have shown in Chapter 2 and Chapter 5 of the present thesis. 
Strikingly, only the presence of signet ring cell histology is used during the 
preoperative selection process for CRS+HIPEC, as there are no known biomarkers 
that are capable of predicting chemotherapeutic efficacy and outcome after 
CRS+HIPEC. Four molecular subtypes of colorectal cancer have been identified on 
the basis of the gene expressions levels and combined to a new classification system, 
the consensus molecular subtypes (CMS) classification including CMS1 to CMS4. The 
majority of the colorectal PM belong to the CMS4 subtype (75%), which represents a 
particular class of highly aggressive tumours that seems to be associated with worse 
survival outcomes and poor response to current anticancer therapy. Identification 
of the molecular subtype of colorectal PM can have therapeutic consequences and 
might serve as an additional selection criterion for CRS+HIPEC in the future. Highly 
experienced HIPEC centres can make an important contribution by storing tissue 
and blood samples from their patients in an institutional or national biobank for 
translational research.
Improvement of tumour detection
Preoperative imaging modalities
Accurate preoperative assessment of the PCI would be extremely useful in 
differentiating patients who are candidates for CRS+HIPEC from those who are not 
in an earlier stage. Many imaging modalities are available for preoperative staging in 
general, such as ultrasonography, computed tomography (CT), magnetic resonance 
imaging (MRI), or positron emission tomography (PET) scans. Unfortunately, all of 
these preoperative imaging modalities greatly underestimate the intraoperative PCI. 
Surgical oncologists are still discovering the real extent and potential resectability 
of colorectal PM during an exploratory laparotomy, which causes patient selection 
to take place in the operating room rather than in an outpatient setting. Chapter 
3 and Chapter 4 describe the added value of DLS in the preoperative workup for 
CRS+HIPEC to prevent non−therapeutic laparotomies in patients with extensive 
disease. In the near future, it is possible that DLS will play a smaller role in patient 
selection because detection rates of colorectal PM from current preoperative 




weighted MRI images (DW−MRI) shows that it seems possible to distinguish patients 
with extensive disease from patients with resectable disease (i.e., PCI ≤20), and 
therefore might be used as a non−invasive tool to select patients with colorectal 
PM for CRS+HIPEC. An accurate preoperative assessment of the PCI allows not 
only excluding patients with extensive disease and predicting the likelihood of 
complete cytoreduction but also confers several other advantages. As described 
in Chapter 6 of the present thesis, experienced HIPEC surgeons are still struggling 
to predict the extent of surgery (ES) prior to CRS+HIPEC despite the presence of 
current preoperative imaging modalities. A more accurate preoperative assessment 
of the PCI will provide crucial additional information for the oncologic surgeon to 
determine the true extent and length of surgery in advance. This information is 
useful in the outpatient clinic to inform patients and their families in a more patient−
tailored way as well as for logistic optimisation of staff planning and operating room 
time.
Intraoperative imaging modalities
Chapter 8 of the present thesis provides an overview of the developments in 
molecular fluorescence guided surgery (MFGS) in patients with colorectal PM. 
Oncologic surgeons still rely heavily on visual and tactile inspection alone for 
intraoperative differentiation between tumour and benign tissue. Considering 
the high tumour recurrence rates after CRS+HIPEC and unnecessary resections 
of benign lesions or organs, there is a clear need for an intraoperative imaging 
technique improving tumour detection. The ultimate goal during cytoreduction is 
to obtain a macroscopically complete cytoreduction by resecting malignant tissue 
only. In recent years, optical molecular imaging using tumour−targeted fluorescence 
tracers has emerged as a promising imaging technique for real−time guidance in 
oncological surgery. The first phase I clinical trials have been performed in patients 
with colorectal PM who underwent an exploratory laparotomy for potential 
CRS+HIPEC and showed high sensitivities for two different fluorescent tracers for 
the detection of colorectal PM lesions. This suggests that clinically suspect but non−
fluorescent lesions during CRS+HIPEC may be safely left in situ in the future and 
subsequently decrease postoperative morbidity after CRS+HIPEC, as the majority 
of the complications and revalidation time seems to be related to the ES itself. 
Although these results seem promising, further validation in phase II clinical studies 
is required, with larger patient cohorts that are sufficiently powered to estimate 
the diagnostic accuracy. Eventually, in phase III studies, the impact of MFGS in 
CRS+HIPEC surgery on survival outcomes need to be evaluated.
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MFGS may also be useful in an earlier stage; in patients with suspicion of colorectal 
PM who undergo DLS to assess the presence and extent of colorectal PM. 
Assessment of the PCI during DLS remains challenging, as small tumour lesions 
could be easily missed and clinically suspicious lesions could be benign, leading to 
underestimating or overestimating the extent of colorectal PM. In 2016, our research 
group proved the feasibility of colorectal PM by using bevacizumab−IRDye800CW 
in patients who underwent an exploratory laparotomy for potential CRS+HIPEC. 
Meanwhile, a new fluorescent camera has been designed by SurgVision BV to be used 
during DLS. Currently, we are completing the study design of the SELECT trial; a non−
randomised, non−blinded, prospective, single−centre phase I feasibility study with 
bevacizumab−IRDye800CW for patients with suspicion of colorectal PM who are 
scheduled for DLS. If bevacizumab−IRDye800CW is also feasible during DLS, which is 
a very different setting compared to open surgery, it might provide a more accurate 
investigation of the extent of colorectal PM. Ultimately, all of these strategies may 
reduce overtreatment, morbidity, and costs while maintaining the same or better 
effectiveness with a lower recurrence rate and improved QoL.
PCI cut−off value for the curative treatment of colorectal PM
Many attempts have been made to discover the PCI cut−off value beyond which 
CRS+HIPEC should be contra−indicated in patients with colorectal PM, because the 
potential small survival benefit does not outweigh the treatment−related morbidity 
and mortality. This cut−off has been set at various levels without any worldwide 
consensus. In the current scientific literature, cut−off values between 15 and 25 are 
reported. Most HIPEC teams perform CRS+HIPEC only in patients with a PCI ≤20; 
this cut−off value is also stated in our national Dutch HIPEC protocol. Chapter 2 of 
the present thesis—including survival data from 433 Dutch HIPEC patients—shows 
an unexpectedly poor survival benefit for patients with a PCI between 11 and 20 
when compared to survival outcomes with modern systemic therapies. The 2−year 
survival rate after CRS+HIPEC is less than 50% in this group of patients with relatively 
extensive colorectal PM. We hope these survival data will provide an increased 
awareness among HIPEC surgeons, which may even lead to a lower PCI cut­off value 
in the Netherlands in the near future.
Early detection and treatment of patients at risk for colorectal PM
Prevention is better than cure
Proactive strategies have been developed in an attempt to prevent or diagnose 
colorectal PM at an earlier stage in patients with high risk of developing colorectal 




show some promising results, although these results need to be confirmed by 
various currently recruiting clinical trials. Patient selection for these approaches is 
based on independent risk factors for the development of colorectal PM, including 
pT4 stage tumours, mucinous subtype, emergency surgery, positive cytology of 
peritoneal lavage, lymph node metastases, and non−radical resections during 
primary tumour resection.
Second−look surgery
Second−look surgery is based on routinely performing a reoperation in asymptomatic 
patients with high risk of developing colorectal PM after an initial curative primary 
tumour resection. In pilot studies, up to 71% of the asymptomatic high−risk patients 
have pathologically confirmed colorectal PM during routine second−look surgery 
within one year after primary tumour resection, with most patients being eligible 
for CRS+HIPEC at that moment. Current and future randomised clinical trials are 
required to evaluate the optimal timing of second−look surgery and its relationship 
to adjuvant systemic chemotherapy after primary tumour resection, and most 
importantly, to ascertain the role on long−term survival benefit. A treatment shift 
in our standard of care may occur from conventional surgery to a more aggressive, 
early radical approach in the near future.
Prophylactic HIPEC
Prophylactic HIPEC is an even more proactive strategy as this strategy focuses on 
the prevention of metachronous onset of colorectal PM. In patients with high−risk 
colorectal tumours, HIPEC is administered simultaneously as an adjuvant treatment 
to primary tumour resection. Currently, several phase III trials are recruiting 
high−risk patients to investigate the influence of prophylactic HIPEC on survival 
outcomes. Recently, the results from the Dutch COLOPEC trial have been published; 
a multicentre, open−label, randomised controlled trial that assessed the added 
value of prophylactic HIPEC with oxaliplatin in 204 patients with a pT4 stage or 
performed colon tumour. Treatment with prophylactic HIPEC with oxaliplatin did not 
improve the peritoneal metastasis−free survival 18 months after surgery. Results 
from other phase III clinical trials must be awaited before conclusions can be drawn. 
Even if a significant survival benefit can be achieved by using another therapeutic 
drug to perform HIPEC, other issues such as optimal patient selection and timing 
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Uitdagingen bij het selecteren van patiënten voor CRS+HIPEC
De motivering voor dit proefschrift wordt in hoofdstuk 1 toegelicht. Zorgvuldig 
geselecteerde patiënten met beperkte en resectabele colorectale peritoneale 
metastasen (PM) kunnen in opzet curatief behandeld worden met cytoreductieve 
chirurgie gecombineerd met hyperthermische intraperitoneale chemotherapie 
(CRS+HIPEC). Deze complexe abdominale procedure gaat gepaard met een 
aanzienlijke postoperatieve morbiditeit en mortaliteit, een vermindering van de 
kwaliteit van leven tot één jaar na de ingreep, met daarnaast een hoog risico op 
het vroegtijdig terugkeren van de ziekte. Een complex samenspel van patiënt 
gerelateerde factoren, tumor gerelateerde factoren en behandeling gerelateerde 
factoren bepalen deze postoperatieve uitkomsten. Voor medici en patiënten 
is het bijna een onmogelijke opgave om de potentiële overlevingswinst van 
deze uitgebreide procedure af te zetten tegenover het bijkomende risico op het 
optreden van postoperatieve morbiditeit, mortaliteit, en de kans op vermindering 
van kwaliteit van leven en functionele gesteldheid. Volgens de huidige beschikbare 
literatuur worden overlevingsuitkomsten na CRS+HIPEC met name sterk beïnvloed 
door de uitgebreidheid van de aanwezige peritoneale ziekte (beschreven met de 
PCI−score), de volledigheid van de uitgevoerde cytoreductie (beschreven met de 
CC−score) en het aanwezig zijn van zegelring cel pathologie in het tumorpreparaat. 
Deze essentiële prognostische overlevingsfactoren worden op het moment van 
de operatieve exploratie of zelfs pas na afloop van de procedure bepaald en zijn 
daarmee dus helaas niet geschikt om adequaat patiënten in de preoperatieve 
poliklinische setting te selecteren voor CRS+HIPEC. Dit proefschrift besteed aandacht 
aan het identificeren van nieuwe en mogelijk veelbelovende preoperatieve factoren 
die in een eerder stadium het individuele risico op het optreden van postoperatieve 
morbiditeit en de mogelijke overlevingswinst na CRS+HIPEC kunnen voorspellen.
Deel I – Biologische en klinische prognostische factoren om patient-selectie 
voor CRS+HIPEC verder te optimaliseren
We onderzochten in hoofdstuk 2 of postoperatieve morbiditeit en overlevings­
uitkomsten na CRS+HIPEC beïnvloed worden door het moment van het ontstaan 
van colorectale PM (synchroon of metachroon). Wereldwijd zijn er geen eenduidige 
definities voor synchrone en metachrone colorectale PM en daarom werden voor 
dit hoofdstuk de meeste gebruikte definities in de wetenschappelijke literatuur 
geselecteerd. Patiënten met synchrone colorectale PM bleken reeds al colorectale 
PM te hebben bij de primaire diagnose van colorectale kanker. Patiënten met 
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metachrone colorectale PM ontwikkelden colorectale PM na een initiële ‘curatieve’ 
colorectale resectie. De resultaten van deze observationele multicenter−studie, 
bestaande uit 433 patiënten die tussen februari 2006 en december 2017 CRS+HIPEC 
ondergingen in twee Nederlandse tertiaire verwijzingscentra, toonden aan dat 
patiënten met metachrone colorectale PM significant vaker een vroeg recidief van 
ziekte kregen na CRS+HIPEC. Opvallend genoeg bleek de algehele overleving na 
CRS+HIPEC vergelijkbaar tussen patiënten met synchrone en metachrone colorectale 
PM. Met aanvullende analyses bleek dat de groep van patiënten met metachrone 
colorectale PM zeer heterogeen was en dat een subgroep van patiënten met een PCI 
boven de 10 de slechtste algehele en ziektevrije overleving na CRS+HIPEC had. Wij 
raden dan ook aan om extra voorzichtig te zijn bij het selecteren van patiënten voor 
CRS+HIPEC wanneer er sprake is van de aanwezigheid van metachrone colorectale 
PM met een PCI boven de 10.
De diagnostische laparoscopie (DLS) is geïmplementeerd in het gestandaardiseerde 
preoperatieve selectieproces voor CRS+HIPEC In het Universitair Medisch Centrum 
Groningen (UMCG) om niet−therapeutische laparotomieën (open−dicht procedures) 
bij patiënten met vermoeden op colorectale PM te voorkomen. Hoofdstuk 3 
beschrijft de haalbaarheid en veiligheid van het routinematig verrichten van DLS 
bij 184 patiënten met verdenking op colorectale PM. Een goede laparoscopische 
evaluatie van het abdomen was mogelijk bij 75% van de patiënten, terwijl 84% van 
de patiënten al eerdere buikoperatie(s) hadden ondergaan. Grote postoperatieve 
complicaties (Clavien−Dindo III−IV) traden op bij slechts vijf patiënten (2.7%) die 
allemaal tijdens DLS niet geschikt bleken voor CRS+HIPEC. Een andere belangrijke 
bevinding was het onverwacht hoge percentage van patiënten (50.5%) die potentiële 
kandidaten waren voor CRS+HIPEC volgens preoperatieve beeldvorming, maar 
uiteindelijk tijdens DLS niet geschikt werden geacht voor CRS+HIPEC. Enerzijds 
benadrukt dit de beperkingen van de huidige beeldvormende technieken in het 
detecteren van de aanwezigheid en omvang van peritoneale ziekte en anderzijds 
ondersteunt dit de toevoegde waarde van DLS voorafgaand aan CRS+HIPEC. In 
bijna de helft van de patiënten met verdenking op colorectale PM kon de DLS een 
onnodige laparotomie voorkomen.
De implementatie van DLS in het gestandaardiseerde preoperatieve selectieproces 
voor CRS+HIPEC wordt geëvalueerd in hoofdstuk 4, waarbij ook aandacht wordt 
besteed aan de impact op het voorkomen van niet−therapeutische laparotomieën. In 
2012 werd de DLS voor deze specifieke indicatie geïntroduceerd in het preoperatieve 




met colorectale PM die een laparotomie ondergingen voor mogelijke CRS+HIPEC 
worden vergelijken met 124 patiënten met colorectale PM die een laparotomie 
ondergingen voor mogelijke CRS+HIPEC na de introductie van de DLS in het 
preoperatieve selectieproces voor CRS+HIPEC. Het aantal niet−therapeutische 
laparotomieën daalden significant van 35.4 naar 21.0% na de introductie van de 
DLS, ondanks dat na deze introductie slechts 68.5% van de patiënten een DLS in 
ons academisch centrum ondergingen. Bij twee van de drie patiënten bleek een 
recente abdominale ingreep uitgevoerd in het verwijzend centrum de reden om af 
te zien van een DLS. Bij deze patiënten werd een onverwachts hoger percentage 
niet−therapeutische laparotomieën (28.5%) gevonden. We vermoeden dat chirurgen 
van verwijzende centra de uitgebreidheid van de peritoneale ziekte eerder 
onderschatten en de mogelijkheid om een volledige cytoreductie te bereiken eerder 
overschatten, omdat zij minder ervaring hebben met het exact rapporteren van deze 
twee belangrijke prognostische factoren. Met deze verkregen kennis besteden we 
nu meer aandacht aan het vroeg detecteren en laagdrempelig laten verwijzen van 
patiënten met colorectale PM naar ons academisch centrum. Patiënten ondergaan 
een DLS door één van onze HIPEC chirurgen om de uitgebreidheid en resectabiliteit 
van colorectale PM vast te stellen, onafhankelijk van recente abdominale chirurgie 
in het verwijzend centrum. Met deze aanpassingen verwachten wij in de komende 
jaren dat het percentage niet−therapeutische laparotomieën bij patiënten met 
colorectale PM nog verder zal gaan dalen.
Op dit moment wordt wereldwijd het PCI scoring systeem gebruikt als statische 
eenmalige meting tijdens een exploratieve laparotomie voorafgaand aan een 
mogelijke CRS+HIPEC procedure en bevat als zodanig dus geen informatie over 
eventuele progressie van peritoneale ziekte. Door de introductie van de DLS in 
het preoperatieve selectieproces voor CRS+HIPEC ontstond de mogelijkheid om 
te onderzoeken wat de invloed is van een snelle toename van de PCI in een kort 
tijdsbestek op overlevingsuitkomsten na CRS+HIPEC. In hoofdstuk 5 presenteren 
we de ∆PCI als een onafhankelijke, en met name meer dynamische, prognostische 
factor voor algehele overleving bij patiënten met colorectale PM. We identificeerden, 
vanuit onze prospectief bijgehouden institutionele database, 84 patiënten die 
tussen 2012 en 2018 zowel een DLS als een exploratieve laparotomie voor mogelijke 
CRS+HIPEC procedure ondergingen, waarbij de PCI voor beide procedures bekend 
was. Het verschil in PCI score tussen de DLS en de exploratieve laparotomie (∆PCI) 
werd berekend. Patiënten werden verdeeld in drie categorieën ten aanzien van 
progressie van peritoneale ziekte: (1) stabiele ziekte (∆PCI 0–3); (2) milde progressie 
van ziekte (∆PCI 4–9); en (3) ernstige progressie van ziekte (∆PCI ≥10). De gemiddelde 
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overleving na CRS+HIPEC lag significant lager bij patiënten met een ∆PCI van 4–9 (35 
maanden) of een ∆PCI van ≥10 (24 maanden) dan bij patiënten met een ∆PCI van 0–3 
(48 maanden). Bij de multivariate regressie analyse bleef de ∆PCI een onafhankelijke 
risicofactor voor algehele overleving. Deze prognostische factor is waarschijnlijk een 
uiting van agressievere tumor biologie en zou mogelijk aanvullend gebruikt kunnen 
worden in de klinische beslissing voor het uitvoeren van de CRS+HIPEC procedure 
dan alleen de statische PCI score ten tijde van de exploratieve laparotomie. HIPEC 
chirurgen moeten zich bewust worden van deze ∆PCI geassocieerde afname van 
overleving na CRS+HIPEC en dienen als zij geconfronteerd worden met een ∆PCI 
≥10 tijdens exploratieve laparotomie het uitvoeren van de CRS+HIPEC procedure 
te heroverwegen.
De uitgebreidheid van de cytoreductieve chirurgie tijdens CRS+HIPEC is een bekende 
risicofactor voor het optreden van ernstige postoperatieve morbiditeit en is dus 
essentieel om te weten voorafgaand aan de procedure. Potentiele overlevingswinst 
van de CRS+HIPEC procedure moet in evenwicht zijn met de bijkomende risico’s 
voor het optreden van postoperatieve morbiditeit en mortaliteit. Elke dag proberen 
HIPEC chirurgen deze inschatting nauwkeurig voor hun patiënten te maken 
voordat patiënten worden ingepland voor CRS+HIPEC. Hoofdstuk 6 beschrijft 
een prospectieve, observationele, cohortstudie die onderzocht hoe bekwaam vijf 
ervaren chirurgen zijn in het voorspellen van de uitgebreidheid van de cytoreductieve 
chirurgie voorafgaand aan CRS+HIPEC. Alle chirurgen voorspelden voor elke 
individuele patiënt onafhankelijk van elkaar het reseceren of in situ laten van 22 
verschillende anatomische structuren volgens een gestandaardiseerd formulier 
voorafgaand aan CRS+HIPEC. De werkelijke uitgebreidheid van de cytoreductieve 
chirurgie tijdens CRS+HIPEC werd uit het operatieverslag geëxtraheerd en vergeleken 
met de vooraf voorspelde uitgebreidheid. Honderd eenendertig formulieren 
werden verzameld van 32 patiënten die succesvol CRS+HIPEC ondergingen. Voor 
iedere anatomische structuur werd de positief en negatief voorspellende waarde 
berekend (PVW en NVW, respectievelijk). Een hoge PVW suggereert dat de chirurg 
goed kan voorspellen of de anatomische structuur gereseceerd dient te worden, 
terwijl een hoge NVW aangeeft dat de chirurg goed kan voorspellen of een 
anatomische structuur veilig in situ kan worden gelaten. Het aantal resecties dat 
noodzakelijk bleek te zijn om een complete cytoreductie te bereiken werd slechts 
24 keer correct ingeschat (18.3%), 57 keer overschat (43.5%) en 50 keer onderschat 
(38.2%). Over het algemeen lagen de NVW’s voor de verschillende anatomische 
structuren hoger en toonden minder variatie tussen de chirurgen in vergelijking met 




van deze procedures het vermogen hebben om te voorspellen welke anatomische 
structuren gespaard kunnen worden tijdens CRS+HIPEC, maar in de meeste gevallen 
onvoldoende kunnen voorspellen welke resecties noodzakelijk zullen zijn om een 
complete cytoreductie te bereiken met een onderschatting in bijna 40% van de 
gevallen. Dit fenomeen benadrukt opnieuw dat toekomstig onderzoek zich nog 
meer moet focussen op het optimaliseren van het detecteren van de aanwezigheid 
en uitgebreidheid van colorectale PM voorafgaand aan chirurgie.
Deel II – Nieuwe wegen voor onderzoek.
Minstens één op de drie kankerpatiënten heeft binnen zeven dagen na complexe 
chirurgie klinisch relevant chirurgisch gerelateerd spierverlies (SRML). In de toekomst 
kan preventie van klinisch relevant SRML bij kankerpatiënten een veelbelovende 
strategie zijn om postoperatieve morbiditeit en mortaliteit te verminderen en de 
kwaliteit van leven na chirurgie te vergroten. Er is echter nog steeds een gebrek aan 
wetenschappelijke kennis over dit onderwerp. Hoofdstuk 7 beschrijft daarom ook 
uitvoerig het design van de MUSCLE POWER studie; een observationele, mono−
center, prospectieve, cohortstudie die momenteel de aanwezigheid, impact en 
mogelijke voorspellers voor klinisch relevant SRML na grote abdominale chirurgie 
bij 178 kankerpatiënten in kaart brengt met behulp van o.a. echometingen, 
krachtmetingen en kwaliteit van leven vragenlijsten. Fysieke activiteit gedurende 
de ziekenhuisopname wordt dagelijks gemonitord met een bewegingssensor en 
de eiwitintake wordt dagelijks gemonitord door een diëtist. Cruciale informatie 
over mogelijke voorspellers voor klinisch relevant SRML kan worden gebruikt voor 
toekomstige interventiestudies om postoperatief spierverlies te voorkomen en de 
impact op verschillende postoperatieve uitkomsten en kwaliteit van leven op de 
lange termijn te minimaliseren. De MUSCLE POWER studie is open voor inclusie en 
de afgelopen vier maanden zijn al meer dan 50 patiënten succesvol geïncludeerd. 
De eindresultaten worden eind 2020 verwacht.
Hoofdstuk 8 beschrijft de principes van intra−operatieve moleculaire beeldvorming 
en biedt een chronologische overzicht over de ontwikkelingen van moleculaire 
fluorescentie geleide chirurgie (MFGS) bij patiënten met colorectale PM. Momenteel 
zijn chirurgen volledig afhankelijk van hun visuele en tactiele inspectie tijdens 
een procedure om te differentiëren tussen benigne en maligne laesies. Het hoge 
percentage aan vroege recidieven na CRS+HIPEC laat zien dat er behoefte is aan 
een beeldvormende modaliteit die de oncologisch chirurg intra−operatief kan 
helpen bij het differentiëren tussen benigne en maligne weefsel. De afgelopen 
jaren heeft MFGS zich ontwikkeld tot een veelbelovende real−time intra−operatieve 
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beeldvormende techniek om tumordetectie te verbeteren door gebruik te maken 
van tumorgerichte fluorescerende tracers. Een tumorgerichte fluorescerende tracer 
is gebaseerd op het concept van een dragermolecuul dat is geconjugeerd aan een 
fluorescerende kleurstof die specifiek kan binden aan een bepaald tumor doelwit. 
Deze intra−operatieve beeldvormende techniek kan worden toegepast als een soort 
‘rode−vlag’ techniek om zo te helpen bij optimale tumoridentificatie, waardoor de 
chirurg tijdens de procedure kleinere tumor laesies makkelijker kan identificeren en 
tegelijkertijd kan differentiëren tussen benigne en maligne weefsel. Bevacizumab­
IRDye800CW, een veelbelovende tumorgerichte fluorescerende tracer gericht 
op de vasculaire endotheliale groeifactor (VEGF−A), zal in de nabije toekomst in 
het UMCG worden gebruikt voor een nieuwe fase−I studie om tumorweefsel van 
colorectale PM te detecteren tijdens DLS (de SELECT trial). Indien bevacizumab­
IRDye800CW accuraat detecteerbaar is tijdens een DLS wordt het in de toekomst 
mogelijk om de uitgebreidheid van peritoneale ziekte in een eerder stadium 
nauwkeuriger te onderzoeken. Uiteindelijk kunnen dit soort nieuwe strategieën 
mogelijk overbehandeling, postoperatieve morbiditeit en kosten verminderen met 
behoud van dezelfde of zelfs betere effectiviteit van de procedure met een lagere 
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Bij het schrijven van dit dankwoord word ik omringd door de geluiden van de 
sloopwerkzaamheden van het eeuwenoude Triadegebouw. Het einde is in zicht! 
Voor zowel mijn tijd als promovendus als voor de onderzoekskamer waarin ik velen 
uren heb doorgebracht. Een strakke planning ging hier aan vooraf en dit was alleen 
mogelijk door de steun en inzet van vele mensen om mij heen. Een aantal van hen 
wil ik daarom hieronder in het bijzonder bedanken.
Graag bedank ik als eerste alle kankerpatiënten die zich belangeloos hebben 
ingezet voor de verschillende klinische studies ondanks dat zij zich bevonden in 
een zeer hectische en stressvolle periode van hun leven. Een operatie is voor veel 
patiënten een major life event en dit geldt zeker voor de patiënten die een dermate 
complexe en risicovolle procedure als een HIPEC ondergaan. Jullie deelname, jullie 
persoonlijke verhalen en jullie enthousiasme om de zorg voor toekomstige patiënten 
te verbeteren hebben mij enorm geraakt. Jullie hebben mij de mens achter de cijfers 
laten zien.
Prof. dr. G.M. van Dam, lieve Go, wat ben ik een enorme geluksvogel geweest dat 
jij mijn professor was. Het schept natuurlijk al een band als je beide op dezelfde 
dag in februari 2018 de kliniek van het UMCG verlaat om aan nieuwe doelen te gaan 
werken. Ik krijg nog steeds een enorme lach op mijn gezicht als ik terugdenk aan 
mijn eerste EMIM congres in San Sebastián in Spanje. Ik had slechts enkele weken 
gesnuffeld aan de bijzondere wereld van fluorescentie en kwam er daar pas achter 
wat voor zeer gewaarde wereld−expert jij eigenlijk bleek te zijn op dit gebied! Als ik 
jouw naam liet vallen wilden iedereen opeens wel graag met mij praten. Laten we 
het maar een korte periode van onbewuste onbekwaamheid noemen. Ondertussen 
weet ik wel beter. Met jou heb ik een enorm enthousiaste, ambitieuze maar vooral 
ook gezellige professor aan mijn zijde gehad die op borrels vaak pas diep in de nacht 
vertrok om bijvoorbeeld nog even snel het vliegtuig te gaan halen. Jouw relaxte, 
no−nonsense houding beviel perfect en soms hoefde ik alleen te zeggen dat er ‘even 
een paar grijze haren nodig waren’ en dan wist je genoeg. Je hebt mij elke keer op 
het hart gedrukt om mijn proefschrift spoedig af te ronden, omdat tegelijkertijd 
promoveren en in opleiding zijn tot chirurg vanuit jouw eigen ervaring voor niemand 
aan te raden was. Niet alleen dit advies maar ook vele anderen heb ik in mijn oren 
geknoopt. Helaas hebben we weinig fluorescent licht samen gezien, maar lieve Go 
fluorescente geleide chirurgie gaat werkelijkheid worden in de dagelijkse kliniek en 
ik beloof je dat ik dan bij elke procedure even aan jou zal denken.
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Dr. S. Kruijff, drukke drukke drukke Schelto, wat een top copromotor ben jij voor 
mij geweest! Je hebt een enorme drive voor alles wat je doet. Je vliegt overal rond en 
kan nooit stilzitten, maar maakt altijd acuut tijd voor jouw promovendi als er zaken 
spelen. In het begin hadden we bijna dagelijks contact en probeerde ik al struikelend 
al jouw ideeën bij te benen. Toen ik eenmaal hardloopschoenen had gekocht en de 
bochtige modderige paadjes had verruild voor het asfalt ging we samen pas echt 
als een speer. Door de snelle een−tweetjes tussen ons verliepen de verschillende 
onderzoeksprojecten zeer voorspoedig. Ik durf wel te zeggen dat zonder jou dit 
proefschrift nu nog lang niet was afgerond. Tijdens mijn promotietijd heb ik je wel 
eens gekscherend de filosofische chirurg genoemd. Misschien een gekke combinatie 
maar het geeft wel aan dat je veel aandacht had voor mijn persoonlijke ontwikkeling 
en daar ook heldere en kritische vragen over durfde te stellen. Ook buiten het 
werk kon je mij uitdagen. Een heerlijk voorbeeld is het potje tafeltennis tijdens de 
circuittraining waarbij het balletje de grond niet mocht raken. Keihard juichen als 
dit met een mooie smash dus wel lukte om dan vervolgens samen als straf “de 
beruchte trap” op en af te rennen. Het lachen ging al snel over in hijgen en we 
kwamen erachter dat dit geintje drie keer flikken tijdens dezelfde circuittraining toch 
wat ambitieus bleek te zijn. Heerlijk chirurgisch fanatisme. Het kan geen toeval zijn 
dat de dag dat ik terugkom naar het UMCG als vierde jaars AIOS chirurgie in 2023 
op een maandag valt; circuit maandag! Ik zeg we prikken deze datum direct voor 
een mooi ouderwets potje tafeltennis.
Hooggeleerde leden van de leescommissie, prof. dr. I.H.M. Borel Rinkes, prof. dr. 
M.A.T.M. van Vugt en prof dr. W. Helfrich, hartelijk dank voor jullie tijd en kritische 
beoordeling van mijn proefschrift.
Uiteraard wil ik ook alle co−auteurs van de verschillende wetenschappelijke 
artikelen hartelijk bedanken voor hun inspanning en geleverde bijdrage. Swades, 
Reickly en Hendrien wat is het toch heerlijk om mensen om je heen te hebben die 
helpen bij het zorgvuldig invullen en bijgehouden van de verschillende databases, 
waardoor publicaties op een gegeven moment als warme broodjes van de band 
konden rollen. Koen en Ignace wat konden jullie veel data van patiënten uit 
het Catharina ziekenhuis in Eindhoven aanleveren! Een hele mooie vruchtbare 
samenwerking, maar het meest heb ik toch wel gelachen om Koen met zijn duizend 
en één (zeker relevante) suggesties om het manuscript nog verder te verbeteren… 
vier weken na de deadline. Hopelijk staan we snel weer eens ergens in een Utregse 
kroeg met een zelfgetapt biertje in de hand. Willemijn waar moet ik in hemelsnaam 




geweest. Wat was het top om iemand te hebben die de statistiek wel begreep en 
alle ‘losse klusjes’ eventjes tussendoor deed. Succes met de laatste loodjes van je 
eigen proefschrift. Ik zal wat boeken weggooien om jouw proefschrift tegen die 
tijd in mijn boekenkast te kunnen plaatsen. Steven jij was de reddende engel aan 
het begin van mijn promotietijd. Jij gaf mij de zwembandjes die nodig waren om 
niet volledig te verzuipen bij het schrijven van een review over de ontwikkelingen 
die binnen de moleculaire fluorescente geleide chirurgie plaatsvonden. Altijd mooi 
om ‘onze gepubliceerde figuren’ weer terug te zien bij nationale en internationale 
congressen. Succes in het Martini ziekenhuis en ik ga onze (verhitte) discussies 
stiekem wel missen. Laura, heldin van de prehabilitatie poli, wat heb ik jou over de 
jaren zien groeien van semi−arts naar promovendus bij de HPB chirurgie. Jouw droge 
humor kan ik altijd enorm waarderen. Dank voor alle inclusies voor de MUSCLE 
POWER studie en in de toekomst bedenken we vast een studie waar de galblaas 
patiënten wel aan mogen deelnemen. Alain, wat was het leuk om samen te werken 
met een radioloog en te leren hoe je een goede echo maakt van spierweefsel! 
Jouw lach toen ik vertelde dat de spieren van het bovenbeen van mijn vriend wel 
2.5 keer dikker waren dan die van mij vergeet ik niet snel. Prof. dr. C.P. van der 
Schans, beste Cees, dank voor het meedenken en uitlenen van alle belangrijke 
materialen die we nu nog steeds voor de MUSCLE POWER studie gebruiken. Prof. 
dr. G.H. de Bock, beste Truuske, dank voor je eindeloze uitleg over de statistische 
methodiek die we moesten gaan gebruiken voor de MUSCLE POWER studie. Ik 
moest soms erg worstelen met jouw kritische vragen over wat ik nu eigenlijk echt 
wilde onderzoeken, maar het is de opzet van de studie zeker ten goede gekomen. 
Frederik, Fredje, wat heb jij mij altijd enorm gesteund! Zowel tijdens mijn gehele 
promotietijd als ook in de aanloop naar mijn sollicitatie om een opleidingsplaats bij 
de chirurgie te bemachtigen. Je hebt een zeer goede indruk gemaakt als kerstman 
bij het jaarlijkse arts−assistentendiner en ik ben altijd blij als ik jou weer bij een 
borrel of op een congres zie staan. Toch moet hier zeker ook vermeld worden dat 
je met ieder manuscript actief meedacht en met veel enthousiasme elke keer weer 
de uitgebreidheid van chirurgie stond te voorspellen. Jouw ‘extra’ aantekeningen op 
het extent of surgery formulier paste helaas niet altijd in de database, maar ik heb 
enorm genoten om ze allemaal te lezen. De Zuid­Afrikaanse wijn Pinnotage komt nog 
jouw kant op. Dit is de wijn die ik destijds, toen ik hoorde dat ik was aangenomen 
voor de opleiding, al voor je wilde kopen maar waarbij ik uit puur enthousiasme 
per ongeluk de verkeerde fles bij de Gall & Gall had meegepakt. Carlijn, wat vind ik 
het altijd fijn om even met jou te kunnen sparren en het liefste dan met een goede 
cappuccino erbij. Ik heb veel bewondering voor hoe je alles altijd toch weer weet 
te combineren; van levertransplantatie in de nacht tot je gezinsleven overdag. Je 
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bent altijd bloedfanatiek. Vooral over het voor jou niet bestaande thema ‘vrouwen 
in de chirurgie’ kon je je zo heerlijk opwinden. Thanks voor de support!! Prof. dr. 
J.M. Klaase, lieve Joost, je hebt mij een aantal keer een heel belangrijke duwtje in 
de goede richting gegeven zonder dat je dit altijd zelf hebt beseft. Zo liet je duidelijk 
doorschemeren dat promoveren bij Go en Schelto een enorme kans was die ik beter 
niet kon laten liggen. Zoals iedereen nu kan zien had je daar volledig gelijk in. Met de 
MUSCLE POWER hebben we intensief mogen samenwerken en ik heb enorm genoten 
van je gedrevenheid en je effectieve ‘perifere aanpak’ van allerlei geneuzel achter de 
komma. Toch, als je aan mij vraagt wat ik nou echt het allermooiste aan jou vind, dan 
is het wel die kleine glimlach op je gezicht als ik weer eens zonder nadenken er een 
onnozele opmerking uitflap. Dank voor al je vertrouwen en we houden zeker contact.
Natuurlijk mogen, naast Schelto Kruijff, ook de andere HIPEC chirurgen niet in 
dit dankwoord ontbreken. Zij hebben niet alleen alle onderzoeksplannen en 
manuscripten zorgvuldig beoordeeld, maar uiteraard ook met veel zorg alle HIPEC 
patiënten daadwerkelijk geopereerd. Lukas Been en Patrick Hemmer wat een 
gouden duo zijn jullie! Ik keek dan ook vaak stiekem jullie gang in om te zien of 
de deur open stond zodat ik even kon komen buurten. Met Patrick wist ik zeker 
dat de getallen in mijn manuscript nauwkeurig werden nagelopen, dat elk nieuw 
paar gekochte schoenen direct werd opgemerkt en dat de zin ‘Hentzen pas op hè’ 
veelvuldig zou worden uitgesproken. Lukas had altijd de gave om meteen primair 
enthousiast te reageren en dat is altijd prettig als je je onderzoekslijnen probeert 
uit te rollen. Tevens wist ik zeker dat Patrick ook door iemand anders dan mijzelf 
erop gewezen werd om onderzoekszaken snel af te ronden. Robert van Ginkel in 
het begin noteerde jij nog al jouw suggesties met pen in de zijlijn van een geprint 
exemplaar van het manuscript en vond ik deze dan terug in mijn postvak. Heerlijk! 
Hopelijk staan we over een paar jaar weer samen op de skipiste en daarbij mogen 
eigenlijk de foute bontjas met te korte mouwen, de paarse hoed met zebraprint 
en de dikke sigaar niet ontbreken. Dank voor je steun tijdens het promoveren en 
uiteraard voor je hulp bij de kers op de taart; een opleidingsplek bij de chirurgie in 
de mooiste regio van Nederland!
Mijn onderzoekscollega’s binnen de OMIG groep wil ik bedanken voor alle support, 
goede tips en hilarische en gezellige momenten tijdens de diverse congressen. Madelon, 
Ruben, Boudewijn, Pascal, Iris, Milou, Luc, Floris, Wouter, Pieter, Steven, Siqi, 
Luc, Jasper, Majory, Wido, Matthijs, Bobby en Jouke het was mij een waar genoegen! 
Pieter jou wil ik extra bedanken voor het overnemen van de SELECT trial. Hopelijk 




Uiteraard wil ook al mijn collega’s van de chirurgie uit zowel de Isala klinieken in 
Zwolle als het UMCG in Groningen enorm bedanken voor hun enthousiasme, steun 
en het belangrijkste van allemaal voor de enorme gezelligheid op zowel de werkvloer 
als tijdens de vele georganiseerde activiteiten.
Petra, Manon, en Caroline hoe vaak heb ik wel niet mijn werkdag bij jullie opgestart? 
Heerlijk om op het krukje bij het secretariaat, verscholen achter de kast, even met 
jullie de laatste ergernissen, roddels, hoogtepunten en dieptepunten door te nemen. 
Jullie wisten mij ook altijd tussendoor weer binnen te lokken door taart en andere 
zoetigheid uitgebreid uit te stallen. Ik ga jullie echt missen en ik hoop dat ik over 
een paar jaar snel weer plaats kan nemen bij jullie op de kruk. Dan zal ik een keer 
een taart meenemen waar nog geen stukje ’s nachts van is opgegeten. Beloofd.
Uiteraard wil ik mijn twee paranimfen bedanken. Kristine, jij bent natuurlijk al mijn 
maatje vanaf de allereerste coschapdag. Als studiegenootje, huisgenootje en beste 
vriendin hebben we al zoveel samen beleefd. Gelukkig kunnen we ondertussen 
om de meeste dieptepunten keihard lachen. Samen uit samen thuis hebben we 
altijd nagestreefd, ook al vond dit soms kruipend plaats. Voor mij ben jij de SPSS 
queen en wat was het fijn om die hulplijn in te schakelen als ik er weer eens niks 
van begreep. De statistiek ging daardoor honderd keer sneller, waardoor er meer 
tijd over was voor een goede cappuccino of een lekker wijntje. Ik vind het top dat 
je vandaag naast mij staat! Ik weet zeker dat je een zeer gewaardeerde intensivist 
gaat worden en ik hoop dat we elkaar ook in het ziekenhuisleven weer gaan treffen. 
Toch lieve Kris is er altijd één ding geweest wat ik zo jammer heb gevonden. Met de 
achternaam Koekkoek had je toch eigenlijk gewoon psychiater moeten worden?? 
Leonie, wat heb jij het promoveren een stuk leuker gemaakt! Ik heb uitgerekend dat 
we in deze periode ieder ergens tussen de 400 en 500 cappuccino’s samen hebben 
opgedronken. Het aantal gebakjes was iets lastiger te bepalen dus die berekening 
heb ik maar achterwege gelaten. Jouw droge en soms (inkt)zwarte humor was elke 
keer weer een verademing. Ik hoop dat de S.T.E.R.F. en A.N.J.E.R. groep apps nog 
lang blijven bestaan, want wat zijn alle verhalen, afbeeldingen en filmpjes elke keer 
weer om te smullen.
Tot slot wil ik ook graag mijn vrienden en (schoon)familie bedanken. Heerlijk dat 
jullie alleen weten dat ik promoveer over ‘iets met uitgezaaide darmkanker’ of dat 
zelfs geen eens. Toch hebben jullie een zeer belangrijke bijdrage geleverd door 
bijna alle randvoorwaarden te creëren die nodig zijn om als arts en promovendus 
zeer gelukkig en stralend door het leven te gaan. In het bijzonder wil ik mijn ouders 
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bedanken voor hun onvoorwaardelijke steun en trots. In het begin hielden jullie nog 
druk een lijst bij met mijn projecten, maar dat sneuvelde al snel toen bleek dat deze 
lijst nogal onderhevig was aan veranderingen. Christiaan, Miriam en Jasper, wat 
is het een rijkdom dat ik de afgelopen jaren zeven keer (ja echt zeven keer!) tante 
ben geworden. De urenlange gesprekken die zijn daarmee wel ten einde gekomen, 
maar tussen alle kindergeluiden door maken jullie toch altijd nog wat tijd voor mij 
vrij. Ook met mijn schoonfamilie heb ik ontzettend veel mazzel. Gerard, Nel, Marcel 
en Alex bedankt voor alles!
Ronald, jij verdient echt een eigen alinea!! De cover van dit proefschrift is toch om 
te smullen?? Ik kijk elke keer weer met verbazing wat jij met jouw creatieve geest 
en ontwerp skills allemaal in een handomdraai produceert. Ook wordt dankzij jouw 
nuchterheid en flexibiliteit het ziekenhuisleven spontaan een stuk minder hectisch. 
Van hangen op de bank in een trainingsbroek tot TukTuk rijden in Sri Lanka; al onze 
momenten samen had ik voor geen goud willen missen en gelukkig zullen er nog 
vele volgen. Jij bent mijn allerbeste maatje. Ik zou met niemand anders zo gek durven 







Judith Eleonora Katharina Regina Hentzen werd op 17 mei 1989 geboren te Utrecht. 
Zij groeide op als jongste dochter van Ab Hentzen en Maria Verkleij samen met 
haar twee oudere broers Christiaan en Jasper en oudere zus Miriam. In 2007 
behaalde zij haar gymnasium diploma aan het Leidsche Rijn College te Utrecht. 
Aansluitend volgde zij de HBO opleiding Verpleegkunde aan de Hogeschool van 
Utrecht en behaalde een jaar later haar propedeuse. In 2008 kon Judith beginnen 
aan de opleiding Geneeskunde aan de Universiteit van Utrecht. Tijdens haar 
opleiding Geneeskunde liep zij onder andere een coschap Kindergeneeskunde 
in het Muhimbili Hospital in Tanzania. Haar wetenschapstage vond plaats in het 
Academisch Medisch Centrum te Amsterdam, waarbij zij onder leiding van prof. dr. 
B.W. Mol en dr. W.M. van Ankum landelijk onderzoek verrichtte naar de behandeling 
van miskramen in Nederland. In het voorjaar van 2015 begon zij als arts­assistent 
niet in opleiding bij de afdeling chirurgie in de Isala klinieken te Zwolle. In dezelfde 
periode voltooide zij onder leiding van dr. G.A. Patijn haar wetenschappelijke 
onderzoek naar het optimaliseren van antibiotica profylaxe binnen de hepato­
pancreato­biliaire chirurgie. Aansluitend werkte zij vanaf 2017 als arts­assistent niet 
in opleiding bij de afdeling chirurgie in het Universitair Medisch Centrum Groningen. 
In het voorjaar van 2018 is zij onder leiding van haar promotor prof. dr. G.M. van 
Dam en copromotor dr. S. Kruijff gestart met haar promotieonderzoek naar de 
chirurgische behandeling van uitgezaaide dikke darmkanker, dat resulteerde in dit 
proefschrift wat nu voor u ligt. Na twee jaar gewerkt te hebben als promovendus 
startte zij in januari 2020 met haar opleiding tot chirurg. De eerste drie jaar van haar 
opleiding vinden plaats in de Isala klinieken te Zwolle (Opleider V.B. Nieuwenhuijs). 
Vervolgens zal zij haar opleiding voort zetten in het Universitair Medisch Centrum 
Groningen (Opleiders dr. R.J. van Ginkel en prof. dr. J.M. Klaase).
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